






1. Transcutaneous  immunization  of  mice  with  cholera  toxin‐adjuvanted  diphtheria 









4. Besides  being  presented  by  migratory  skin  dendritic  cells,  soluble  antigen,  when 




mechanical  engineers  should  ensure  further  improvement  of  transcutaneous 
immunization and essentially revolutionize the current vaccination practice. 
‐‐‐‐This thesis 
6. The  field  of  vaccine  delivery  would  benefit  from  more  direct  head‐to‐head 
comparisons between administration routes in which the same doses of vaccine and 
dosing regimens were employed. 
‐‐‐‐Mikszta  JA,  et  al.,  Expert  Rev.  Vaccines  7,  1329‐1339,  2008 
7. Vaccine adjuvants straddle a fine line between tissue toxicity and efficacy. 
‐‐‐‐Wilson‐Welder  JH,  et  al.,  J  Pharm  Sci  98  (4),  1278‐1316,  2008 
8. Considerable activity in the field of dendritic cell targeting is expected, as it has the 
potential  of  yielding  a wealth  of  vaccines,  possibly  the  first  vaccines  generated by 
immunologists. 
‐‐‐‐Ueno  H  et  al.,  Immunol  Rev.  219:118‐142,  2007 
9. The formulation of the antigen and route of delivery can affect the Th1/Th2 bias of 
the  immune  response,  and  the  type  of  immune  response  that  will  be  protective 
varies with the disease in question. 
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Over the last two centuries, vaccination has been one of the most successful 
medical interventions in reduction of infectious diseases [1]. However, most 
vaccines are administrated by injection, which requires syringes, needles, and 
trained personnel. Injection can be painful and causes stress, especially in 
children. For pediatric vaccination programs, poor compliance is one of the 
reasons for incomplete vaccination coverage, which impairs herd immunity 
and may lead to unnecessary death from vaccine-preventable diseases. The 
needs for effective as well as non-invasive vaccine administration have 
boosted the research on nasal [2], transcutaneous [3], oral [4] and pulmonary 
delivery of vaccines [5]. 
The transcutaneous route is particularly attractive because the skin is highly 
accessible with unique immunological characteristics. It has been known for a 
long time that an effective immune response can be induced via the skin [3]. 
One successful example of transcutaneous vaccination is scarification in the 
case of smallpox immunization in humans [6]. The presence of professional 
antigen-presenting cells (APCs) in the epidermis and dermis mediates the 
cutaneous immunization [7]. Another primary reason for considering the 
transcutaneous route is the potential for safe immune stimulation, as it avoids 
the direct contact of potent (even slightly toxic) adjuvants with the general 
blood circulation [8]. However, the uppermost layer of the skin, the stratum 
corneum, acts as a barrier for diffusion and therefore a major obstacle to 
transcutaneous vaccine delivery. Currently, the main challenges for 
cutaneous immunization are: i) to enhance the transport of antigens across 
the skin barrier and ii) to improve the immunogenicity of topically applied 
vaccines. 
In this chapter, approaches for improving transcutaneous immunization (TCI), 
e.g. vaccination through intact or pretreated skin, will be reviewed. This 
chapter starts with a brief introduction to vaccines and adjuvants, followed by 
a description of the barrier and immunological functions of the skin. The 
second part includes a description of innate and adaptive immune responses 
upon contact with an antigen and the function of skin dendritic cells (DCs). 
The third part summarizes the experimental approaches of enhancing 
transcutaneous antigen delivery and improving the immunogenicity of vaccine 
formulations. Finally, some safety concerns and concluding remarks are 




Table I. Terms used in this chapter 
 
Term Interpretation 
Adjuvant Substance that enhances the immunogenicity of an antigen
Cutaneous immunization Both intradermal and transcutaneous immunization 
Particle elasticity The ability of vesicles to deform and pass through openings 
smaller than their actual size 
Intradermal immunization Antigen delivery into the dermis via a syringe and needle 
Transcutaneous immunization Antigen delivery into the epidermis and dermis through 
intact or pretreated skin 
Microneedles Needles shorter than 1 mm 
2. Vaccines and adjuvants 
Vaccines can be defined as antigen formulations that induce specific, 
non-toxic and long-lasting immune responses to prevent or treat disease [9]. 
Traditional vaccines are designed to mimic the immune response that would 
otherwise be induced by an active infection, thereby avoiding the undesirable 
consequences of the disease [10]. New vaccines can also trigger or enhance 
immune responses for therapeutic purposes, e.g. anti-cancer vaccines. 
However, the focus of this chapter will be on vaccines that prevent infectious 
diseases. 
To be effective, a vaccine must contain some parts of the disease-causing 
agent, e.g. bacterium, virus, or toxin, or a substance derived from it, e.g. a 
recombinant protein or a synthetic peptide, and it may include one or more 
adjuvants. Antigens in the vaccine formulations are recognized, taken up and 
processed by APCs and subsequently presented to T lymphocytes 
(generating antigen-specific T cells). Vaccination regimens generally employ 
prime-boost strategies. Repeated administration of the same antigen induces 
stronger activation of effector cells (immunoglobulin-producing B cells 
(plasma cells), cytotoxic T cells and helper T cells, Th), and also a small 
population of memory B and T cells. These memory cells provide a faster and 
stronger secondary immune response to the same antigen upon subsequent 
exposure, e.g. in the form of an infection by a pathogen carrying this specific 
antigen [11, 12]. The primary mechanism of protection after vaccination is 
mediated by the generation of neutralizing antibodies and/or the induction of 
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cell-mediated immunity depending on the disease in question [13]. Currently 
available vaccines can be classified into three categories: modified live, 
inactivated and subunit vaccines. 
Vaccines containing modified live organisms, such as the Sabin oral polio 
vaccine, induce the most potent and long-lasting immune response. They 
generally require the fewest number of inoculations, do not need adjuvants 
and are very effective at inducing both cellular and humoral immunity [14]. 
The largest drawback is their possible replication in immune compromised 
vaccinees. Moreover, there is a risk that an attenuated strain reverts to a 
virulent one. In this way, severe side effects may occur. 
Inactivated vaccines comprise the whole organism that has been killed by 
treatment with heat or chemicals. Examples are the typhoid and cholera oral 
vaccine and the injectable hepatitis A virus. They are potent inducers of 
humoral immunity and possess a longer shelf life than live vaccines. However, 
the degree of cell-mediated immunity induced can be weak. Although safer 
than modified live vaccines, inactivated vaccines are highly reactogenic and 
associated with side effects such as high fever accompanied by severe pain, 
redness and swelling at the injection site. 
Subunit vaccines, including DNA vaccines, contain only a portion of the 
organism or the gene coding for it. Being free of reactogenic agents, subunit 
vaccines are very safe. Toxoids, inactivated bacterial toxins such as 
diphtheria toxoid (DT) and tetanus toxoid (TT), are the first and very 
successful subunit vaccines employed for human use [15]. These toxoids are 
adjuvanted with alum to improve their immunogenicity. The newly developed, 
often recombinant, subunit vaccines mostly are poorly immunogenic, and 
generally require to be formulated with adjuvants. 
Adjuvants are substances that accelerate, prolong or enhance 
antigen-specific immune responses when used in combination with vaccine 
antigens. Adjuvants generally demonstrate their features due to one or 
several of the following mechanisms: 
i). provide a “depot” for the antigen, creating an antigenic reservoir for a 
prolonged delivery; 
ii). facilitate targeting of the antigen to APCs and/or enhance phagocytosis; 
iii). enhance and modulate the type of immune response induced by the 
antigen alone [16-19]; 
iv). provide a danger signal from damaged or stressed cells that the immune 
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system needs in order to respond to the antigen as it would during an 
active infection [11]. 
Colloidal aluminum hydroxide and aluminum phosphate, commonly referred 
to as alum, have been the most widely used adjuvants since 1926. Until now, 
alum is the only adjuvant approved (in fact, tolerated) by FDA for use in 
humans. It is the standard benchmark to which the efficiency of other 
adjuvants is usually compared [20, 21]. The mechanism of adjuvanticity of 
alum has long been thought to be providing an antigenic depot at the site of 
injection. Recent studies have shown that alum may also act via a different 
mechanism, as the alum crystals activate directly an intracellular innate 
immune response system called the Nalp3 (NACHT-LRR-PYD-containing 
protein [22]) inflammasome, or indirectly through release of the endogenous 
danger signal uric acid [23, 24]. While alum is effective at inducing strong 
humoral immunity, alum-based vaccines generally fail to induce cell-mediated 
immunity [25]. 
Most vaccines are delivered intramuscularly or subcutaneously. This may 
partially be due to the widespread availability of needles and syringes by 
which these tissues are easily accessible. There is, however, hardly any 
compelling evidence suggesting that they are ideal tissues for vaccination 
from an immunological point of view [3]. The skin is known to be a potent 
immune stimulatory tissue, but its full potential for vaccination has not yet 
been exploited. 
3. Immunological function of the skin 
3.1. Skin structure 
The skin is the largest organ of the human body. It represents the outermost 
physical barrier between the body and the surrounding environment. It 
protects us against external mechanical impacts, ultraviolet radiation, 
dehydration, and microorganisms. The skin consists of three main layers: 
epidermis, dermis, and subcutaneous fat tissue (Fig. 1). The epidermis is the 
outermost layer of the skin. The human epidermis varies in thickness from 50 
to 150 μm. It can be divided into four layers, which are, from outside to inside: 
stratum corneum, stratum granulosum, stratum spinosum, and stratum basale. 
The barrier function of the skin is located in the stratum corneum. This layer 
consists of rigid, desmosome-linked epithelial cells, known as corneocytes, 
embedded in a highly organized lamellar structure formed by intercellular 
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lipids. The unique arrangement of this layer (15-20 μm thick in human) results 
in a practically impermeable barrier which reduces the passage of molecules, 
especially those larger than 500 Da [26]. Underneath the stratum corneum 
resides the viable epidermis, which consists of three layers; stratum 
granulosum, stratum spinosum and stratum basale. The main cell type in the 
viable epidermis is the keratinocyte. However, melanocytes, Merkel cells and 
Langerhans cells (LCs), although less abundantly present, also play important 
roles in the functioning of the viable epidermis. 
 
Figure 1. Structure of the skin. The skin consists of three main layers: epidermis, dermis, and 
subcutaneous fat tissue. The barrier function of the skin is located in the uppermost layer, the 
stratum corneum. LCs in the epidermis and the dermal DCs in the dermis are the main APCs in 
the skin and the targets of TCI. Image adapted from Watt [27]. 
 
Underneath the viable epidermis is the dermis. The important cell classes in 
the dermis are fibroblasts, mast cells, and dermal DCs (dDCs). The dermis 
also contains blood vessels, lymph vessels, and nerves. This skin layer is the 
major site of cellular and fluid exchanges between the skin and the blood and 
lymphatic networks. The rich blood supply of the dermis plays a role in body 
temperature regulation, immune responses and pain- and pressure- 
regulating mechanisms [28]. 
Beneath the dermis lays the subcutaneous fat tissue. This is an assembly of 
adipocytes linked by collagen fibers. It not only forms a thermal barrier, but 
also functions as an energy storage and a mechanical cushion for the body 
[29]. Appendages such as sweat glands, pilosebaceous units, and hair 
follicles are structures penetrating the skin and originate either from the 
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dermis or the subcutaneous fat tissue. These appendages form important 
discontinuities of the skin [28]. 
Besides the barrier function, the skin also has important immunological 
functions due to the presence of the skin-associated lymphoid tissue (SALT) 
[30, 31]. The SALT is constituted by APCs, such as LCs and dDCs, together 
with keratinocytes, mast cells, subsets of T lymphocytes and the skin lymph 
nodes. Although considerable amounts of microbes are covering our skin, 
homeostasis is maintained and we stay remarkably healthy. When microbes 
break the skin barrier, the immune system faces a number of options: whether 
or not to respond, and what the right type of response is. This decision can be 
a matter of life and death exemplified by for instance leprosy [32]. The skin is 
involved in both innate and adaptive immunity. The adaptive response 
enables vaccination and generally becomes more effective with each 
successive encounter with the same antigen, whereas the innate immune 
mechanism provides immediate, but short-lasting defense against infections. 
In the following sections about the immunological functions of the skin, the 
human immune system is discussed, unless stated otherwise. 
3.2. Innate immunity 
The most important skin cells involved in the innate immune response are the 
skin DCs that sample the environment, process the antigens and present 
these to T cells. Several distinct types of DCs are present in the skin [33]. 
However, as this is an emerging field of research, here only the two most 
established types of skin DCs, LCs and dDCs, will be described. They are two 
types of myeloid DCs. LCs are epidermal DCs that account for only 1% of the 
total epidermal cell population, but cover nearly 20% of the skin surface area 
[34]. LCs can be distinguished from other subsets of DCs by their expression 
of langerin/CD207 (Fig. 2), CD1a and E-cadherin and the presence of a 
unique intracytoplasmic organelle, the Birbeck granule. The dDCs are 
characterized by DC-SIGN (DC-specific intercellular adhesion molecule-3 
(ICAM-3)- grabbing non-integrin, also known as CD209), CD11b, factor XIIIa 
and CD14 expression [35, 36]. They are present in higher numbers than LCs 
in the skin. These cells are continuously produced from the hematopoietic 
stem cells and distributed in an immature state as antigen-capturing cells. 
Recently a new subset of skin DCs has been found in the skin, i.e. the 
langerin positive CD103+ DCs, which are reported to be most efficient in 
processing viral antigens into the major histocompatibility complex class I 
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(MHC I) pathway, thereby activating CD8+ T cells [37]. Currently, this topic is 
of great interest and novel vaccines targeting specific DC subsets will be 
designed [38]. 
Skin DCs, together with macrophages recruited from circulating blood, exert 
their sentinel role by sampling and processing potential pathogens invading 
the skin. Immature DCs are activated by numerous agents derived from 
microbes, dying cells and cells of the innate and adaptive immune system. 
These responses are initiated by binding of the agents to 
pathogen-recognition receptors (PRRs). Although PRRs are expressed on 
many cell types, research on PRR activation mainly focuses on DCs, because 
of their important role in controlling immune responses [39]. Agents that 
trigger these receptors are referred to as pathogen-associated molecular 
patterns (PAMPs) and danger-associated molecular patterns (DAMPs) [40]. 
DAMPs include the endogenous signals, e.g. heat-shocked proteins (HSPs) 
secreted or presented by other somatic cells when dying or otherwise 
stressed; PAMPs usually represent exogenous signals, such as the 
conservative motifs of microbial products [41]. Detailed information about the 
PRRs, especially the Toll-like receptors (TLRs), and the corresponding 
PAMPs and DAMPs will be discussed later. 
 
Figure 2. Epidermal LCs. Immune fluorescence staining of MHC II (green) and langerin/CD207 
(blue) in epidermal sheets freshly isolated from the ear skin of a normal adult mouse (C3H, H2k). 
Confocal images show that all MHC II+ cells in the epidermis express langerin. Picture adapted 
from Erikson et al. [42]. 
The antigen-presenting process is profoundly affected by PAMP and DAMP 
induced cytokines. Keratinocytes, accounting for about 90% of the total 
epidermal cell population, play an important role. In case of danger, e.g. skin 
barrier disruption, keratinocytes produce a wide range of cytokines such as 
interleukin-α (IL-1α), IL-1β, granulocyte-macrophage colony-stimulating factor 
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(GM-CSF) and tumor necrosis factor-α (TNF-α), which interact with DCs and 
help to maintain an appropriate balance between reactivity and tolerance of 
the immune system [43, 44]. For example, migration and maturation of LCs 
are initiated by pro-inflammatory cytokine IL-1β and keratinocyte-derived 
TNF-α [45, 46]. Besides keratinocytes, neutrophiles, macrophages, and mast 
cells also secrete cytokines that influence DC maturation [47, 48]. The change 
(differentiation) of LCs and dDCs during maturation includes increased 
expression of MHC molecules and co-stimulatory molecules, increased 
production of cytokines such as IL-1β, IL-6, IL-12, and chemokines such as 
CXCL1, 2, 3, 8 and CCL3-5, as well as the enhanced emigration of these cells 
from the skin to the paracortical area of draining lymph nodes [49, 50]. In the 
lymph nodes, skin-derived DCs present the processed antigens of the 
pathogen, together with the activation stimuli, to naïve resting T-lymphocytes 
surrounding them [51, 52]. This occurs in an antigen-specific fashion and 
results in the expansion of the respective clone(s) to mature into extremely 
potent immune stimulatory cells, controlling the development of adaptive 
immunity [53]. 
3.3. Pattern-recognition receptors 
TLRs are important PRRs involved in host defense against a variety of 
pathogens. TLRs have been a central focus for immunologists and 
vaccinologists since they were discovered by Gay and Keith almost 20 years 
ago [54]. So far, ten TLR members have been identified in humans and three 
more in mice, each thought to selectively recognize diverse bacterial, viral 
stimuli or endogenous signals (Table II) [55]. TLRs can be divided into 
subfamilies, according to the ligands they recognize and to their cellular 
localization. The subfamily of TLR 1, 2, 4 and 6 recognizes lipids, whereas 
TLR 3, 7, 8, and 9 recognize nucleic acids [41]. Generally, TLRs that detect 
bacterial products other than nucleic acids (TLR1, 2, 4, 5, 6, 10 and 11) are 
expressed on the cell surface, whereas those detecting nucleic acids (TLR 3, 
7, 8, and 9) are located intracellularly, typically on late endosomes or 
lysosomes. Such restricted localization might provide the mechanism by 
which DCs avoid spontaneous activation by self nucleic acids [56, 57]. When 
activated, TLRs recruit adapter molecules within the cytoplasm of cells to 
propagate a signal, which ultimately leads to the induction or suppression of 
genes that orchestrate the inflammatory response. Activation of different 
Transcutaneous immunization 
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TLRs regulates gateways for gene modulation and tailors the type of the 
induced immune responses.  
 
Table II. TLRs and their natural ligands in humans and mice [58-63]  
TLR Ligands Ligand location 
TLR1+TLR2 Tri-acyl lipopeptides Bacteria 
TLR2+TLR6 Di-acyl lipopeptides Mycoplasma 
TLR2 Glycolipids Bacteria 
 Lipopeptide Bacteria 
 Lipoprotein Bacteria 
 Lipoteichoic acid  Bacteria 
 HSP60, 70 and 90, grp96 Host cells* 
 Zymosan Fungi 
TLR3 Double-stranded RNA (dsRNA) Virus 
TLR4 LPS Gram-negative bacteria 
 HSPs Bacteria and host cells* 




 Heparan sulfate fragment Host cells* 




TLR5 Flagellin  Bacteria 
TLR7/8 Single-stranded RNA (ssRNA) Virus 
TLR9 Unmethylated CpG DNA  Bacteria 
TLR10 Unknown Unknown 
TLR11 (mice only) Profilin Toxoplasma gondii 
TLR12 (mice only) Unknown Unknown 
TLR13 (mice only) Unknown Unknown 
*endogenous danger signals, DAMPs  
TLR expression on LCs and dDCs are different and also differs from other 
subtypes of DCs at mucosal surface or in the blood circulation. Epidermal LCs 
freshly isolated from the human skin express TLR1, 2, 3, 6 and 10 but not 
TLR 4 and 5. Dermal DCs do express TLR2, 4 and 5, responsible to the 
recognition of bacterial PAMPs. Van der Aar et al. proposed that the LCs’ 
unresponsiveness to bacteria may contribute to tolerance to bacterial 
commensals that colonize the skin, avoiding deleterious inflammatory 
responses [64]. The TLR distribution on immune active skin cells (human and 
mouse) are presented in Table III. Some of the data are still under debate 
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because of different isolation methods for generating the specific types of 
cells. This DC heterogeneity and the differences in the epithelial 
microenvironment may influence the immune modulation function of certain 
adjuvants and thereby the choice of adjuvants for TCI.  
It is generally accepted that the detection of pathogens by TLRs initiates the 
mobilization of the host defense against most, if not all, infectious agents. 
However, recent results highlight the role of other PRRs that cooperate with 
TLRs or compensate for TLR specialization [65]. In the absence of TLR 
activities, most viruses and intracellular bacteria are recognized by alternative 
intracellular receptor families, including nucleotide oligomerization domain 
(NOD)-like receptors (NLRs), retinoic acid inducible gene based (RIG)-I-like 
receptors (RLRs) and c-type lectin-like receptors (CLRs) [66]. NLRs are a 
family of receptors recognizing intracellular microbial components, as recently 
reviewed [67, 68]. C-type lectins act as anchors for a large number of 
microbes, including viruses, bacteria, parasites, and fungi and allow their 
internalization. CLRs bind the carbohydrate moiety of glycoproteins and carry 
out multiple functions [69, 70]. In general, activation and maturation of DCs 
are the consequence of signal transduction within the PRR network, resulting 
in appropriate immunity against invading pathogens or infections. 
 
Table III. TLR distribution in immune active skin cells [71-79] 
 
Cell type Human Mouse 
Keratinocytes 1-6, 9, 10 2, 4, 7, 9  
LCs 1, 2, 3, 6, 10 2, 3, 4, 7, 9  
dDCs 2, 4, 5 9  
Myeloid DCs 1, 2, 3, 4 1, 2, 3, 4, 7, 9  
Plasmacytoid DCs 7, 9 7, 9  
Macrophages/Monocytes 1, 2, 4, 5, 8 3, 4, 7, 9  
Mast cells 3, 9 2, 3, 4, 7, 8, 9 
3.4. Adaptive immunity 
Adaptive immunity provides pathogen-specific, long-lasting protection to the 
host. DCs are an important link between innate and adaptive immunity. They 
educate and stimulate B and T lymphocytes and play a central role in both 
stages, both cell-mediated and humoral immunity [39]. Adaptive immunity 
starts with the DC-T cell interaction, followed with the proliferation of T and B 
lymphocytes in the secondary lymphoid organs, i.e. spleen and lymph nodes. 
Both cells develop from a common lymphoid progenitor in the bone marrow. T 
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cells differentiate further into either CD4+ helper or CD8+ cytotoxic T cells. 
Antigen recognition by B and T lymphocytes differs from that by cells of the 
innate immune system in that; the latter recognize conservative motifs using 
PRRs, whereas B- and T-cell receptors specifically recognize a large variety 
of epitopes. 
3.4.1. B cells 
The humoral immune response is mediated by B cells. These cells recognize 
their cognate antigen in its native form. They recognized free (soluble) antigen 
in the blood or lymph using their membrane bound-IgM or IgD, which act as B 
cell receptors. In most cases, B cell activation, e.g. clonal proliferation and 
terminal differentiation into plasma cells, requires not only recognition of 
antigens, but also cytokines produced by CD4+ Th cells, who are activated 
first after contact with APC presenting processed antigen in MHC II molecules. 
Special antigens, such as repeating carbohydrate epitopes from many 
bacteria, may also directly stimulate B cells by cross-linking the IgM antigen 
receptors, thereby activating them in a T cell independent manner [80]. B cells 
can also take up antigens and present them by MHC II to CD4+ T cells. 
Interactions between B cells and CD4+ Th cells stimulate both cell types. For 
example, Th2 cells are triggered to synthesis CD40L, which can bind to CD40 
on B cells. As a consequence, B cells start producing large amount of 
antigen-specific antibodies into the blood circulation. These antibodies assist 
in the destruction of microbes by binding to them and making them easier 
targets for phagocytes and activation of the complement system. 
3.4.2. CD4+ T cells 
In contrast to B cells, T cells only recognize their cognate antigen in a 
processed form, as a peptide fragment presented by an APC’s MHC molecule 
to the T cell receptor. For complete CD4+ T cell stimulation, this antigen 
presentation is required but not sufficient. Interaction of co-stimulatory 
molecules (CD80 and CD86) on DCs surface with their T cell equivalents 
(CD28), the secretion of stimulatory cytokines (IL-2) and a polarization signal 
(IL-4 and IFN-γ etc.) are also necessary [72, 81]. TLR recognition and 
activation in DCs induces the up-regulation of the activation markers CD80 
and CD86, and contributes to the activation of T cells. Once a CD4+ T cell is 
activated by a DC, it can differentiate into different types of Th cells. The 
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differentiation of CD4+ Th cells is particularly sensitive to the type of stimulus 
presented to the DC. Depending on the nature of the invading pathogen, a DC 
can induce the differentiation of CD4+ Th cells into Th1, Th2, Th17 or 
regulatory T cells (Treg) [82] (Fig. 3). Most bacterial and viral products, 
including lipopolysaccharide (LPS), bacterial DNA and dsRNA, drive the 
differentiation towards a Th1 functional phenotype [83, 84]. Th1 cells secrete 
IL-2, IL-12, IFN-γ and TNF-β, and lead to cell-mediated immunity, such as 
macrophage activation and inflammatory responses. Furthermore, Th1 cells 
provide a helper function for class switch of antibody-producing plasma cells, 
particularly those involved in opsonization and virus neutralization [85]. In the 
presence of parasitic pathogens, extracellular bacteria and allergens, naïve T 
cells are differentiated into Th2 cells. Th2 type cytokines, including IL-4, IL-5, 
IL-10 and IL-13, mediate humoral immunity and support the production of the 
IgG1 and IgE subclasses. The Th2 cells are the cells that can interact with B 
cells. Upon interaction, the T cells start producing CD40 ligand (CD40L) which 
can interact with CD40 on DCs and B cells. In this way, the activation of more 
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Figure 3. The adaptive immunity controlled by DCs. The specific pathway followed by CD4+ T 
cells, whether it involves Th1, Th2, Th17 or Treg cell differentiation, is significantly governed by 
DCs and depending on the nature of the invading pathogens. 
Th1 and Th2 cells are reciprocally regulated by a range of cytokines produced 
by themselves or by cells of the innate immune system. With the discovery of 
Th17 cells and the increasing role of antigen-induced Treg cells in controlling 
diseases [87], the relative simplicity of the Th1/Th2 paradigm needs 
modification. Nevertheless it still provides a model and reference for 
understanding disease pathogenesis and host immunity. The dominant type 
of immune response induced is determined by many factors, including the 
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route of antigen delivery, antigen doses, duration of antigen presentation, 
number, or frequency of immunizations and inclusion of adjuvants. 
3.4.3. CD8+ T cells 
Naïve CD8+ T cells become cytotoxic T cells when they are activated by DCs 
presenting antigens in the context of MHC I in the lymph nodes. Upon 
activation they migrate back to the sites of infection, where their main function 
is to kill tumor cells or cells infected by viruses or intracellular bacteria. The 
activation of a cytotoxic T cell response is the main mechanism of vaccines 
developed for cancer therapy. CD4+ T cells seem to be required to help CD8+ 
T cells fight certain pathogens. Cross-talk between both types of T cells is 
also mediated by CD40-CD40L interactions [88]. 
3.4.4. Memory cells  
The basis of vaccination lays in the existence of memory B and T cells. These 
cells enable faster and stronger responses to pathogen-derived antigens 
encountered before [89]. These cells are long-lived and almost do not divide. 
However, upon contact with a familiar antigen, they start dividing quickly and 
induce secretion of large amounts of antibodies and/or cellular responses. 
This process is nicely illustrated by the enhanced immune response obtained 
after booster vaccinations. More recent knowledge on memory cells can be 
found in a recent review by Sallusto and Lanzavecchia [90]. 
3.4.5. Skin DCs in adaptive immunity 
Under inflammatory conditions, LCs and/or the langerin positive CD103+ 
dDCs are highly efficient at inducing cytotoxic high-avidity CD8+ T cells [37, 
91]. LCs are strong activators of naïve CD4+ T cells, inducing their polarization 
into Th1 or Th2 cells. However, they are not able to promote the development 
of naïve B cells into IgM-secreting plasma cells [91]. In contrast, dDCs induce 
the differentiation of naïve B cells into IgM-secreting plasma cells through the 
secretion of IL-6 and IL-12, but are not very efficient at priming naïve CD8+ T 
cells [91, 92]. Dermal DCs preferentially activate CD4+ T cells, which help 
immunoglobulin production by B cells. LCs and dDCs appear to be equally 
potent at activating the proliferation and differentiation of memory T and B 
cells. More specifically, it is demonstrated that dDCs migrate into the outer 
paracortex of the lymph nodes, just beneath the B cell follicles, whereas LCs 
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migrate into the T cell-rich inner paracortex [93, 94]. Therefore, in summary, 
dDCs preferentially induce humoral immunity, while LCs and CD103+ dDCs 
induce cellular immunity. This concept is of particular importance in vaccine 
formulation design and delivery for selective activation of the desired type of 
immune response. 
Besides being presented by migratory skin DCs, soluble antigen, however, 
can directly diffuse into the draining lymph nodes through lymphatics and 
reach the lymph node-resident DCs [93]. Murine studies suggest that these 
two waves of antigen delivery to lymph nodes yield different immune 
responses. DCs can also activate innate immune cells such as natural killer 
cells [95, 96] and natural killer T cells [97]. 
4. Transcutaneous immunization 
To be efficient, TCI faces at least two main challenges: the transport of 
antigen and adjuvant across the skin barrier, and subsequently the 
stimulation of the antigen uptake by DCs, as well as DC maturation and 
migration in an appropriate manner. Efforts are classified into two categories: i) 
physical/chemical methods to overcome the skin barrier; ii) co-administration 
of adjuvants to potentiate and redirect the immune response. 
4.1. Overcoming the skin barrier 
Disruption of the skin barrier increases the transcutaneous permeation of 
antigen and makes it more readily available for sampling by APCs. 
Furthermore, disruption of the skin barrier beyond a certain extent may be 
considered as physical trauma by the immune defense system of the skin. 
Danger signals, such as HSPs or the hyaluronic acid fragment (Table II), 
induce the secretion of pro-inflammatory cytokines by the keratinocytes and 
facilitate APC activation, resulting in improved immunogenicity of topically 
applied vaccines [98, 99]. The physiological differences between mouse and 
human skin should be taken into consideration when transferring techniques 
of skin barrier disruption from one to the other. Between the species, the 
density of the characterized LCs resident in the skin is comparable [100, 101]. 
However, human skin is thicker and less hairy than mouse skin [100, 102]. 
Correspondingly, the depth of LC locations is greater in humans. The physical 
and chemical approaches utilized to overcome the skin barrier and improve 




Figure 4. Approaches and devices for TCI. (a) i.d. immunization; (b) SoluviaTM (BD) [103]; (c & d) 
Micro-TransTM , solid microneedle array and its SEM image [104]; (e, f & g) hollow microneedle 
array, MicroJet® (NanoPass) [105, 106]; (h & i) blunt-tipped microneedle array, OnVax® (BD) 
and its EM image [107]; (j) microneedle array with electroporation, EasyVax® [108]; (k & l) 
powder and liquid jet systems [109, 110]; (m) smart vaccine patch from Intercell [111]; (n) 
PassportTM patch (Altea) [110]; (o) coated and hollow microneedle arrays (3M) [112]. 
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4.1.1. Intradermal injection 
The most widely used method to overcome the skin barrier for cutaneous 
immunization to date is intradermal (i.d.) injection, invented by Mendel and 
Mantoux in the early 1900s [113] (Fig. 4a). It is able to deliver antigens into 
the dermis precisely and reproducibly. Clinical trials with hepatitis B, influenza, 
and therapeutic cancer vaccines have shown that i.d. vaccination is safe and 
effective. In many cases, benefits such as stronger immune responses with a 
lower antigen dose compared to subcutaneous (s.c.) or i.m. injection were 
observed. These underline the effectiveness of the skin as a site of 
immunization [3]. However, traditional i.d. injection requires well-trained, 
skillful healthcare workers; therefore new devices for i.d. injection are being 
developed. One example is the BD (Becton Dickinson) microinjection system, 
SoluviaTM (Fig. 4b). This is a prefilled syringe with a single 1.5 mm-long, 30G 
intradermal needle designed to deliver 100-200 µl fluid. It is now commercially 
available for a trivalent seasonal influenza vaccine (Sanofi-Pasteur) [114]. 
However, it still employs needles and causes pain. Cutaneous immunization 
in a minimal-invasive and needle-free manner is therefore more desirable. 
4.1.2. Microneedle arrays  
One approach towards painless and needle-free TCI is to dramatically reduce 
the size of needles so that they are barely perceptible. The term microneedles 
in the definition used here refers to needles shorter than 1 mm with a 
cross-sectional diameter of about 300 μm or less. Theoretically, microneedles 
only need to pierce the 15-20 μm thick stratum corneum before reaching the 
viable epidermis. However, the skin is elastic, heterogeneous tissue and 
slightly stretched in vivo. The mechanical and structural properties of the skin 
vary significantly with age, skin type, hydration level, body location and 
among individuals [115, 116]. To ensure effective and reproducible piercing 
regardless of these factors, microneedles need to be fabricated much longer 
than 20 μm [117]. The diameter of the microneedle is also important. A too 
small diameter can only provide limited diffusion flux. Moreover, very thin 
microneedles are normally very fragile and may easily break in the skin. To 
overcome this risk, microneedle arrays were designed, which can help to 
spread the surface forces between each microneedle, thereby decreasing the 
chances of breakage in the skin. More importantly, by using an array of 
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microneedles, more conduits are created in the skin, thereby increasing 
transcutaneous diffusion of antigen and exposing more APCs. 
The concept of the microneedle array for drug delivery purposes essentially 
dates back to a patent, filed in 1971, by Gerstel and Place at Alza Corp [118]. 
However, it was not until the 1990s that the technique became viable, as by 
then techniques became available to precisely fabricate these microneedle 
arrays in a potentially cost-effective manner. Since then, microneedle 
technology is under active research and various strategies were developed 
using microneedle arrays in transdermal drug delivery, including TCI [119, 
120]. 
Solid microneedle arrays 
A straightforward method is to perforate the skin with solid microneedle arrays 
and apply antigens to the skin surface for subsequent diffusion into the skin. 
Henry et al. demonstrated four orders of magnitude increase in permeability 
for calcein and bovine serum albumin (BSA) through human epidermis in vitro 
after penetration with a microneedle array of 150-μm needle length [121]. 
Banks et al. reported that the flux across microneedle array-pretreated skin 
was augmented by increasing the charge of the drug [122] and Verbaan et al. 
showed that 200-nm particles can diffuse through conduits formed by solid 
microneedle arrays [123]. 
Coated microneedle arrays 
Besides pretreatment, arrays of microneedles with vaccines coated in the 
form of powder or a film have been developed. Although only a very low 
amount of antigen can be coated, this may be sufficient to generate a 
protective immune response. The coated microneedle array is inserted into 
the skin and then removed, thus depositing its payload to a maximum depth 
determined by the length of the microneedle. Matriano et al. delivered 1 μg 
ovalbumin (OVA) by precoated microneedle arrays and showed up to a 
100-fold increase in immune responses over i.m. injection of the same dose 
[124]. In that study, an array with 300-μm long microneedles, made of titanium, 
was applied to the skin by an impact insertion applicator. Later, Widera et al. 
from the same group carried out an extensive study on microneedle 
fabrication parameters. The immune response was found to be dose 
dependent, however, practically independent of depth of delivery, density of 
microneedles, or area of application. Notably, OVA delivered with short 
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microneedles (225 μm) in a high density array (725 microneedles/cm2) 
induced a similar immune response as compared to longer microneedles (600 
μm) at a lower density (140 microneedles/cm2) [117]. 
Coatings are usually applied by dipping microneedles in the vaccine 
formulations. A systematic study performed by Gill and Prausnitz 
demonstrated that excipients reducing surface tension of the coating solution 
improve coating uniformity, while excipients increasing solution viscosity 
increase coating thickness. The amount of coated antigen can be adjusted by 
its concentration in solution. Both hydrophilic and hydrophobic molecules 
could be uniformly coated onto microneedles. Coatings could be localized just 
to the needle shafts and formulated to dissolve within 20 s in porcine cadaver 
skin [125, 126]. More recently, Chen and his coworkers reported a novel 
gas-jet coating method, with which they achieved uniform coating of a wide 
variety of molecules, e.g. ethidium bromide (394 Da), OVA (44 kDa) and 
OVA-encoding DNA (3.2 MDa), to microneedle arrays (30 to 90 μm needle 
length) [127]. As they used arrays of very small and densely packed 
microneedles, they claimed that only the gas-jet coating method, but not the 
dip-coating method, was able to localize the coating primarily to the needle 
shafts instead of the back plate. In the same study, they performed TCI with 
OVA on mouse ear skin using two dip-coated microneedle array-containing 
patches (3364 needles/16 mm2, delivering 1.2 μg OVA each) and induced 
comparable antibody titers to those from i.m. injection of 6 μg OVA. 
Hollow microneedle arrays 
By solid microneedle arrays pretreatment, antigen delivery is based on 
passive diffusion along the conduits. Although this is a relatively easy 
approach from a technical point of view, in general it leads to a low 
bio-availability of the applied vaccines. Using hollow microneedle arrays to 
inject the vaccine into the epidermis or the superficial layers of the dermis, 
one can precisely steer the flow rate using a syringe or a pump and provide a 
more controlled vaccine delivery. However, avoiding leakage is the biggest 
challenge for a hollow microneedle array due to the short needle length. A 
hollow needle with the opening facing the skin will punch out a piece of tissue. 
This leads to blockage of the fluid path. A large fluidic pressure applied by a 
piston or pump against this resistance will cause leakage. By geometrically 
shaping the needle tip and partially retracting the needles after insertion, thus 
avoiding blockage and relieving the compressed tissue, the flow resistance 
Transcutaneous immunization 
 21
can be decreased substantially [128]. The first hollow microneedle array, 
150-μm long, made of silicon, was presented by McAllister et al. [129]. Luttge 
et al. reported injection of insulin in diabetic rats through a 350-μm long, 9×9, 
silicone microneedle array via a pump at a rate of 0.045 mg/h (estimated to 
be >1 μl/h based on the solubility of insulin [130]). Comparable reduction of 
glucose levels were achieved as compared to conventional s.c. injection (Fig. 
4f) [105]. Hafeli et al. demonstrated injection of radio-labeled human serum 
albumin (HSA) into mouse skin using 200-μm long, 2×3 microneedle arrays. 
After injection of about 3 μl fluid, the resulting relative skin uptake (the volume 
in the skin divided by the ejected volume) was 36.0 ± 19.9% [131]. Lower 
doses (3 μg) of influenza vaccines delivered by a hollow microneedle array 
(0.45-μm long, 4×1, Microjet® developed by Nanopass, Fig. 4e) elicited 
immune responses similar to those induced by full-dose (15 μg) i.m. 
vaccination in human volunteers [106]. In this study, a blanched bleb 
appeared after injection. Leakage was noted during injection in 7 out of 60 
subjects, without significantly affecting the immune response. 
Dissolvable microneedle arrays 
Another design is the dissolvable microneedle array. Kolli et al. tested 500-μm 
long microneedles made of maltose. They demonstrated that microchannels 
in the skin were created and about a ten-fold increase of the transdermal 
delivery of nicardipine hydrochloride was achieved [132]. The VaxMat®, made 
of sugar matrix containing vaccines by TheraJect Inc., are fabricated in 
various lengths from 100 μm to 1,000 μm and assembled with an adhesive 
patch. Upon piercing, the microneedles dissolve and antigen diffuses into the 
epidermis and dermis within minutes [133]. 
Combined approaches using microneedle arrays 
The BD’s OnVax® device employs blunt-tipped microneedles measuring 
50–200 μm in length over a 1 cm2 area (Fig. 4h and 4i). These 
“microenhancer arrays” were coated with vaccines and used to scrape the 
skin gently in order to expose LCs to the vaccine without pain sensation. 
Using a hepatitis B DNA vaccine-coated microneedle array (100 μg dose), 
stronger and less variable immune responses were achieved compared to 
conventional i.m. and i.d. injection. Moreover, 100% of seroconversion was 
achieved after only two immunizations, whereas only 40-50% conversion was 
obtained by the conventional techniques, unless more immunizations were 
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applied. This enables “wipe and go” vaccination with easy self-administration 
[107].  
The EasyVaxTM device has been designed to insert coated microneedle 
arrays into the skin followed by electrical pulses to deliver DNA into the cells 
(Fig. 4j). Mice vaccinated with smallpox DNA vaccine induced neutralizing 
antibody titers greater than those elicited by the traditional live virus vaccine 
administered by scarification [108]. 
Some trends can be noticed after ten years study in this field: 
i) instead of piercing on dermatomed skin in vitro, recently more relevant 
and adequate experimental evaluations are being performed in vivo; 
ii) the length of the microneedle falls more often in the range of 200-500 μm, 
which allows effective piercing with less pain sensation; 
iii) an impact applicator or insertion device is often used, which enhances the 
uniformity of skin piercing with shorter needle length; 
iv) hollow microneedle arrays have gained more attention for its potential of 
precise dose control, while the device needs to be improved with respects 
to leakage-free injection and simplicity. 
4.1.3. Tape-stripping 
Tape-stripping and skin abrasion employs adhesive tape or emery paper to 
(partially) remove the stratum corneum. Glenn et al. have reported that mild 
abrasion by making 15 strokes on the skin surface results in the removal of 
approximately 29% of the stratum corneum, which can greatly enhance the 
passive diffusion of an antigen. This study confirmed that stratum corneum 
disruption before applying a vaccine patch (containing 50 μg heat-labile 
enterotoxin from E. coli, LT) results in robust immunity comparable to that 
obtained after active toxin infection and immunity induced by oral cholera 
vaccine [134]. For reproducible and easy-to-use tape-stripping, a skin 
preparation system (SPS) has been developed by Iomai (current Intercell). In 
the SPS device, an abrasive strip of fine-grit sandpaper is used to provide 
mild and controlled stratum corneum disruption by the length of the strip with 
only one stroke instead of 15 strokes. Following the same immunization 
protocol, comparable LT-specific antibody titers were obtained from the 
groups treated by trained physicians and a self-treated group [135]. 
Cyanoacrylate skin surface stripping (CSSS) facilitates more the follicular 
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penetration by removing cellular debris and sebum from the hair follicle 
openings, thereby enhancing vaccines to be delivered to the follicular LCs 
[136]. It is reported that topical application of modified vaccinia Ankara 
particles (~290 nm) after CSSS pretreatment induced protection against 
vaccinia virus challenge in mice [137]. 
4.1.4. Jet injection 
Powder jet injection employs the PMEDTM device to deliver vaccines (Fig. 4k, 
Pfizer), formulated as dry powder, mainly to the epidermis by releasing 
compressed helium at 40 bar pressure from a gas cylinder. This route of 
vaccination is referred to as epidermal powder immunization (EPI) in the 
following discussion. Liquid jet injection uses liquid vaccine formulations 
instead of the powder to puncture the skin and deliver vaccines without the 
use of needles (Fig. 4l). This technique was invented in the 1860s and the 
multi-use-nozzle jet injection was introduced in 1950s, developed by the U.S. 
military. Billions of vaccines doses have been administered by this method 
until in 1985, when it was related to a large hepatitis B outbreak [138]. This 
abandoned technique now resurrects with safer design, e.g. disposable 
cartridges prefilled with vaccines [139]. 
4.1.5. Ultrasound 
Tezel et al. applied low-frequency ultrasound to disrupt the skin barrier till the 
skin resistance decreased from 60 to below 5 kΩ/cm2 [140]. Functioning as a 
physical adjuvant, ultrasound enhanced the immune response induced by 
topical application of 100 μg TT in mice, probably by enhancing the antigen 
transport across the skin barrier and the activation of LCs. It generates a 
potent systemic immune response without using a toxin adjuvant or skin 
abrasion. 
4.1.6. Electroporation  
Electroporation of intact skin involves transmitting high-voltage electrical 
pulses to disrupt lipid structures, thereby creating transient pores in the lipid 
regions of the stratum corneum. It has been reported to enhance the 
permeation of highly-charged macromolecules (heparin) across the stratum 
corneum reaching therapeutic levels [141]. Electroporation was found to 
stimulate the exodus of LCs from the skin, which may be an additional 
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advantage for vaccination purposes. TCI of 130 μg OVA-peptide with 100 μg 
CpG oligo deoxynucleotides (CpG) as an adjuvant by electroporation into 
mouse skin was shown to generate a strong cytotoxic T-cell response 
comparable to that induced by i.d. injection of the antigen with Freund’s 
complete adjuvant [142]. Electroporation also permeabilizes the viable cells, 
thereby increasing the uptake of the antigen. However, with the formation of 
transient pores in the stratum corneum during electroporation, resistance can 
drop rapidly and dramatically. Therefore the electric field may distribute to the 
deeper tissues, causing pain and muscle contractions, especially at higher 
pulse voltages required for pore formation. Although this can partially be 
avoided by using closely spaced microelectrodes to constrain the electric field 
within the stratum corneum, the use of electroporation in TCI for human is 
limited by the complexity of device design [143]. 
4.1.7. Thermo-ablation 
Thermo-ablation makes tiny conduits by burning away small micrometer- 
sized areas of the stratum corneum. This can be obtained by pulsed laser 
[144], arc discharge [145] or short-duration resistive heating [146]. The latter 
is employed by the PassPortTM system, commercialized by Altea 
Therapeutics Corp (Fig. 4n). The use of this system creates 80 micropores 
within a 1-cm2 area with a filament attached to an applicator for the electrical 
current supply. This area is covered with a disposable liquid reservoir patch 
containing vaccine formulation. TCI using this system by application of 3 μg of 
recombinant H5 influenza hemagglutinin and 25 μg CpG three times with 4 
week intervals induced robust serum antibody responses in mice and 
provided protection against a lethal challenge with a highly pathogenic avian 
H5N1 influenza virus [146]. 
4.1.8. Chemical approaches 
Water is one of the most frequently used penetration enhancers. Occlusion 
and hydration of skin tissue progressively increases its permeability, as 
hydrated stratum corneum results in swelling of the corneocytes, pooling of 
fluid in the intercellular spaces and dramatic microscopic changes in its 
structure at very high hydration levels [147]. Consequently, methods such as 
occlusive patches or hydrophobic ointments (e.g. vaseline) also lead to 
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increased skin permeability. Occlusive patches have been successfully 
utilized and combined with various TCI approaches [148-150] (Fig. 4m). 
Other penetration enhancers act by diminishing the barrier of the skin. A great 
variety of chemicals are known to posses this capability as reviewed by 
Williams and Barry [151]. More recently, six hundred formulations of 
commonly used chemicals were screened for their potency in both 
transcutaneous permeation enhancement and adjuvanticity by Karande and 
his coworkers. Methodology described in this study provides a rational 
strategy for the design of TCI formulations by testing chemicals on both 
permeation-enhancing properties and adjuvanticity in vitro. OVA formulated 
with chemical or mixture of chemicals superior in both properties showed 
higher immunogenicity in vivo. Notably, chemicals with either high 
permeation-enhancement potency or high adjuvanticity alone did not 
guarantee high immunogenicity [152]. 
4.1.9. Deformable vesicular antigen delivery systems 
The vesicular antigen delivery systems, as a combined physical/chemical 
approach, have also been exploited to enhance the permeation of antigens in 
TCI. These vesicles are reported to pass through pores/tunnels smaller than 
their actual size, owing to their highly deformable bilayer [153]. They also 
have the potential advantages of boosting the immune response because of 
their similar size and structure to microorganisms, the natural pathogens 
which are actively sampled by the APCs [154]. 
Transfersomes® 
Transfersomes® are ultradeformable liposomes. Liposomes are closed 
spherical structures consisting of bilayers of hydrated amphiphilic lipids. 
Liposomes have first been identified as adjuvants in 1974 [155]. They may 
exert their adjuvanticity by providing a sustained antigen release, epitope 
multimerization and particulate antigen delivery to APCs. Liposomes, 
especially cationic liposomes, have been extensively explored as carriers for 
protein and DNA vaccines as they can carry both membrane-associated and 
water soluble antigens [156, 157]. 
The ultra deformability is generated by incorporation of an edge activator, 
often a surfactant, in the lipid bilayer [158, 159]. The original composition of 
Transfersomes® was soybean phosphatidyl choline (SPC) with sodium 
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cholate and small amount of ethanol [160]. Transfersomes® are applied in a 
non-occlusive manner as it has been suggested that the hydration gradient in 
the stratum corneum will drive the intact vesicles into the viable epidermis 
[161]. However, the claim has not yet been substantiated [153]. Structural 
changes in the stratum corneum have been identified and vesicle structures 
have been visualized within the stratum corneum lipid regions, but no intact 
vesicles have been ascertained in the viable tissues [153]. Nevertheless, 
several groups have reported that Transfersomes® substantially increase the 
transport of small molecules across the stratum corneum [158, 162-164]. 
The use of Transfersomes® to formulate antigens in TCI has also been 
reported in a few studies. When using antigens such as HSA, gap junction 
protein (GJP) and TT, potent humoral immune responses were induced in 
murine models with antibody levels comparable to those obtained through s.c. 
injection of HSA, GJP in Transfersomes® and alum-adsorbed TT, respectively 
[165-167]. Transfersomes® (named elastic liposomes by Mishra et al.), 
prepared with SPC, Span 80 and ethanol, were loaded with hepatitis B 
surface antigen (HBsAg). Comparable IgG titers and much higher secretory 
IgA titers against HBsAg were induced when elastic liposomes loaded with 10 
μg HBsAg were applied onto intact mouse skin as compared to those 
obtained by i.m. injection of the same dose of alum-adsorbed HBsAg [168]. 
Other elastic vesicles 
A number of other types of elastic vesicle compositions have also been 
evaluated in TCI, e.g. with high percentage of ethanol being introduced into 
the vesicles, the ethosomes; or constructed from non-ionic surfactant and 
cholesterol, the niosomes. Ethosomal systems were shown to be much more 
efficient at delivering a fluorescent probe to the skin in terms of quantity and 
depth, than either conventional liposomes or a water/ethanol solution. TCI of 
HBsAg-loaded ethosomes has been reported to induce immune response 
comparable to i.m. injection of HBsAg-alum [169]. BSA-loaded niosomes, 
composed of sorbitan monostearate/sorbitan trioleate (Span 60/Span 85), 
cholesterol and stearylamine, were coated with a modified polysaccharide 
O-palmitoyl mannan (OPM) for targeted delivery to the LCs. This niosomal 
formulation elicited significantly higher serum IgG titers as compared with 
alum-adsorbed BSA and plain uncoated niosomes in TCI, but lower than 
those obtained after i.m. injection of BSA-alum [170]. 
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Van den Bergh et al. introduced a series of surfactant-based elastic vesicles, 
consisting of a bilayer-forming surfactant sucrose-laurate ester (L-595), an 
edge activator octaoxyethylene-laurate ester (PEG-8-L) and a charge inducer 
sodium bistridecyl sulfo succinate (TR-70) [171, 172]. It has been suggested 
that these elastic vesicles act as carrier systems to transport 
low-molecular-weight drugs into the stratum corneum [173-176]. Studies 
using freeze fracture electron microscopy have visualized channel-like 
regions together with vesicular structures in the deep layer of stratum 
corneum after non-occlusive treatment with elastic vesicles [172]. Therefore, 
there is a potential for antigen-loaded vesicles as effective formulations for 
TCI, although there is no evidence that vesicles diffuse intact into the viable 
epidermis.  
 
Table IV. New technologies targeting vaccine delivery into the skin 
 
a. Microneedle related approaches 
Technology Vaccine (development phase) Company or Ref 
Soluvia™, (prefilled 
microinjection) 
Trivalent inactivated seasonal 
influenza vaccine (clinical phase III) 




Microneedle injection Anthrax vaccine (pre-clinical) BD, [177] 
Micro-TransTM, (solid 
microneedle array) 
DNA, OVA, influenza (pre-clinical) BD, 3M, 
Valeritas/biovalve, 
[121] 
OnVax® (coated, blunt-tipped 
microneedle array) 
Hepatitis B DNA vaccine (pre-clinical) BD, [107] 
Macroflux® (coated 
microneedle arrays) 




Influenza (clinical phase I) Debiotech, 3M, 
NanoPass, [106] 
EasyVax® (microneedle 
array with electro-poration) 
Smallpox DNA vaccine (pre-clinical) [108] 
VaxMat® (dissolvable 
microneedle vaccine array) 




b. Other physical and chemical approaches 
Technology Vaccine/(development phase) Company or Ref 
SPS (topical patch and skin 
abrasion) 
Trivalent inactivated seasonal influenza 
(clinical phase II) 
Heat-labile enterotoxin from E. coli (LT) 
for travelers’ diarrhea (clinical phase III) 














Inovion, MedPulser DNA 
delivery system 
OVA peptide (pre-clinical) 
DNA dengue (clinical phase I) 
[142] 
PassPortTM system (topical 
patch with thermo-ablation)  
Influenza & DNA (pre-clinical) Altea, [146] 
PMEDTM (powder jet 
injection) 
DNA HIV (preclincal) 
Herpes simplex virus (HSV) type 2 
(clinical phase I) 
DNA melanoma gp100 (clinical phase I)
Influenza DNA vaccine (clinical phase I) 
Hepatitis B DNA coated gold 
micro-particles (clinical phase II) 








Biojector® 2000 (liquid jet 
injection) 
Inactivated polio vaccine (IPV) (clinical 
phase II) 
DNA vaccines for cancer, HIV & 





Low frequency (20KHz) 
ultrasound 




The stages of development of the approaches mentioned are summarized in 
Table IV. The long list of strategies/devices developed to overcome the skin 
barrier and enable painless, needle-free TCI reflects a very competitive and 
fast developing field. 
4.2. Immune potentiators and modulators 
Adjuvants, immune potentiators and modulators, are substances that 
enhance the immunogenicity of an antigen. Due to the advances in 
understanding innate immunity, the range of adjuvant candidates is enlarging 
dramatically. In many established, as well as experimental vaccine 
formulations, ligands for PRRs, cytokines or messenger molecules involved in 
the signal transduction of PRRs are incorporated, as reviewed by Wilson et al. 
[10]. As the route of administration determines the targeted subgroup of APCs, 
the immune modulation effectuated by adjuvants may differ depending on the 
site of vaccination. For example, in general, mucosal administration of antigen 
and adjuvants induces secretory-IgA which provides mucosal protection. 
Some representative adjuvants and the biased antibody isotypes in lab 
animals are listed in Table V, corresponding to the route of administration and 
their basic mechanisms of action. Their immune modulation properties in TCI 
on microneedle-treated skin will be further studied in this thesis. 
4.2.1. Bacterial exotoxins 
Bacterial ADP-ribosylating exotoxins possess a high degree of 
immunogenicity and adjuvanticity. Among them, cholera toxin and LT are the 
ones most intensively studied [190]. 
CT is a protein molecule consisting of five nontoxic B subunits (CTB) 
surrounding a single, toxic A subunit (CTA). Both the CTB-mediated specific 
binding to the GM1-ganglioside receptor and the ADP-ribosyl transferase 
activity of CTA were reported to be of importance in the immune stimulatory 
properties of CT [191, 192]. CT is a predominantly Th2 biased immune 
modulator when co-administrated with antigens by the intravenous route, oral 
administration or co-cultured with human blood monocytes-derived DCs in 
vitro [192]. Although diarrhea associated with CTA has prevented its use as a 
mucosal adjuvant, topical application of a high dose of CT does not appear to 




Table V. Antibody isotype bias induced in lab animals (mainly rodents) of selected adjuvants, 
the corresponding route of administration, and their basic mechanisms of action. 
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LT shares 82% of amino acid homology with CT and both bind to the 
GM1-ganglioside receptors preferentially on the DCs in vivo [201, 210, 211]. 
LT induces a stronger Th1 response than CT [210]. An immune stimulatory 
patch containing LT has been shown to enhance the immune protection 
induced by i.m. injection of influenza vaccine in the elderly [179]. The clinical 
phase I trial of an LT patch has been shown to be effective in ameliorating the 




Prokaryotic DNA contains unmethylated CpG dinucleotides within nucleic 
acid motifs that are recognized by the innate immune system of vertebrates 
[213]. These immune stimulatory motifs are the ligands for TLR9, found 
primarily in intracellular vesicles of phagocytic cells [213]. By signaling 
through TLR9, CpG induces production of reactive oxygen species and 
activation of NF-κB (nuclear factor κ-light-chain-enhancer of activated B cells), 
followed by the secretion of pro-inflammatory cytokines such as IL-12, TNF-α 
and IFN-γ, resulting in a Th1 biased response [207, 214]. CpG motifs are 
capable of stimulating secretion of immunoglobulins and modulating 
pre-existing immune responses [207, 215]. Therefore, synthetic CpG has 
been considered as candidate immune modulatory adjuvant. CpG has been 
included in many experimental vaccines and demonstrated enhanced 
protection against a variety of pathogens including Ebola virus, Bacillus 
anthracis, Francisella tularensis, L. monocytogenes, Cryptococcus 
neoformans, malarial antigens, anti-H. influenzae glycoconjugates and 
melanoma antigens [207, 216-220]. CpG has shown adjuvant activity in 
combination with dermally and mucosally delivered antigens as well [208, 
209]. 
4.2.3. LPS 
LPS, the major outer membrane constituent of Gram-negative bacteria, 
stimulates APCs through TLR4 [221]. LPS induces high level production of 
pro-inflammatory cytokines. A drawback of LPS is its toxicity and pyrogenicity 
in humans. Therefore, detoxified forms of LPS were developed, such as 
monophosphoryl lipid A (MPL), developed by removing a phosphate group, 
sugar moiety and an ester-linked fatty acid group; and lpxL1 LPS, containing 
penta- instead of hexa-acylated lipid A. These LPS derivates show less 
toxicity, while retaining their immune stimulatory properties [222, 223]. Similar 
to LPS, MPL interacts with TLR4 on APCs and induces strong, mixed 
Th1/Th2 responses with a bias to Th1, and cytotoxic T cell responses [224]. 
Since freshly isolated human LCs do not express detectable levels of TLR4 
and do not mature in response to its LPS ligands, LPS and its detoxified 
analogs are of research interest for studying antigen delivery and 
immunological mechanisms in TCI. 
Chapter 1 
 32
4.2.4. Virus-like particles 
Virus-like particles (VLPs) are viral proteins, such as capsid proteins, that 
spontaneously form particles resembling virions. They are relatively stable 
and inert particles. They do not contain encapsulated viral genes that could 
be potentially harmful. However, the constituent viral capsid proteins retain 
their native conformation and receptor-binding capacity and are therefore 
highly immunogenic [225]. Antigens delivered by VLPs have the potential to 
be presented via MHC II following endosomal processing, but endosomal 
escape into the cytosol will also allow for antigen presentation via the MHC I 
pathway [225]. This allows for induction of both humoral and cell-mediated 
immunity. Young et al. immunized mice on intact skin with VLPs in 
combination with CT and CpG. Antigen-specific IFN-γ secretion and 
secretory-IgA on the mucosal surface were induced as well as systemic IgG1 
[226]. 
4.2.5. Quil A  
Quil A, a saponin-based adjuvant, is composed of immune stimulatory 
fractions extracted from the bark of the tree Quillaja saponaria. QS21 is a 
purified saponin fraction from Quil A [194]. Besides their immune stimulatory 
properties, saponins interact with lipids of cell membranes and cause cell lysis. 
The tissue-reactive toxic nature has plagued their development as adjuvants 
[227]. By mixing phospholipids and cholesterol with saponins under controlled 
conditions, 40 nm cage-like particles, referred to as ISCOMs, can be created. 
They were first described in 1984 by Morein et al. [198]. ISCOMs have been 
shown to promote both humoral and cellular immune responses with several 
different antigens. As TCI does not introduce direct contact between vaccine 
and adjuvants with the general blood circulation, Quil A, QS21 and ISCOMs 
might be safely combined with TCI for further formulation development. 
4.3. Combined approaches for improving TCI 
Approaches discussed so far can be combined for the sake of improving TCI 
and tuning the immune responses for specific preventive or therapeutic needs. 
Synergy between different families of immune potentiators and modulators 
has long been studied and widely used in vaccination practice. In AS04, an 
adjuvant system developed by GlaxoSmithKline, MPL was added and 
adsorbed onto aluminum hydroxide or aluminum phosphate, thereby skewing 
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the Th2 biased response induced by the alum towards the Th1 direction. It is 
now marketed in vaccines against viral infections, such as FENDrixTM 
(hepatitis B) and CervarixTM (human papillomavirus, HPV) [228]. Immune 
modulators may also be combined with antigen delivery systems. Schlosser 
et al. reported that co-encapsulation of CpG or PolyI:C with OVA into the 
same PLGA particles induced higher antigen-specific, cytotoxic T-cell 
responses than its addition in a soluble form, most likely by targeting antigen 
and adjuvant to the endosomes within the same cell [229]. In AS01, another 
adjuvant system from GlaxoSmithKline, MPL and QS21 was incorporated into 
liposomes with the aim to favor Th1 responses and improve the CD8+ cell 
mediated immunity. The AS01 formulation of RTS,S (recombinant fusion of 
circumsporozoite protein and HBsAg) is now being evaluated in a phase III 
field study against malaria [230, 231]. Antigen-adjuvant conjugates and 
antigen-adjuvant fusion constructs are also potential candidate formulations 
for TCI [232, 233]. With the advance in understanding the functional 
specialization of skin DC subsets, immune modulation by targeted delivery of 
antigen and adjuvant predominantly to one of these skin DC subsets is 
theoretically possible yet challenging. For instance, tape-stripping and 
microneedle arrays with very short needle lengths will expose mainly LCs to 
the antigens following TCI, whereas ligands binding to specific receptors may 
be utilized to home antigen to a single skin DC subset. 
4.4. Safety concerns 
Most of the skin barrier disruption approaches mentioned are simple and 
hygienic in practice as most of them employ disposable devices or cartridges 
for single application only. Disinfecting the site of application with 70% ethanol 
beforehand and covering with patches afterwards can provide sufficient 
protection against potential infections and cross contaminations. Notably, the 
conduits created by microneedle arrays are reported to be open for up to 72 h 
under occlusive conditions and close within several hours when not occluded 
[234, 235]. This provides an option for a controlled antigen delivery through 
the conduits and prevention of a pathogenic contamination. 
The newest and most promising vaccine developments employ a variety of 
strategies for immune stimulation that enhance the responses to specific 
antigens. However, the advantages of immune stimulation are inevitably 
accompanied by acute safety risks associated with systemic adverse 
reactions. A balance between potency and adverse reactions will need to be 
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achieved for widespread acceptance of human vaccines [215, 222]. The risk 
of different types of side reactions associated with vaccination depends on the 
level and Th1/Th2 balance of the immune response, as well as the 
administration technique [8, 236, 237]. Th1 responses are usually linked to 
inflammatory cellular responses. The production of IFN-γ in particular, 
potentially favors type IV delayed type hypersensitive reactions (the Gell and 
Coombs classification), such as eczema and pruritus [238]. Th2 lymphocytes 
that contribute to IgE antibody responses, can favor immediate or late 
hypersensitivity reactions, involving mast cells and eosinophils, respectively 
[8].  
Cutaneous immunization avoids the general blood circulation while favoring 
lymphatic drainage of antigens. The risk of systemic shock is likely to be lower 
than observed for the i.m. or s.c. routes [8]. Therefore, cutaneous 
immunization is attractive for its potential for safe and potent immune 
stimulation. However, unlike injectable vaccines which have been 
administrated billions of times, the thorough safety profile of cutaneous 
immunization, including TCI, is yet to be established. 
4.5. Concluding remarks 
TCI provides effective, easy-to-use, painless, and needle-free vaccination 
with fewer side effects and safer handling than the conventional injections. 
The main challenges are to ensure reliable and accurate delivery of antigens 
into the epidermal and/or dermal skin tissue and to formulate antigens with 
adjuvants and/or particulate carrier systems for selective activation of the 
proper PRRs existing in the skin DC subsets. Joint efforts from immunologists, 
vaccinologists, pharmaceutical scientists, and (fine) mechanical engineers 
should ensure further improvement of TCI and essentially revolutionize the 
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Aim and scope of this thesis 
The aim of the work described in this thesis was to improve the 
immunogenicity of antigens in transcutaneous immunization (TCI) by using 
microneedle arrays, immune-modulators, and antigen- containing vesicle 
formulations. The study objectives include: 
i). To investigate the use of microneedle arrays to potentiate immune 
responses of topically applied antigen; 
ii). To combine microneedle arrays with adjuvants to modulate immune 
responses induced in TCI; 
iii). To prepare, characterize and evaluate surfactant- and lipid-based vesicle 
formulations for vaccine delivery across the stratum corneum into the 
viable layers of the skin; 
iv). To investigate the immunogenicity of topically applied antigen using 
antigen-loaded vesicular carrier systems in vivo; 
v). To improve TCI by combining antigen-loaded vesicle formulations with 
microneedle array pretreatment of the skin. 
Organization of the thesis and experimental approaches 
Chapter 1 provides a comprehensive review of the current research status of 
TCI, including a brief introduction to vaccines and adjuvants, the structure and 
barrier functions of the skin, and the innate and adaptive immunity involved in 
cutaneous immune defense. The main part of this chapter summarizes the 
strategies and experimental approaches of enhancing transcutaneous 
antigen delivery and improving/optimizing the immunogenicity of vaccine 
formulations. 
Chapter 3 describes the microneedle arrays and the impact insertion 
applicator developed for TCI. This system was first evaluated for effective 
piercing of mouse skin in vivo. Then, the effect of microneedle array 
pretreatment on TCI of diphtheria toxoid and influenza vaccine is presented. 
The 300 μm-long assembled microneedle array is used in the research 
described in Chapter 4 --- a comparative study on the immune potentiation 
and modulation functions of various adjuvants in TCI of DT onto microneedle- 
pretreated skin. 
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In Chapter 5 and 6 studies are presented on the potential of DT-containing 
vesicle formulations in TCI. Two types of DT-containing vesicle formulations, 
i.e. negatively charged surfactant vesicles and positively charged (elastic) 
liposomes, are prepared and characterized in vitro. Selected formulations are 
tested in TCI onto intact and microneedle array-pretreated mouse skin. These 
vaccinations were compared with vaccination through intradermal and 
subcutaneous injection. Human peripheral blood mononuclear cell-derived 
immature dendritic cells are used to assess the immune-stimulatory potential 
of these formulations. 
A summary of the outcome of this work, a general discussion and 
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The majority of vaccines are administered parenterally, however, multiple 
injections by syringes and needles require trained personnel and cause stress 
to children and parents in the pediatric vaccination program. In case of 
influenza, since the virus undergoes frequent antigenic variation, the current 
solution of controlling this disease by vaccination requires annual injections. 
Multiple injections (the pediatric vaccination program and influenza 
vaccination) raise the demand of a patient-friendly vaccine delivery. 
Transcutaneous immunization (TCI) offers an attractive route as it has the 
advantage of improved compliance and may lead to comparable or more 
potent immune responses than the conventional injection [1]. An enhanced 
immune response is expected because the skin is populated with a high 
number of immune-competent dendritic cells (DCs) in the dermis and 
Langerhans cells (LCs) in the epidermis [2, 3]. After activation, they migrate to 
the draining lymph nodes, present antigens to T cells and initiate systemic 
humoral and cellular immune responses [4-7].  
As the natural function of the skin is to protect the body against water loss and 
unwanted environmental influences, it is also the major obstacle for dermal 
delivery of vaccines. The barrier function of the skin is located in the 
uppermost layer of the skin, the stratum corneum. It consists of corneocytes 
embedded in a highly organized crystalline lamellar structure of the 
intercellular lipid matrix. This unique arrangement of the 15-20 μm thick layer 
results in a practically impermeable barrier for many compounds. To 
overcome this barrier and achieve effective TCI, formulations with potent 
adjuvants, particular carrier systems, penetration enhancers as well as 
physical methods e.g. thermal ablation [8], microdermabrasion [9] 
electroporation [10] and cavitational ultrasound [11] have been studied in 
animal models and human, resulting in improved antibody titers compared to 
non-adjuvanted vaccine on intact skin and in some cases protective immunity 
was achieved. Recently, phase II trial of TCI using E. coli heat-labile 
exterotoxin applied on the skin after mild abrasion was successful in 
mitigating traveler’s diarrhea [12]. However, low immunological efficiency, 
safety issue of adjuvants, poor patient compliance and complexity of 
application still pose severe problems hindering wide-spread introduction of 
TCI for mass vaccination campaigns.  
Transcutaneous immunization of diphtheria toxoid and influenza vaccine  
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A fast developing technique for TCI is to increase the skin permeability using 
a microneedle array. It was first proposed by Gerstel and Place in the 1970s 
[13]. Prausnitz resumed the study using microneedle arrays in transdermal 
drug delivery 10 years ago when the technology of fabrication in micron 
dimensions became readily available [14]. Currently, it is under active 
development in several groups at universities and companies. Based on the 
transient formation of mechanically produced conduits in the skin, antigens 
are able to pass through the stratum corneum and taken up by the LCs and/or 
the DCs [15]. These microneedles should be long enough to penetrate the 
stratum corneum, but short enough to avoid the contact with the nerves in the 
deeper skin tissue. In this way painless vaccination via the skin can be 
achieved. Successful TCI studies with equal or higher vaccination efficacy 
than i.m. injection have been reported by Mikszta et al. applying anthrax 
vaccine by intradermal injection with microneedle in rabbits [16] and Widera 
et al. using ovalbumin by an antigen-coated microneedle array in hairless 
guinea pigs [17]. However, practically the elasticity of the skin makes effective 
piercing by microneedle array very difficult. For reliable piercing in human skin, 
arrays with microneedle lengths typically of 500 µm and longer are required 
[18]. So far, effective and reproducible stratum corneum piercing by the 
microneedle array remains a very important issue, which influences the dose 
control of dermally delivered drugs including vaccines.  
We have reported that microneedle arrays manufactured from commercially 
available 30G hypodermal needles applied by a handheld applicator are able 
to enhance the transport of hydrophilic molecules with a molecular weight up 
to 72 kDa through dermatomed human skin in vitro [18]. The microneedle 
arrays used in that study were rather long (from 550 to 900 µm). As a 
consequence they might cause pain sensation and the recovery of skin 
barrier may take longer time. The necessity to pierce the skin reproducibly 
with shorter microneedle arrays is therefore obvious. Recently, in our group 
an electric impact insertion system has been developed which drives 
microneedle array into the skin at a predetermined velocity [19]. The elasticity 
of the skin can thus be counteracted, allowing the penetration of the shorter 
microneedle arrays in vitro into human skin. In the current study, the piercing 
ability of shorter microneedle arrays was validated and optimized in mouse 
skin in vivo using handheld and electric applicators before performing a TCI 
study, since mouse skin is thinner but more flexible than human skin. 
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Diphtheria is an example of a disease that is readily preventable by 
vaccination but remains a threat to public health due to short protection period 
and improper vaccination schedule. This had led to studies investigating TCI 
as a vaccination platform for diphtheria [20-22]. These studies revealed that 
dermal vaccination induced systemic response when applied with adjuvants 
multiple times on physically disrupted skin. In our current studies, diphtheria 
toxoid (DT) and influenza subunit vaccine (H3N2), average MW of 68 kDa 
and 228 kDa (trimmer), respectively, were both used in TCI studies aiming to 
examine the potential advantage of microneedle array pretreatment. Cholera 
toxin (CT), a well-known potent adjuvant, was co-administered to further 
improve the immune responses of these two vaccines. Our results show that 
microneedle arrays, with a needle length of 300 μm applied by the electric 
applicator, were able to pierce the mouse skin. It was very effective in 
increasing the immune response of DT. For the influenza TCI, 
co-administration of CT significantly improved the immune response against 
influenza, however, independent of microneedle array pretreatment of the 
skin.  
Materials and methods 
Materials 
The human influenza vaccine is composed of the mono-valent bulk subunit 
vaccine A/Panama/2007/99 RESVIR-17 (H3N2, trimer, larger aggregates of 
trimmers exist due to the cluster of its hydrophobic trans-membrane domains) 
and was kindly provided by Solvay Pharmaceuticals (Weesp, The 
Netherlands). Antigen concentration was based on haemagglutinin content. 
Diphtheria toxin (DTa 79/1) and diphtheria toxoid (batch 98/40, protein 
content 12.6 mg/ml by BCA assay, 1 μg equal to approximately 0.3 Lf) were 
provided by The Netherlands Vaccine Institute (NVI, Bilthoven, The 
Netherlands). Horseradish peroxidase (HRP) conjugated goat anti-mouse IgG 
(γ chain specific), IgG1 (γ1 chain specific) and IgG2a (γ2a chain specific) 
were purchased from Southern Biotech (Birmingham, US). Chromogen 3, 3', 
5, 5'-tetramethylbenzidine (TMB) and the substrate buffer were purchased 
from Biosource B.V (Nivelles, Belgium). O-phenyldiaminedihydro-chloride 
(OPD), lyophilized bovine serum albumin (BSA), Tween 20, Trypan blue and 
cholera toxin were purchased from Sigma (Zwijndrecht, The Netherlands). 
Tween 80 was purchased from Merck (Darmstadt, Germany). Nimatek® (100 
mg/ml Ketamine, Euovet Animal Health B.V., Bladel, The Netherlands), 
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Visagel® from Eurovet, Rompun® (20 mg/ml Xylazine, Bayer B.V., Mijdrecht, 
The Netherlands) from Bayer and the injection fluid (0.9% NaCl) were 
obtained from a local pharmacy. All other chemicals used were of analytical 
grade and all solutions were prepared with distilled water. 
Female BALB/c mice (H2d), 8-week old at the start of the experiment were 
purchased from Charles River (Maastricht, The Netherlands), and maintained 
under standardized conditions in the animal facility of the Leiden/Amsterdam 
Centre for Drug Research, Leiden University. The study was carried out under 
the guidelines compiled by the Animal Ethic Committee of The Netherlands. 
Methods 
Microneedle arrays and applicators 
Three types of microneedle arrays were used in this study. First, the 
assembled microneedle arrays were manufactured from commercially 
available 30G hypodermic needles (BD, Alphen a/d Rijn, The Netherlands) as 
described previously [18]. The needles were assembled as a 4×4 array on a 
polymer plate with the surface area of around 0.5 cm2. Serials of assembled 
microneedle arrays were fabricated with needle lengths of 300, 550, 700 and 
900 µm (Fig. 1A). The second type was made of stainless steel wire with a 
diameter of about 200 µm and a length of 300 µm, with a tangentially cut tip 
[19]. This type will be referred to as solid microneedle array (Fig. 1B). The 
third one is silicon hollow microneedle arrays with a length of 245 µm, 
available as 4x4 and 9x9 arrays (Fig. 1C) and produced as described 
previously [19].  
Piercing of mouse skin with microneedle arrays 
The abdominal skin of the mouse was shaved 24 h prior to microneedle array 
treatment. Just before the treatment, mice were anaesthetized by 
intraperitoneal injection of 150 mg/kg ketamine and 10 mg/kg xylazine. The 
shaved skin area was wiped with gauze soaked in 70% ethanol. A skin fold of 
the shaved abdominal region was supported by styrofoam and pierced by 
microneedle arrays. The handheld applicator was pressed 1 min manually 
with the assembled microneedle arrays ranging from 300-900 μm 
microneedle length. The electric applicator was used with a velocity of 3 m/s 
and a retention time of 1 s for all types of microneedle arrays not longer than 
300 μm [19].  
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Figure 2. Experimental 
setup for visualization 
of microneedle array 




Figure 1. Three types of microneedle arrays; (A) assembled (B) solid and (C) silicon hollow 
microneedle arrays. 
In vivo evaluation of piercing 
Immediately after piercing of the mice, the 
trans-epidermal water loss (TEWL) was measured by 
a Tewameter (TM 210, Courage + Khazaka, Köln, 
Germany). After placement of the probe on the 
pierced surface of the skin, the TEWL values were 
measured for 1 min and a mean value was calculated. 
To evaluate the uniformity of skin piercing, the site of 
piercing was covered with a hollow Hilltop® chamber 
(Miamiville, US) and filled with 300 µl 0.4% Trypan 
blue PBS solution for 1 h (Fig. 2). Subsequently the dye solution and chamber 
were removed and the mouse was sacrificed by cervical dislocation. The 
pierced skin was excised and examined under a magnifier. Successful 
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piercing of the microneedle arrays through the skin was scored by the 
appearance of blue dots in arrays at the dermal side of the skin. 
Dermal diphtheria and influenza vaccination 
The mice were shaved on their abdomen and rested for 24 h. On the day of 
vaccination, the mice were anaesthetized; the shaved skin area was wiped 
with 70% ethanol. A microneedle array was pierced into the skin using the 
electric applicator. For diphtheria vaccination, only the 300 µm-long solid 
microneedle array was investigated. Groups of 8 mice were immunized with 
100 μg DT or 100 μg DT plus 100 μg CT with and without microneedle array 
pretreatment. DT and CT were applied on the skin in 70 μl 0.01 M citrate 
buffer at pH 5.0. DT formulations were carefully spread to wet the entire skin 
area of application (microneedle array-pretreated or untreated, ~ 2 cm2 area 
restricted by a metal ring) and incubated occlusively for 1h. For the control 
group, 5 μg DT absorbed by AlPO4 (Adju-Phos®; Brenntag Biosector, 
Denmark) in 100 μl saline solution was injected subcutaneously. The AlPO4 
adsorbed DT (DT-alum) was prepared as previously described and the 
adsorption of DT was between 70% and 80% [23]. 
For influenza vaccination, after piercing the array was withdrawn and a hollow 
Hilltop® chamber was attached to the skin with medical tape. The chamber 
was filled with 30 μg influenza haemagglutinin in 300 μl PBS (surface area 
around 1.2 cm2) for 1 h incubation. Groups of 6 mice were immunized as 
follows: (a) PBS with solid microneedle array (300 μm-long, 4×4) treatment; (b) 
vaccine alone on untreated skin; (c) vaccine with silicon hollow microneedle 
array (245 μm-long, 4×4) treatment; (d) vaccine with silicon hollow 
microneedle array (245 μm-long, 9×9) treatment; (e) vaccine with solid 
microneedle array (300 μm-long, 4×4) treatment; (f) vaccine with 100 μg CT 
and solid microneedle array (300 μm-long, 4×4) treatment and (g) vaccine 
with 100 μg CT on untreated skin. The control group received an 
intramuscular injection of 15 µg influenza haemagglutinin in 100 μl 
physiological saline solution per mouse. 
In both studies, after 1 h incubation the mice were extensively washed with 
lukewarm tap water, patted dry and washed again. The TCI and control 
groups were boosted twice using the same protocol at day 21 and day 42 
(approximately the same skin region for the TCI groups), and sacrificed at day 
56. Blood samples were obtained from the tail vein one day before each 
immunization and total blood was collected from the femoral artery under 
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anesthesia before euthanasia. Blood samples were collected in MiniCollect® 
tubes (Greiner bio-one, Alphen a/d Rijn, The Netherlands) till clot formation 
and centrifuged 10 min at 10,000g to obtain cell-free sera, then transferred to 
new tubes as aliquots and kept at -80 ºC until further use. 
Vero cell test 
The diphtheria toxin-neutralizing antibodies in mouse sera were assessed by 
a Vero cell test as previously described [24]. Complement in the serum was 
inactivated by heating at 56 ºC for 45 min. Then 2-fold serial dilutions of 
individual sera were prepared with complete medium 199 (CM199, Gibco, 
Breda, The Netherlands) and applied to microtitre plates (50 μl/well). Then, 50 
μl diphtheria toxin, DTa 79/1 (0.0005 Lf/ml) in CM199, was added to each well. 
The plates were incubated for 2 h at 37 ºC for neutralization. Subsequently, 
50 μl CM199 with 2.5×105 Vero cells/ml was added to each well. A reference 
antitoxin as well as an untreated cell control was included in each plate. The 
plates were covered with a plate sealer and incubated at 37 ºC in 5% CO2 for 
6 days. Each well was checked for the presence of living cells by microscope. 
The neutralizing antibody titer was expressed as the dilution factor of the most 
diluted serum that still had living Vero cells.  
Serum IgG, IgG1 and IgG2a assay 
The IgG subtype profile of influenza-specific antibodies was checked on day 
20, 41 and 56 with ELISA as previously described [25]. Briefly, ELISA plates 
(Greiner, Alphen a/d Rijn, The Netherlands) were coated overnight at 4 °C 
with 200 ng/well of influenza subunit antigen (H3N2) in coating buffer (0.05 M 
sodium carbonate/ bicarbonate, pH 9.6). Plates were subsequently washed 
twice with PBS containing 0.05% Tween 20, pH 7.6 (PBST) and then blocked 
by incubation with 1% (w/v) BSA in PBST for 1 h at 37 °C. Thereafter the 
plates were washed three times with PBST. Two-fold serial dilutions of sera 
from individual mouse were applied to the plates and incubated for 2 h at 
37 °C. Plates were then washed three times with PBST and incubated with 
HRP-conjugated goat antibodies against either mouse IgG1 or IgG2a for 1.5 h 
at 37 °C. Antibodies were detected by OPD and expressed as the reciprocal 
of the calculated sample dilution corresponding with absorbance of 0.2 above 
the background at 492 nm [26]. DT specific antibodies (IgG, IgG1 & IgG2a) 
and CT-specific IgG titers were determined with the same procedure by 
coating the plate with 140 ng DT or 66.7 ng CT per well, detecting antibody by 
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TMB and measuring optical absorbance at 450 nm. If a reading was above or 
below the relevant standard curve, further measurements were taken with 
lower or higher dilutions. 
Hemagglutination inhibition (HI) assay 
Serum samples were collected on day 20, 41 and 56 after influenza TCI. HI 
assay were performed at ViroClinics (Rotterdam, The Netherlands), 
according to WHO standard procedure using haemagglutinin antigens 
representing the stains of virus included in the vaccine [27]. Two-fold serial 
dilutions of the serum samples in PBS were incubated with the titrated antigen 
solution and 1% Turkey erythrocytes. The results are given as titers, meaning 
the highest dilutions of the serum which achieves complete inhibition of 
hemagglutination. All sera were titrated simultaneously in duplicate. Detection 
limit of this assay was 10 and non-responding sera were assigned an arbitrary 
titer of half the detection limit. 
Statistical analysis 
Statistical comparisons were made using two-tailed unpaired Student’s t-test 
or one way ANOVA with Tukey post test where suitable using the software 
Prism Graphpad. A p value less than 0.05 was considered to be significant.  
Results 
In vivo evaluation of piercing in mouse skin 
In the first set of experiments, the piercing capacity of microneedle arrays in 
vivo on mouse skin was evaluated using assembled microneedle arrays (300 
to 900 µm long) and the handheld applicator. Figure 3a shows a clear trend 
between the TEWL and the needle length of the microneedle arrays, and 
demonstrated higher TEWL than those of the untreated control. 
The 4x4 microneedle arrays with a needle length > 550 µm formed patterns of 
blue dots on both the stratum corneum side and the dermal side of the skin 
while no blue spots could be observed after application of 300 μm-long ones 
(Fig. 3b). This clearly indicates that microneedle with needle lengths of 550 
µm and longer applied manually pierced the mouse skin and created conduits, 































Figure 3. Assembled microneedle arrays with needle length of 300, 550, 700 and 900 μm were 
applied by the handheld applicator on mouse skin in vivo; (a) TEWL before and after 
microneedle arrays; (mean + SD, n=3). (b) Trypan blue staining. Pictures were taken from the 
stratum corneum and the dermal side of excised mice skin. 
 
As manual piercing of 300 μm-long microneedle was not successful, it was 
decided to optimize the piercing of shorter microneedle array (i.e. ≤ 300 µm) 
by applying the array at an adjustable speed. For this an electric applicator 
was designed. A proper velocity and the sharpness of needles were expected 
to counteract the elasticity of the skin and pierce the stratum corneum more 
effectively as was already demonstrated in human skin [19]. Immediately after 
piercing, TEWL was measured (Fig. 4a). Elevated TEWL compared to the 
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control is consistent with the results obtained by the Trypan blue staining, 
namely short microneedles were able to pierce the skin when projected at the 
speed of 3 m/s. For all microneedle arrays including 245 μm-long silicon ones 
(4x4 and 9x9), blue spot arrays were clearly visible at the dermal side of the 
skin (Fig. 4b), indicating that piercing of all tested microneedle arrays was 
successful. Therefore the short microneedle arrays and the electric applicator 















































Figure 4. 245 μm-long silicon microneedle arrays (4×4 and 9×9), 300 μm-long solid and 300 
μm-long assembled microneedle arrays were applied by the electric applicator on mouse skin in 
vivo; (a) TEWL before and after microneedle arrays treatment (mean ± SD, n=3); (b) Trypan blue 
staining after treatment. Pictures were taken from the dermal side of excised mice skin. 
Dermal diphtheria vaccination 
During the in vivo studies, there was no adverse effect from the shaving, 
anesthetizing, piercing, immunization, or washing procedure observed. 
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Neither erythema nor induration was seen at the immunization site after the 
antigen exposure. 
TCI of DT was performed with or without microneedle array pretreatment, in 
the presence or absence of CT as adjuvant. Plain DT applied on intact skin 
induced low IgG titers. However, when DT was applied on microneedle 
pretreated skin, titers of all IgG subtypes were increased significantly (Fig. 5a, 
p<0.01). The presence of CT on microneedle pretreated skin (after prime, the 
1st boost and the 2nd boost) induced respectively 4, 20 and 4 fold higher IgG 
titers than those without CT. However, CT made less significant difference in 
DT-specific IgG titers on untreated skin. IgG levels of all TCI groups increased 
after each boost, while in the group of CT with microneedle pretreatment, IgG 
titers reached the maximum level after the 1st boost and remained at a plateau 
after the 2nd boost. IgG titers of this group showed the same level as 
compared to the group with DT-alum injection. The ratio of IgG1 to IgG2a 
titers indicate whether the immune responses are biased towards T helper 
type 1 (Th1) or T helper type 2 (Th2). Th2 biased immune responses were 
found in the TCI groups with microneedle pretreatment where similar 
IgG1/IgG2a ratios to the injection group were detected (Fig. 5b). It appears 
that the CT lowered the IgG1/IgG2a ratio and therefore skewed the immune 
response to Th1 direction. Without microneedle array pretreatment, no 
protective effect was induced from TCI on intact skin in the presence and 
absence of CT as indicated from the Vero cell test (Fig. 5c). However, with 
microneedle pretreatment, CT did stimulate the production of 
toxin-neutralizing antibodies. Serum samples from the group with CT and 
microneedle pretreatment contained similar toxin-neutralizing capacity 
compared to that of the DT-alum injection group (p>0.05). 
CT-specific IgG titers were also checked in this context to determine whether 
CT itself or its subunits were transported across the skin (Fig. 6). CT is a very 
immunogenic antigen and the IgG titer reached very high level after prime 
independent of microneedle array treatment and remained at a plateau. This 
demonstrates that CT or its subunits were transported across the stratum 
corneum even in the absence of microneedle array treatment. 
 













































































































Figure 5. Immune responses in mice (n=8) after DT TCI with microneedle array (300 μm-long 
solid, 4×4) pretreatment on day 0, 21 and 42. (a) DT-specific serum IgG titer measured on day 
20, 41, and 56. Non-responders were given an arbitrary value of 1. (b) DT-specific serum IgG1 
and IgG2a titers determined on day 56. Ratios of IgG1/IgG2a titers of individual mouse were 
shown as mean + SD (*IgG2a titers below detection limit). (c) Neutralizing antibody titers of 
individual mouse, as measured with Vero cell test. Data shown are the dilution factor of the most 
diluted serum sample which protects Vero cells to survive incubation with diphtheria toxin. 
(MN=microneedle array pretreatment) 


















Figure 6. CT-specific serum IgG responses in mice (n=8) following the immunization by 100 μg 
of DT and CT on day 0, 21 and 42. Antibodies were measured on day 20, 41, and 56 and data 
displayed as mean ± SD. (MN=microneedle array pretreatment) 
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Dermal influenza vaccination 
HI assay determines the titer of functional antibodies, by measuring the 
inhibition of red blood cell agglutination by influenza virus. In the influenza TCI 
study, non-adjuvanted vaccine on intact skin induced low HI titers. Different 
from DT TCI, no improvement was achieved by the application of any 
microneedle arrays (Fig. 7a). However, when CT was co-administrated as 
adjuvant, it drastically increased the immune response to influenza vaccine, 
independent of microneedle pretreatment. The presence of CT resulted in 
higher HI titers than in the absence of CT, around 8 fold after prime, 32 fold 
after the 1st boost and 8 fold after the 2nd boost, respectively. A similar trend 
was observed in IgG subtype titers as compared to HI titers (Fig. 7b & 7c). No 
differences in HI and IgG subtype titers were indicated among the groups with 
treatment of different microneedle arrays and the group without treatment. 
Discussion 
The objective of this study was to evaluate microneedle array treatment in TCI 
of DT and influenza vaccine as a potential alternative method for injection. 
The benefit from using microneedle arrays are: i) increase in antigen transport 
across the skin barrier due to the created conduits, ii) increased targeting to 
DCs in the dermis as the conduits can reach the upper part of the dermis [19] 
and/or iii) activation of the LCs and DCs, which result in an increased immune 
response. Recently, microneedle arrays have attracted considerable attention 
in the application of dermal vaccination. Studies including dermal 
administration of influenza vaccine, plasmid DNA encoding hepatitis B 
surface antigen and recombinant protective antigen of Bacillus anthracis 
resulted in immune responses at least as strong as those generated by 
subcutaneous or intramuscular injection [16, 28, 29]. Influenza intradermal 
vaccination using hollow microneedle has shown dose-sparing and been 
proven to be safe in human clinical trials [30]. Further application of 
microneedle array in dermal vaccination and transdermal drug delivery is 
promising. 
When using microneedle arrays, the microneedles should pierce the skin 
reproducibly without any pain sensation. Recently, skin irritation, pain 
sensation and skin barrier function were examined using microneedle arrays 
with a length varying between 200 and 550 μm in vivo in human volunteers 
using the same electric applicator as used in this study. The microneedle 
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arrays caused only minimal pain sensation and skin irritation, while a 
reduction in skin barrier function was observed [31]. These properties make 
the microneedle array and its applicator an excellent candidate delivery 







































































































































































































Figure 7. Immune responses in mice (n=6) after influenza TCI with microneedle arrays 
pretreatment on day 0, 21 and 42. (a) Hemagglutination inhibition was tested against influenza 
virus (H3N2) on day 20, 41 and 56 using Turkey red blood cells. Data displayed as the dilution 
factor of the most diluted serum sample that inhibits influenza agglutination (mean + SD), 
non-responding sera were assigned an arbitrary titer of 5, half of the detection limit. (b) & (c) 
Serum IgG1 & IgG2a titers against influenza subunit antigen (H3N2) were measured with ELISA 




Piercing mouse skin 
The first part of this study was to examine and validate the in vivo piercing 
capacity of various microneedle arrays (the assembled, solid and silicon 
hollow arrays with different needle lengths) using both the handheld and the 
electric applicators. The low TEWL values measured before microneedle 
array treatment but after shaving indicated that the shaving and the 70% 
ethanol wipe did not increase the permeability of the skin and the integrity was 
well preserved (Fig. 3 and 4). With the handheld applicator, piercing was only 
possible with 550 μm and longer microneedles. By using the newly designed 
electric applicator and driving microneedle arrays at the speed of 3 m/s, 300 
μm and even 245 μm long microneedles pierced mouse skin in vitro and in 
vivo in a reproducible manner, similar as observed in human skin in vitro [19]. 
This is an important observation considering that mouse skin is much more 
flexible than human skin and demonstrates that piercing with an optimal 
velocity effectively counteracts the elasticity of the mouse skin. 
Comparison of dermal DT and influenza immunization 
Microneedle array pretreatment 
Through TCI on intact skin, neither DT nor influenza vaccine induced 
substantial immune responses as indicated by low level of IgG and functional 
antibody titers. During TCI after microneedle array pretreatment, the vaccine 
has to diffuse along the conduits into the skin. However, only a fraction of the 
total dose may enter these conduits. Microneedle array pretreatment provided 
major improvement as compared to plain DT applied on intact skin, and with 
the presence of CT, it reached similar levels of serum IgG and 
toxin-neutralizing antibody titers as those of the DT-alum injection group. TCI 
with influenza presented a different result as compared to DT. The immune 
responses induced by plain vaccine were very low as indicated by the HI and 
IgG titers when compared to CT-adjuvanted vaccine, independent of 
microneedle array pretreatment. Several reasons may account for this result. i) 
Lower potency of the subunit influenza vaccine as compared to DT; ii) Lower 
concentration of vaccine applied (0.1 μg/μl influenza vaccine vs. 1.45 μg/μl 
DT); iii) The aggregates formed by the hydrophobic transmembrane domains 
of haemagglutinin trimmers may further reduce its permeation. The relatively 
low immune responses induced by plain influenza vaccine in barrier-disrupted 
skin were also reported by Garg et al. who vaccinated mouse with subunit 
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influenza vaccine (H5N1) using the PassportTM system (a patch device 
creating pores by thermal ablation) [8] and Skountzou et al. who applied 
inactivated influenza virus (WIV, PR8) on tape-stripped mouse skin pretreated 
with 70% ethanol [32]. 
Adjuvanticity of CT 
In the current study, the presence of CT played an important role in enhancing 
both immune responses. It was previously shown that CT is toxic when 
administered mucosally, while it does not exert any toxicity when applied 
transcutaneously [33]. From the results described here, the adjuvanticity of 
CT on dermal delivered vaccines is antigen dependent. It was shown by the 
Vero cell test that CT, as an adjuvant in DT dermal vaccination, failed to 
stimulate protective responses to diphtheria toxin when co-administered on 
intact skin. However, high toxin-neutralization capacity could be achieved 
when applying DT and CT on microneedle array pretreated skin. 
CT-adjuvanted influenza TCI induced substantially higher immune responses 
concerning HI as well as IgG subtype titers in the serum, which were much 
higher than those after intramuscular injection of plain vaccine. Therefore, the 
addition of CT may lead to dose sparing benefit for influenza TCI. 
Furthermore, one should be aware of the difference in efficiency of TCI when 
comparing the murine model with human. The mouse skin has much thinner 
stratum corneum with considerably higher density of hair follicles than human 
skin. The relative area of application in mice is much larger than in humans. 
TCI in mice, therefore, can be successful even without physical pretreatment 
of the skin for certain antigens. However, when moved to humans, it is more 
difficult to get a protective response [34]. Potent adjuvant as well as 
microneedle array pretreatment may be necessary to archive effective 
protection and dose sparing. 
Antigen penetration through the skin barrier 
CT is well known as a potent antigen for dermal vaccination which actually 
initiated the research on TCI [35]. The current study showed clearly that CT, 
as an antigen with MW of 84 kDa, induced high levels of CT-specific lgG titers 
without increasing skin permeability. The response to TCI of influenza vaccine 
does not rely on microneedle array pretreatment, either. In general it is stated 
that when molecules are larger than 500 Da, the skin penetration reduces 
drastically [36]. Although TCI of vaccine and adjuvant is intended for delivery 
to the more superficial epidermis, it is remarkable that CT and influenza 
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vaccine or their subunits can penetrate the stratum corneum different from DT. 
We speculate that the vaccines may diffuse through the hair follicles as it has 
been shown that particles up to 40 nm can diffuse through the hair follicular 
opening and reach epidermal LCs [37, 38]. Taking the data of influenza and 
DT vaccination together, microneedle array pretreatment and CT 
co-administration seem to involve different diffusion pathway and 
immunological mechanisms. The fact that CT is a more potent adjuvant for 
influenza subunit vaccine than for DT may be due to the properties of the 
individual antigen, e.g. pathology of the disease, antigenicity of the vaccine, 
charge of the vaccine molecule, particular status of the vaccine and the 
molecular interactions between antigen and CT. It is not fully understood and 
requires more investigation. 
 
In summary, we showed in this study that TCI can be strongly improved by 
using microneedle arrays combined with adjuvant. For DT, the microneedle 
array pretreatment is essential to obtain high antibody response, which is 
modestly augmented further by co-administration of CT. TCI of DT and CT 
after microneedle treatment results in comparable protection as injection of 
DT-alum. In contrast, for influenza vaccine, CT is very efficient in potentiating 
the immune response but does so independent of microneedle array 
pretreatment of the skin. TCI of influenza vaccine with CT is superior to the 
injection method.  
Transcutaneous immunization of diphtheria toxoid and influenza vaccine  
 73
References 
1. Glenn, GM and Kenney, RT, (2006): Mass vaccination: solutions in the skin. Curr 
Top Microbiol Immunol 304, 247-68. 
2. Glenn, GM, et al., (2003): Transcutaneous immunization and immunostimulant 
strategies. Immunol Allergy Clin North Am 23, 787-813. 
3. Banchereau, J and Steinman, RM, (1998): Dendritic cells and the control of 
immunity. Nature 392, 245-52. 
4. Kenney, RT, et al., (2004): Induction of protective immunity against lethal anthrax 
challenge with a patch. J Infect Dis 190, 774-82. 
5. Chen, D, et al., (2004): Epidermal powder immunization: cellular and molecular 
mechanisms for enhancing vaccine immunogenicity. Virus Res 103, 147-53. 
6. Gupta, PN, et al., (2005): Tetanus toxoid-loaded transfersomes for topical 
immunization. J Pharm Pharmacol 57, 295-301. 
7. Tierney, R, et al., (2003): Transcutaneous immunization with tetanus toxoid and 
mutants of Escherichia coli heat-labile enterotoxin as adjuvants elicits strong 
protective antibody responses. J Infect Dis 188, 753-8. 
8. Garg, S, et al., (2007): Needle-free skin patch delivery of a vaccine for a potentially 
pandemic influenza virus provides protection against lethal challenge in mice. Clin 
Vaccine Immunol 14, 926-8. 
9. Glenn, GM, et al., (2007): Transcutaneous immunization with heat-labile 
enterotoxin: development of a needle-free vaccine patch. Expert Rev Vaccines 6, 
809-19. 
10. Zhao, YL, et al., (2006): Induction of cytotoxic T-lymphocytes by 
electroporation-enhanced needle-free skin immunization. Vaccine 24, 1282-90. 
11. Ogura, M, et al., (2008): Low-frequency sonophoresis: Current status and future 
prospects. Adv Drug Deliv Rev 60, 1218-23. 
12. Frech, SA, et al., (2008): Use of a patch containing heat-labile toxin from 
Escherichia coli against travellers' diarrhoea: A phase II, randomised, double-blind, 
placebo-controlled field trial. Lancet 371, 2019-2025. 
13. Gerstel, MS and Place, VA, Drug delivery device. 1976: US. 
14. Henry, S, et al., (1999): Microfabricated microneedles: A novel approach to 
transdermal drug delivery. J Pharm Sci 88, 948. 
15. Prausnitz, MR, (2004): Microneedles for transdermal drug delivery. Adv Drug Deliv 
Rev 56, 581-7. 
16. Mikszta, JA, et al., (2006): Microneedle-based intradermal delivery of the anthrax 
recombinant protective antigen vaccine. Infect Immun 74, 6806-10. 
17. Widera, G, et al., (2006): Effect of delivery parameters on immunization to 
ovalbumin following intracutaneous administration by a coated microneedle array 
patch system. Vaccine 24, 1653-64. 
18. Verbaan, FJ, et al., (2007): Assembled microneedle arrays enhance the transport of 
compounds varying over a large range of molecular weight across human 
dermatomed skin. J Control Release 117, 238-45. 
19. Verbaan, FJ, et al., (2008): Improved piercing of microneedle arrays in dermatomed 
human skin by an impact insertion method. J Control Release 128, 80-8. 
Chapter 3 
 74
20. Scharton-Kersten, T, et al., (1999): Principles of transcutaneous immunization using 
cholera toxin as an adjuvant. Vaccine 17 Suppl 2, S37-43. 
21. Scharton-Kersten, T, et al., (2000): Transcutaneous immunization with bacterial 
ADP-ribosylating exotoxins, subunits, and unrelated adjuvants. Infect Immun 68, 
5306-13. 
22. Upadhyay, P, (2006): Enhanced transdermal-immunization with diphtheria-toxoid 
using local hyperthermia. Vaccine 24, 5593-8. 
23. Metz, B, et al., (2003): Physicochemical and immunochemical techniques predict 
the quality of diphtheria toxoid vaccines. Vaccine 22, 156-67. 
24. Miyamura, K, et al., (1974): Micro cell culture method for determination of 
diphtheria toxin and antitoxin titres using VERO cells. II. Comparison with the 
rabbit skin method and practical application for seroepidemiological studies. J Biol 
Stand 2, 203-9. 
25. de Haan, L, et al., (2001): Nasal or intramuscular immunization of mice with 
influenza subunit antigen and the B subunit of Escherichia coli heat-labile toxin 
induces IgA- or IgG-mediated protective mucosal immunity. Vaccine 19, 2898-907. 
26. Verweij, WR, et al., (1998): Mucosal immunoadjuvant activity of recombinant 
Escherichia coli heat-labile enterotoxin and its B subunit: induction of systemic IgG 
and secretory IgA responses in mice by intranasal immunization with influenza virus 
surface antigen. Vaccine 16, 2069-76. 
27. WHO Collaborating Center for Influenza Viruses. Version 31. 1981. 
28. Mikszta, JA, et al., (2005): Protective immunization against inhalational anthrax: a 
comparison of minimally invasive delivery platforms. J Infect Dis 191, 278-88. 
29. Mikszta, JA, et al., (2002): Improved genetic immunization via micromechanical 
disruption of skin-barrier function and targeted epidermal delivery. Nat Med 8, 
415-9. 
30. Van Damme, P, et al., (2009): Safety and efficacy of a novel microneedle device for 
dose sparing intradermal influenza vaccination in healthy adults. Vaccine 27, 454-9. 
31. Bal, SM, et al., (2008): In vivo assessment of safety of microneedle arrays in human 
skin. Eur J Pharm Sci 35, 193-202. 
32. Skountzou, I, et al., (2006): Transcutaneous immunization with inactivated influenza 
virus induces protective immune responses. Vaccine 24, 6110-9. 
33. Godefroy, S, et al., (2005): Effect of skin barrier disruption on immune responses to 
topically applied cross-reacting material, CRM(197), of diphtheria toxin. Infect 
Immun 73, 4803-9. 
34. Frech, SA, et al., (2005): Improved immune responses to influenza vaccination in the 
elderly using an immunostimulant patch. Vaccine 23, 946-50. 
35. Glenn, GM, et al., (1998): Skin immunization made possible by cholera toxin. Nature 
391, 851. 
36. Bos, JD and Meinardi, MM, (2000): The 500 Dalton rule for the skin penetration of 
chemical compounds and drugs. Exp Dermatol 9, 165-9. 
37. Toll, R, et al., (2004): Penetration profile of microspheres in follicular targeting of 
terminal hair follicles. J Invest Dermatol 123, 168-76. 
38. Vogt, A, et al., (2006): 40 nm, but not 750 or 1,500 nm, nanoparticles enter 
epidermal CD1a+ cells after transcutaneous application on human skin. J Invest 








Immune modulation by adjuvants combined with 
diphtheria toxoid administered topically in BALB/c mice 




Zhi Ding1, 3, Elly Van Riet1, Stefan Romeijn1, Gideon F.A. Kersten2, Wim 
Jiskoot1 and Joke A. Bouwstra1 
 
1 Department of Drug Delivery Technology, Leiden/Amsterdam Centre for Drug Research, 
2333 CC, Leiden, The Netherlands 
3 Department Research and Development, Netherlands Vaccine Institute (NVI), Bilthoven, 
The Netherlands 
4 State Key Laboratory of Pharmaceutical Biotechnology, Biochemistry Department Nanjing 
University, Nanjing 210093, PR China 
 




Currently, most vaccines are administrated by injection. Costs, risks and 
discomforts associated with the use and abuse of needles have boosted 
research on needle-free vaccinations [1]. Around ten years ago, Glenn et al. 
reported for the first time data on transcutaneous immunization (TCI) and 
showed that strong immune responses could be induced by topically applied 
cholera toxin [2]. TCI is particularly attractive because of the high accessibility 
of the skin and the presence of antigen-presenting cells (APCs) in the 
epidermis and dermis, in particular the Langerhans cells (LCs) and the dermal 
dendritic cells (DCs) [3]. However, the upper layer of the skin, the stratum 
corneum, acts as a barrier for diffusion of macromolecules and therefore is a 
major obstacle to dermal vaccine delivery. To overcome this barrier and 
achieve effective TCI, physical methods such as intradermal injection [4, 5], 
thermal ablation [6], microdermabrasion [7] electroporation [8] and 
cavitational ultrasound [9] have been used. Physical disruption of the skin 
barrier increases the percutanous penetration of the antigen and makes the 
antigen more readily available for sampling by APCs [10]. Moreover, 
disruption of the skin barrier may induce a chain of molecular events that lead 
to the secretion of pro-inflammatory cytokines and facilitate APC activation.  
A relatively novel approach to disrupt the skin barrier in a controlled manner 
with little pain sensation is the use of microneedle arrays. It was proposed first 
by Gerstel and Place already in the 1970s [11]. Ten years ago, when the 
technology for fabrication in micron dimensions became readily available, 
Prausnitz resumed the study using microneedle arrays in transdermal drug 
delivery [12]. When used as a pretreatment, microneedle arrays enable 
antigens to diffuse along the transiently formed tiny conduits through the 
stratum corneum. Thereby antigens may be able to approach the LCs in the 
epidermis and the DCs in the dermis [13]. Using an ovalbumin-coated 
microneedle array, Matriano et al. evaluated the uniformity of skin piercing, 
and studied the dose of the vaccine used and the kinetics and magnitude of 
antibody titers induced in hairless guinea pigs [14]. Widera et al. investigated 
the influence of important fabrication parameters, e.g. length and density of 
the microneedles, area and coating of the microneedle arrays, on vaccination 
efficiency of TCI [15]. Hooper et al. reported that smallpox DNA 
vaccine-coated microneedle arrays applied topically in combination with 
electroporation protected mice against lethal challenge [16]. Recently, Van 
Damme et al. tested the injectable microneedle array in human volunteers 
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using influenza vaccine, resulting in a comparable seroprotection rate as 
compared to i.m. injection with 5 fold dose sparing [17]. These interesting 
results show that TCI using microneedle arrays is promising. However, after 
more than ten years of extensive research [18, 19], there continues to be a 
need for further improvement of microneedle array mediated TCI, e.g. by 
using potent adjuvants or novel ways of applying the microneedle arrays. 
Recently a new electric applicator was developed in our lab. It is designed to 
insert microneedle arrays into the skin with a predetermined velocity and 
thereby counteracts the elasticity of the skin. This applicator enables us to 
reproducibly pierce human and mouse skin in vivo with microneedles with a 
length of 300 μm or less [18]. DT was recruited as a model antigen to evaluate 
the potential of microneedle array pretreatment in TCI. We mentioned in 
Chapter 3 that the immunogenicity of topically applied DT was dramatically 
improved by microneedle array pretreatment as compared to untreated skin. 
 








Cholera toxin Exotoxin +1 +++ GM1 ganglioside
lpxL1 LPS Endotoxin ++ ++ TLR4 
Quil A Saponin based +++ ++ Not identified 
CpG Bacterial DNA ++++ + TLR9 
Alum Inorganic salt + +++ Not identified 
1 Humoral and cellular immunity in arbitrary units represent the ability of adjuvants to enhance 
Th2 response or Th1, respectively, to foreign antigens. 
 
The objective of the present study was to determine the effect of adjuvants on 
the quantity and quality of the immune response against DT after TCI on 
microneedle-pretreated skin. The Th1/Th2 balance of the immune response 
depends on several factors including the nature of the antigen and the 
adjuvant, the delivery route and the targeted APCs, as suggested by the ratio 
of IgG1/IgG2a antibody titers [19]. The adjuvants included in this study, 
cholera toxin (CT), lipopolysaccharide (LPS), synthetic oligo deoxynucleotide 
containing a CpG motif (CpG), immunostimulatory fractions extracted from 
the bark of the tree Quillaja saponaria (Quil A) and aluminum phosphate 
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(alum), differ in their adjuvant mechanism and ability to modulate the immune 
response (see Table I) [19]. Immune modulation by these adjuvants was 
evaluated in TCI on microneedle-pretreated skin and compared with 
conventional subcutaneous (s.c.) injection of DT or DT-alum, by measuring 
serum IgG (subtype) titers and neutralizing antibody titers. 
Materials and methods 
Materials 
Diphtheria toxin (batch 79/1), diphtheria toxoid (batch 98/40, protein content 
12.6 mg/ml by BCA assay, 1 μg equal to approximately 0.3 Lf) and the lpxL1 
LPS were provided by the Netherlands Vaccine Institute (NVI, Bilthoven, The 
Netherlands). Horseradish peroxidase-conjugated goat anti-mouse 
(HRP-GAM) IgG (γ-chain specific), IgG1 (γ1-chain specific) and IgG2a 
(γ2a-chain specific) were purchased from Southern Biotech (Birmingham, 
USA). Quil A and Adju-Phos® (alum) were obtained from Brenntag Biosector 
(Copenhagen, Denmark). CpG oligo deoxynucleotide 1826 (5'-tcc atg acg ttc 
ctg acg tt-3', phosphorothioated) was synthesized by Isogen Biosolutions 
(IJsselstein, The Netherlands). Chromogen 3, 3', 5, 5'-tetramethylbenzidine 
(TMB) and the substrate buffer were purchased from Biosource B.V. (Nivelles, 
Belgium). Cholera toxin was ordered from Sigma-Aldrich (Zwijndrecht, The 
Netherlands). Nimatek® (100 mg/ml ketamine, Euovet Animal Health B.V., 
Bladel, The Netherlands), Rompun® (20 mg/ml xylasine, Bayer B.V., Mijdrecht, 
The Netherlands) and the injection fluid (0.9% NaCl) were obtained from a 
local pharmacy. All other chemicals used were of analytical grade and all 
solutions were prepared with distilled water. 
Animals 
Female BALB/c mice (H2d), 8-week old at the start of the experiment were 
purchased from Charles River (Maastricht, The Netherlands), and maintained 
under standardized conditions in the animal facility of the Leiden/ Amsterdam 
Center for Drug Research, Leiden University. The study was conducted in 
conformity with the Public Health Service Policy on use of laboratory animals 
and had been approved by the Research Ethical Committee of Leiden 
University (UDEC, nr. 07016). 
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Methods 
Microneedle array and applicator 
Assembled microneedle arrays were manufactured from commercially 
available 30G hypodermic needles (BD, Alphen a/d Rijn, The Netherlands) as 
described previously [13]. The needles were assembled as a 300 µm-long, 
4×4 array on a polymer back plate with a surface area of about 0.5 cm2. The 
electric applicator was developed and optimized as mentioned in Chapter 3. 
The microneedles were pierced into mouse skin using a velocity of 3 m/s. 
Immunization study 
The DT-alum formulations were prepared as previously described and the 
adsorption of DT to alum was between 70% and 80% [22]. As control groups, 
5 µg of DT (~1.5 Lf) with and without alum in 100 µl solution/suspension was 
administered per mouse by s.c injection. The other vaccine-adjuvant 
formulations were freshly prepared by mixing DT and the adjuvants in buffer 
solution in appropriate amounts as indicated in Table II. 100 µg DT and 
adjuvants per mouse were applied on intact or microneedle-pretreated skin as 
described in Chapter 3. A mutant of LPS, lpxL1 LPS, with reduced toxicity but 
retained adjuvanticity, was employed in this study [23]. The dose of alum and 
lpxL1 LPS used in TCI were based on the w/w ratio of antigen/adjuvant used 
in the injection control group and a previous immunization study, 
respectively [23]. 
During vaccination, mice were anaesthetized by intraperitoneal injection of 
150 mg/kg ketamine and 10 mg/kg xylazine. For all groups receiving 
transcutaneous vaccination, the abdominal skin of the mice, shaved 24 h prior 
to vaccination, was first wiped with 70% ethanol. For TCI group with 
microneedle pretreatment, a skin fold was supported by styrofoam and 
pierced using the microneedle array and the electric applicator. Then 70 μl 
DT-adjuvant formulation was carefully spread to wet the entire skin area of 
application (microneedle array-pretreated or untreated, ~2 cm2 area restricted 
by a metal ring). After 1 h of occlusive incubation, the skin area was 
extensively washed with lukewarm tap water and patted dry twice. All mice 
were immunized three times on day 1, 21 and 42 (at approximately the same 
skin region for all the TCI groups) and sacrificed on day 56. Blood was 
sampled from the tail vein one day before each immunization and the whole 
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blood was collected from the femoral artery during sacrifice. Cell free sera 
were obtained using MiniCollect® tubes (Greiner Bio-one, Alphen a/d Rijn, 
The Netherlands) by centrifugation after clot formation and stored at -80 ºC. 
 
Table II. Formulations prepared for TCI study 
 
DT Dose (µg) Adjuvants Adjuvant Dose (µg) Solvent (pH) Volume (µl) 
For s.c. injection 
5 AlPO4 150 0.9% Saline (7.0) 100 
5 -- -- 0.9% Saline (7.0) 100 
For TCI 
100 -- -- PBS1(7.4) 70 
100 lpxL1 LPS 25 PBS/Tris2 (7.4) 70 
100 Quil A 100 PBS (7.4) 70 
100 CT 100 PBS (7.4) 70 
100 CpG 100 PBS (7.4) 70 
100 AlPO4 3000 0.9% Saline (7.0) 70 
 
1 PBS: 2.67 mM KCl, 1.47 mM KH2PO4, 137.93 mM NaCl, 8.06 mM Na2HPO4·7H2O 
2 PBS/Tris: PBS mixed with 1 mM Tris-HCl (v/v=5:3) 
Serum antibody assay 
Serum IgG, IgG1 and IgG2a titers were determined with ELISA as previously 
described [24]. Briefly, ELISA plate (Microlon®, Greiner Bio-one, Alphen a/d 
Rijn, The Netherlands) wells were coated with DT at 4°C overnight. Two-fold 
serial dilutions of serum samples were applied in the plates and the 
containing DT-specific antibodies were detected by HRP-GAM IgG, IgG1 or 
IgG2a using TMB as substrate. Antibody titers are expressed as the 
reciprocal of the calculated sample dilution corresponding to half of the 
maximum absorbance at 450 nm of a complete s-shaped absorbance-log 
dilution curve. If samples were not diluted in the optimal range, additional 
measurements were performed to generate an s-shaped curve. Subsequently, 
the titers were calculated using a four-parameter fitting of the curve. Samples 
that did not reach the half-saturated absorbance value at the lowest (ten fold) 
dilution were considered as non-responders. 
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Neutralizing antibody assay  
Immunity against diphtheria depends on the presence of circulating 
toxin-neutralizing antibodies. These antibodies were evaluated using Vero 
cell test, the WHO standard method to assess the success of diphtheria 
vaccination, which relies on the inhibition of a cytotoxic dose of diphtheria 
toxin [24]. In brief, after complement inactivation, two-fold serial dilutions of 
serum samples were prepared with complete medium 199 (CM199, Gibco, 
Breda, The Netherlands) and applied to microtiter plates (CELLSTAR®, 
Greiner Bio-one, Alphen a/d Rijn, The Netherlands). Subsequently, 2.5×10-5 
Lf diphtheria toxin was added to the wells. After 2 h incubation at 37 ºC for 
neutralization, Vero cells suspension in CM199 was added to each well. 
Covered with a plate sealer, Vero cells were incubated at 37 ºC in 5% CO2 for 
6 days. The end point was taken as the highest serum dilution protecting the 
Vero cells. 
Statistical analysis 
ELISA titers were logarithmically transformed for better normality before 
statistical analysis. Two-way ANOVA with Bonferroni posttest, one way 
ANOVA with Tukey posttest, or Kruskal-Wallis nonparametric test with Dunns 
posttest were performed as indicated. Statistical analysis was carried out 
using Prism (Graphpad, San Diego, USA) and a p value less than 0.05 was 
considered to be significant. 
Results 
During the immunization study, there was no adverse effect from the shaving, 
anesthesia, piercing, immunization, or washing procedure observed. Neither 
erythema nor induration was seen at the immunization site after exposure of 
antigen and adjuvants.  
Immune response improved by microneedle array pretreatment 
The IgG titers of mice from all groups after prime, 1st boost and 2nd boost (day 
20, 41 and 56) are shown in Fig. 1a-e and an overview of the DT-IgG titers 
after the 2nd boost is shown in Fig. 1f. It is clear that non-adjuvanted DT did 
not result in a substantial IgG response when applied on intact skin (TCI). 
Microneedle array pretreatment provided major improvement to the 
immunogenicity of DT. After prime, more mice responded with higher mean 
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IgG titers in the presence of microneedle array pretreatment in the TCI groups. 
After the 1st boost, all mice of those groups responded and the IgG titers were 
100 fold higher as compared to TCI on intact skin (p<0.01) and the difference 
of IgG titers was further increased to over 1000 fold after the 2nd boost 
(p<0.001, Fig. 1a). Immunogenicity of DT was further improved by the 
co-administered adjuvants e.g. Quil A, CpG and CT. The improvement by the 
adjuvant in question is indicated by the space in between the black and the 
brown lines in Fig. 1b, 1c, 1d and 1e, respectively. DT-specific IgG titers in the 
CT group after the 2nd boost were the highest among all TCI groups and 
reached levels very close to those from DT-alum injection group (p>0.05). For 
the adjuvants in the absence of microneedle array pretreatment, their effects 
on the DT immunogenicity were more variable and less pronounced. Only CT 
moderately improved the IgG titers after the 2nd boost (Fig. 1a and 1e, p<0.05), 
while the presence of the other adjuvants did not augment the IgG titers 
significantly. Comparing the two injection control groups, alum speeded up 
IgG development and increased the IgG titers significantly (p<0.001 after 1st 
boost). However, when DT-alum was applied on microneedle-pretreated skin, 
no adjuvanticity was observed as the IgG titers were lower than those of plain 
DT (data not shown). 
Immune modulation by adjuvants in TCI on microneedle-pretreated skin 
Focusing on the TCI with microneedle pretreatment, immune modulation 
functions of the adjuvants were investigated. The DT-specific IgG1 and IgG2a 
titers in the sera collected after prime, the 1st boost and the 2nd boost (day 21, 
42 and 56) were determined (Fig. 2). For all adjuvants, IgG1 showed similar 
titers as compared to the total IgG titers and each vaccination showed a 
booster effect. After the 1st boost, Quil A and CT enhanced the IgG1 titers 
significantly as compared to plain DT (p<0.01 and 0.001, respectively). After 
the 2nd boost, only CT significantly enhanced the IgG1 titers as compared to 
plain DT (p<0.01). A clear effect of the adjuvants on the IgG2a titers was 
observed after the 2nd boost, which increased in the following sequence: plain 
DT, LPS, Quil A, CT and CpG. 
The IgG1/IgG2a ratio, which is considered a measure for the Th1/Th2 
balance of the immune response [25], of individual mice from each group after 
the 2nd boost was calculated and presented in Fig. 3. Plain DT and DT-alum 
induced an Th2 biased response when delivered via s.c. injection. Applying 
plain DT by the microneedle-mediated TCI induced the same IgG1/IgG2a 
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ratio as by s.c. injection. With adjuvants, the ratio decreased in the following 
sequence: plain DT, Quil A, CT and CpG, suggesting that the Th2 biased 
immune response induced by plain DT was skewed towards the Th1 
direction. 
 












































































































































Figure 1. DT-specific IgG titers to transcutaneously delivered DT with and without microneedle 
pretreatment of the skin: (a) Plain DT; (b) DT + LPS; (c) DT+ Quil A; (d) DT + CpG; (e) DT + CT. 
Sera were collected after prime, the 1st and 2nd boost (day 20, 41 and 56) and antibodies were 
determined with ELISA. TCI with DT+LPS was not carried out. An overview of the DT-specific 
IgG titers after the 2nd boost from the microneedle-mediated TCI are shown in (f). Data are 
shown as mean + SD (n=8). Non-responders were given an arbitrary titer of 10. 





























































































Figure 2. DT-specific IgG1 and IgG2a titers. Sera were collected after prime, the 1st and 2nd 
boost (day 20, 41 and 56) and antibodies were determined with ELISA. Data shown as mean + 
SD (n=8). Non-responders were given an arbitrary titer of 1. (* p<0.05, ** p<0.01, *** p<0.001, 
two way ANOVA with Bonferroni posttest) 
 

















Figure 3. DT-specific IgG1/IgG2a ratios of individual mouse. Sera were collected on day 56, 
DT-specific IgG1 and IgG2a titers were measured with ELISA. IgG1/IgG2a ratios were 
calculated only using IgG2a responders. Data shown as mean + SD (n=8, ** p<0.01 and *** 
p<0.001, one-way ANOVA with Tukey posttest). 
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Figure 4. Diphtheria toxin-neutralizing antibody titers. Serum samples were collected after the 
2nd boost (day 56) and determined with Vero cell test. Data are expressed as logarithm of the 
highest dilution that was still capable of protecting the Vero cells from the challenge of diphtheria 
toxin. (-●-: the TCI groups, -○-: the injection groups, * p<0.05, ** p<0.01, *** p<0.001, 
Kruskal-Wallis nonparametric test with Dunns posttest) 
Protective immunity of DT in TCI with microneedle pretreatment 
The protective immunity of DT with the serial of immune modulators was 
evaluated using the Vero cell test (Fig. 4). Although for LPS, Quil A and CpG 
groups the neutralizing antibody titers were not significantly different from 
those for plain DT, improvement was seen for the CT group (p<0.05). The 
mean titer was very close to that of the DT-alum injection group, and the 
difference was not significant (p>0.05). As expected, the groups that had 
received formulations on untreated skin (TCI) did not show detectable 
neutralizing antibody titers.  
Discussion 
This is the first study in which the immune modulatory activity of several 
known adjuvants was directly compared in TCI with microneedle array 
pretreatment, using DT as a model antigen. In this study, we first compared 
the immune responses of DT formulated with different adjuvants in TCI on 
intact or microneedle-pretreated skin. Then we focused our study on the 
modulation capability of these adjuvants to the immune responses of the 
latter. 
Application of DT on intact skin did not induce a substantial immune response 
in the absence or presence of the tested adjuvants. The poor penetration of 
DT across the stratum corneum seems to be the limiting factor, since the 
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antibody titers of DT in TCI was strongly increased by microneedle array 
pretreatment. The skin barrier disruption and increased DT diffusion across 
the stratum corneum provided remarkable improvement to the immune 
response via TCI, similar as the tape-stripping method, however, through a 
practically easier and more controllable approach [26]. Co-administration of 
adjuvants was able to further augment the immunogenicity of DT and 
demonstrated marked differences between the immune stimulatory activities 
of the adjuvants. In the following section, the tested adjuvants are discussed 
individually concerning their mechanism of action and the role of the delivery 
route in the augmentation and modulation of DT immune response.  
CT is a molecule with five nontoxic B subunits (CTB) surrounding a single, 
toxic A fragment (CTA). Both the CTB-mediated specific binding to the GM1 
ganglioside receptors and the ADP-ribosyltransferase activity of CTA have 
been reported to be of importance for the immune stimulatory properties of 
CT [27, 28]. Whereas CT is a well-documented Th2 immune modulator in 
conventional and mucosal vaccination [28], our results point to a more Th1 
biased response against DT when co-administered with CT on 
microneedle-pretreated skin. The Th1 skewing of CT in TCI was also reported 
by Stickings et al. using mutant diphtheria toxin, CRM197, as model 
antigen [29] and by Skountzou et al. using influenza vaccine [30]. This 
suggests that the Th1 skewing of CT is delivery-route dependent. Studies 
performed by Anjuere et al. using ovalbumin as prototype antigen clarified 
that CTB suppresses systemic Th1 responses when given by a mucosal route, 
but potentiates these responses when administered by TCI [31]. This finding 
underscores the role of the epithelial microenvironment in the regulation of 
immune responses and reflects the DC heterogeneity between mucosal 
tissue and skin. 
The signaling of CpG starts by engagement of Toll-like receptor 9 (TLR9), 
followed by induction of pro-inflammatory cytokine (e.g. IL-12, TNF-α and 
IFN-γ) expression, and results in a Th1 biased response [32]. In our present 
study, CpG induced the highest IgG2a titers among all TCI groups and our 
results strongly support a skewing of the Th1/Th2 balance towards the Th1 
direction, similar to the immune modulatory effect of CpG in mucosal and 
injection vaccination. Although at the site of application TLR9 is not 
constitutively expressed by the LCs, it is almost exclusively expressed by the 
keratinocytes in the upper and most differentiated layer of the epidermis. 
Their TLR9 expression and reactivity to CpG is reported to be greatly 
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up-regulated by transforming growth factor (TGF-α), a growth and 
differentiation factor present after skin barrier disruption and during wound 
healing [33].  
Quil A is composed of immune stimulatory fractions extracted from the bark of 
the tree Quillaja saponaria. The Quil A concentration (1.43 mg/ml) used in the 
applied formulation was well above its reported critical micelle concentration 
of 0.3 mg/ml [34]. The average particle size of the DT-Quil A dispersion in 
PBS was about 56 nm with a PDI of 0.10, as measured by dynamic light 
scattering. Quil A is a potent Th1 biased adjuvant when given by i.m. injection 
[35]. In the current study, it improved the IgG titers marginally as compared to 
the non-adjuvanted DT (p<0.05 after the 1st boost; p>0.05 after the 2nd boost). 
The ratios of anti-DT IgG1/IgG2a titers were significantly lowered as 
compared to plain DT (p<0.01), suggesting that it skewed the response 
towards the Th1 direction. 
LPS, major outer membrane constituent of Gram-negative bacteria, 
stimulates APCs through TLR4, induces high levels of pro-inflammatory 
cytokines and usually leads to a strong Th1 response [36]. The DT- lpxL1 LPS 
dispersion applied in our study had a bigger average particle size than Quil A, 
about 300 nm with a PDI of 0.45, indicating that relatively large complexes 
had been formed. The effect of the lpxL1 LPS mutant on the anti-DT IgG, 
IgG1, IgG2a and the neutralizing antibody titers was not significant (p>0.05). 
This may be due to the following factors: i) LCs do not express TLR4 and do 
not respond to bacteria or LPS [37]. TLR4 expression by mouse keratinocytes 
also seems limited. Besides few data available from mice, reports on TLR4 
expression by human keratinocytes are conflicting [38, 39]; ii) Although little is 
known about the actual diffusion of these dispersions across the conduits 
induced by the microneedles, previous studies of our group showed that 
fluorescently labeled particles of ca. 200 nm did pass through the conduits 
created by the same microneedle arrays as used in the present study [18]. 
However, as no quantitative information is available, it is possible that only a 
limited amount of the DT-lpxL1 LPS dispersion reached the DCs in the dermis; 
iii) the LPS mutant may work in a less efficient way as the original LPS in the 
epidermal/dermal microenvironment. Further studies are required to elucidate 
the exact mechanism. The different reactivity of skin immune system to CpG 
and LPS may be involved in a strategic control of host defense to the bacterial 
commensal skin flora [37]. 
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Alum did not show any adjuvanticity when applied on microneedle-pretreated 
skin. It induced lower IgG and IgG1 titers than those of non-adjuvanted DT 
group after each vaccination. Furthermore, alum did not induce detectable 
IgG2a titers and provided no protection in the Vero cell test after the 2nd boost 
(data not shown). This may partially be due to the size of DT-alum particles, 
several microns in diameter, which prevents their diffusion through the 
conduits in sufficient amount to exert a ‘depot’ effect [40]. The adjuvanticity of 
alum could also be dependent on the epithelial microenvironment; the danger 
signal it induces through injection, the uric acid production [41], may not be 
provoked in the dermis and epidermis. 
Interestingly, when comparing IgG subtype titers and neutralizing antibody 
titers between CpG and Quil A groups (Fig. 1 and Fig. 4), the CpG group, with 
similar IgG titers, but much higher IgG2a titers than the other, induced similar 
to slightly lower neutralizing antibody titers, which indicates that IgG2a might 
not contribute to toxin-neutralization. This was confirmed by the comparison 
between CpG and CT groups, also showing that higher IgG2a titers did not 
result in higher neutralizing antibody titers. IgG1 seems to be the main 
neutralizing antibody for protection, as IgG1 titers significantly correlated with 
neutralizing titers. However, IgG1 titers could not be used to predict individual 
neutralizing antibody titers with great accuracy, which is in line with a 
diphtheria vaccination study done in human infants [42]. Therefore, from an 
application perspective, CpG is more suitable for anti-viral immune responses 
such as influenza vaccination where IgG2a provides the main immune 
protection and a Th1 biased response is more desired [43].  
In this study, a high dose of DT, 20 times of that used in the s.c. injection 
group, was applied onto the skin. It is the same as the dose of DT used by 
Glenn et al. in previous studies [26, 48]. High doses were used to ensure 
sufficient delivery and high antigen concentration. In fact, only a fraction of DT 
applied actually enters epidermis/dermis. A limiting factor for diffusion of the 
antigen into the skin is that the mice used for this study can only be kept 
under anesthesia for about one hour. This is not a limitation of the 
transcutaneous route, but a limitation of the animal model used. The high 
doses used until now also indicate that formulation improvement to increase 
the efficiency of vaccination is necessary. Conjugation and encapsulation of 
adjuvants into vaccine-containing particles and specific DC and LC targeting 
approaches could be attractive strategies to further improve the potency of 
vaccine formulations for TCI.  
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Conclusion 
We have shown that the type of adjuvant used has a significant effect on the 
immune response and protective immunity against DT in TCI. The epithelial 
microenvironment and DC heterogeneity also play an important role in the 
regulation of the immune response. This delivery method is applicable to 
many other vaccines by formulating with proper adjuvants and holds a lot of 
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Although vaccination via the needle has led to tremendous advances in the 
control of many infectious diseases [1], there is an increasing demand for 
non-invasive vaccine delivery. Pediatric vaccine program is the best example 
where a high number of antigens need to be introduced in a short period of 
time, leading to complex antigen mixtures and many injections. One of the 
promising routes for non-invasive vaccine delivery is the transcutaneous route, 
as the skin is a highly immune active organ and easily accessible. Human 
skin is composed of three layers, from the surface down, the stratum corneum, 
the epidermis and the dermis. The epidermis has a dense population of bone 
marrow-derived dendritic cells, referred to as Langerhans cells. These 
Langerhans cells, which travel to the draining lymph nodes after activation, 
are highly efficient antigen presenting cells [2, 3]. They are the targets of 
transcutaneously delivered vaccines.  
A major hurdle for successful transcutaneous immunization (TCI) is the 
barrier function of the skin, which resides in the uppermost layer, the stratum 
corneum. This layer is composed of dead, cornified, tightly packed 
keratinocytes embedded in lipid lamellar regions. This layer is considered to 
be only minimally permeable for high-molecular-weight substances, such as 
antigens [4], while chemical penetration enhancers and also physical means, 
such as iontophoresis, only have shown success in delivering small 
molecules across the skin barrier [5]. Therefore, the greatest challenge in TCI 
is improving the transport of antigens across the stratum corneum. Recently, 
several studies have reported that the use of antigen-containing occlusive 
patches induced strong immune responses in an animal model and human 
volunteers. [6-8]. However, successful vaccination largely depends on the 
antigen type and very high antigen doses have been used in these occlusive 
patch studies. Therefore, there is still an urgent demand to improve the 
delivery of antigens into the skin. 
One promising approach for transcutaneous delivery of antigens is the use of 
vesicular formulations, especially elastic vesicles that have highly deformable 
bilayers [9, 10]. For instance, hepatitis B surface antigen (HBsAg)-loaded 
elastic liposomes applied onto intact mouse skin elicited robust systemic and 
mucosal antibody responses against HBsAg [11]. Transfersomes® composed 
of soybean phosphatidylcholine, sodium cholate and sodium dodecyl sulfate 
have also been used in TCI studies. Successes were achieved with these 
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vesicles in combination with antigens such as human serum albumin [12], gap 
junction proteins [13] and tetanus toxoid [14] in murine models. Depending on 
the antigen type, dose, immunization schedule, presence of co-stimulatory 
factors and vesicle composition, immunization with antigen formulations 
based on elastic vesicles can induce effective immune responses with serum 
IgG levels comparable to those obtained after subcutaneous injection. 
A new generation of elastic vesicles were introduced 10 years ago [15], 
consisting of the bilayer-forming surfactant L-595 (sucrose-laurate ester) and 
the micelle-forming surfactant PEG-8-L (octaoxyethylene-laurate ester). 
These elastic vesicles were able to penetrate pores much smaller than their 
diameter [16]. Recently, it was suggested that these elastic vesicles may act 
as carrier systems; after non-occlusive application elastic vesicles and bound 
fluorescent label followed the same route of penetration into the stratum 
corneum and intact vesicle structures have been visualized in the stratum 
corneum [17]. Furthermore, transport studies of small drugs such as pergolide, 
lidocaine, ketorolac and rotigotine [18-21] demonstrated that higher transport 
rates of these drugs, compared to the same drug in buffer solutions or with 
rigid vesicles, can only be achieved when drug molecules are physically 
associated with the elastic vesicles. The drug-loaded elastic vesicles were 
applied non-occlusively since the trans-epidermal osmotic gradient is 
believed to be the driving force for the transport [22]. As these vesicles act as 
drug carrier systems for low-molecular-weight drugs, they may hold promise 
as antigen delivery systems by enhancing antigen partitioning and 
transporting to the deeper layers of the stratum corneum. If intact 
antigen-loaded vesicles are in the stratum corneum close to the viable 
epidermis, the antigen might be released and diffuse into the viable epidermis 
and, after reaching the Langerhans cells, trigger an immune response.  
The aim of the current study was to develop DT-containing elastic vesicle 
formulations for TCI. DT was chosen as a model antigen, since it has been 
used in murine models for TCI studies in combination with mucosal adjuvants 
[23, 24], physical methods such as electroporation [25] and local 
hyperthermia [26]. However, DT alone cannot induce protective immunity 
when applied on intact mouse skin because of the low intrinsic 
immunogenicity of plain DT and/or the insufficient amount of DT delivered via 
the skin [23]. One approach to improve the delivery of DT through the skin 
and make it more immunogenic is utilizing carrier systems such as elastic 
vesicles. As elastic vesicles act as carrier, physical association of DT with the 
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vesicles is expected to be crucially important. Therefore, in the current study, 
the vesicle composition, DT concentration, pH and buffers were optimized to 
obtain high DT association levels as well as good colloidal stability of the 
DT-vesicle formulations. 
Materials and methods 
Materials 
Diphtheria toxoid (MW: 58 kDa; isoelectric point about 4.7), horse anti-DT and 
horse radish peroxidase conjugated anti-DT were provided by the NVI 
(Netherlands Vaccine Institute, Bilthoven, The Netherlands). Sucrose-laurate 
ester (L-595; 30% mono-, 40% di-, and 30% triesters, mean MW 734) was 
kindly supplied by Mitsubishi Kasei (Tokyo, Japan). Octaoxyethylene-laurate 
ester (PEG-8-L; mean MW 552) was a gift from Lipo Chemicals (Paterson, 
New Jersey, US) and sodium bistridecyl sulfo succinate (TR-70; mean MW 
585) was a gift from Cytec B.V. (Rotterdam, The Netherlands). Tween 80 was 
purchased from Merck (Darmstadt, Germany). Tween 20, lyophilized bovine 
serum albumin (BSA) and Folin Ciocalteu’s phenol reagent were obtained 
from Sigma (Zwijndrecht, The Netherlands). Chromogen 3, 3', 5, 
5'-tetra-methylbenzidine (TMB) and the substrate buffer were purchased from 
Biosource B.V (Etten-Leur, The Netherlands). All other chemicals used were 
of analytical grade and all solutions were prepared with distilled water. 
Methods 
Preparation of the vesicle dispersion and DT-loaded vesicle formulations 
Elastic vesicles used in this study consisted of the bilayer-forming surfactant 
L-595, the micelle-forming surfactant PEG-8-L, and the stabilizer TR-70 in the 
molar ratio of either 5:5:1 or 7:3:1. The 5:5:1 and 7:3:1 ratios were selected as 
in previous studies these ratios resulted in stable dispersions containing 
medium elastic (7:3:1) or very elastic (5:5:1) vesicles [15-17]. For clarity, all 
vesicle compositions will be indicated below only by the molar ratio between 
the two main components L-595 and PEG-8-L. Vesicles were prepared using 
a modified sonication method [10]. In brief, the surfactants were dissolved in 
ethanol, while TR-70 was dissolved in an ethanol/isopropanol mixture. The 
solutions were mixed in an appropriate ratio. The organic solvents were then 
evaporated overnight in a vacuum centrifuge and the remaining surfactants 
were dispersed in 0.01 M acetate buffer (Ac, sodium acetate buffer, 8.4 mM 
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H2C2O4 and 1.6 mM Na2C2O4, pH 4.0), citrate buffer (CB, 3.2 mM H3C6H5O7 
and 6.8 mM Na3C6H5O7 adjusted by adding 0.1 M HCl, pH 5.0) or phosphate 
buffer (PB, 7.7 mM Na2HPO4 and 2.3 mM NaH2PO4, pH 7.4). After adding DT, 
the final concentration of total surfactant was 10% w/w. DT with the same 
buffer was added to the vesicle dispersion to a final concentration of 1.7 
mg/ml. The selected concentration of DT derives from the dose and volume of 
formulation needed in future in vivo studies. Subsequently, vesicle 
dispersions were sonicated for 3×5 s using a Branson Sonifier 250 (Branson 
Ultrasonics, Danbury, UK) with 3 mm micro tip at 70 mW energy output. DT 
has lest solubility in buffer at pH 4.7 due to its isoelectric point (pI, 
unpublished data). It was found that solubility of DT in CB is below 1.7 mg/ml 
at pH 4.5 (visible precipitation) and above 1.7 mg/ml at pH 5.0. Therefore, to 
obtain a DT-containing vesicle formulation at pH 4.5, the surfactants mixture 
after vacuum centrifuge was first rehydrated in CB at pH 5.0. After adding DT 
and sonication, a small amount of 0.1 M HCl was added to the DT-vesicle 
suspension, lowered the pH to 4.5. This resulted in a stable DT-containing 
vesicular formulation. The final DT concentration was kept constant for all the 
formulations. Stability studies were carried out from day 1 till day 14 after 
preparation. During these studies the formulations were stored at 4 ºC. 
To investigate whether electrostatic interactions play a role in DT-vesicle 
association, DT formulations were also prepared with 0.01 M phosphate 
buffered saline at pH 7.4 (PBS, PB with 153 mM NaCl) and 0.01 M citrate 
buffered saline at pH 5.0 and 4.5 (CBS, CB with 153 mM NaCl). To achieve 
vesicles with similar size, the sonication period was extended to 80-100 s at 
this higher salt concentration. The formulations were stored at 4 ºC and the 
association studies were carried out within 3 days after preparation. 
Particle size and ζ-potential measurements 
The vesicle size and polydispersity index (PDI) of all formulations were 
measured by dynamic light scattering (DLS) using a Malvern Zetasizer 3000 
HSA (Malvern Ltd., Malvern, United Kingdom). All size measurements were 
performed at 25 °C at an angle of 90° between laser and detector. Before 
measuring, all samples were diluted with their original buffer. For estimation of 
the surface charge of the DT-associated vesicles, 3.0 μl of vesicle formulation 
were diluted in 1.00 ml of 1 mM CB or PB (pH corresponding to that of the 
formulation) and the ζ-potential was measured by laser Doppler 
electrophoresis using the same device. Formulations were measured at 
Chapter 5 
 102
regular time-intervals during a period of 2 weeks after preparation to check 
the colloidal stability. 
Size exclusion chromatography (SEC) 
To determine the amount of DT associated with vesicles in the formulations, 
SEC was performed with a Sepharose CL-4B (Amersham, Uppsala, Sweden) 
column (30 cm long, cross-sectional area 0.79 cm2). A dual λ absorbance 
detector (Waters 2487 EMI ISM Instrument, Etten-Leur, The Netherlands) set 
at 280 nm was used to monitor the separation of the free DT and 
vesicles-associated DT fractions. Empty vesicles and free DT in buffer 
solution were used to determine the collecting time windows of these fractions. 
For each formulation, the corresponding formulation buffer was used as 
eluent at a flow speed of 0.44 ml/min.  
Protein and antigenicity assay  
The protein recovery rate of the DT from the fractions collected after SEC 
were determined by a modified Lowry-Peterson protein assay [27]. The 
antigenicity of the DT from SEC fractions (relative to that of untreated DT) was 
measured by a sandwich ELISA, using horse anti-diphtheria serum and a 
horse anti-diphtheria peroxidase conjugate [28]. ELISA was also performed 
with sonicated DT, DT-vesicle formulations at pH 4.5 and pH 5.0 to study the 
preservation of DT antigenicity. Data were analyzed by use of the principles of 
parallel-line analysis of the OD-log concentration plots as described by 
Tierney et al. [29]. 
Fluorescence spectroscopy 
DT-vesicle formulations and DT solutions before and after sonication were 
studied by fluorescence spectroscopy as described elsewhere [30]. In brief, 
DT incubated at 4 ºC for 4 h with 4 M guanidine-HCl (denatured DT) served 
as control [28, 31]. The selected excitation wavelength was 295 nm (band 
width 2.5 nm) and the emission spectra of the toxoid samples (140 μg/ml) 
were recorded from 300-450 nm (band width 5 nm) at 25 ºC with a 
fluorescence spectrometer (Perkin Elmer LS50B, Massachusetts, US). For 
each sample the emission spectrum was determined from five averaged 
scans (corrected for background fluorescence). 
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SDS-PAGE  
DT solutions before and after sonication and DT-vesicle formulations were 
diluted with corresponding buffer to a concentration of 0.3 mg/ml. 
Non-reducing loading buffer (4x) was added to the samples. SDS-PAGE 
molecular weight markers (broad range; Bio-Rad, Veenendaal, The 
Netherlands) were used for calibration. Approximately 3 μg protein was 
loaded on the gel (4-20% precise protein gel, Pierce, Etten-Leur, The 
Netherlands) and run at 100 V. Protein bands were visualized by Coomassie 
brilliant blue. 
Results 
Effect of DT-vesicle composition on particle size 
In our first series of studies the stability of the selected vesicle formulation 
varying in DT concentrations between 0.2 and 1.7 mg/ml DT was examined 
by visual inspection and DLS. The pH of the formulations was varied between 
4.0 and 7.4. When the formulations were prepared at pH 4.0, pH 4.5, 5.0 and 
7.4 with a DT concentration of 0.2 mg/ml, visible precipitation was observed 
for the 7:3 vesicles, whereas the 5:5 vesicle formulations with up to 1.7 mg/ml 
DT remained stable at pH values of 4.5, 5.0 and 7.4 (Table I). Using DLS, a 
z-average diameter of 80-110 nm was measured for the 5:5 vesicles. 
Therefore in the presence of DT the 5:5 vesicles appeared to be more stable 
than the 7:3 vesicles. The 5:5 vesicle formulations were selected for more 
detailed characterization at pH 4.5, 5.0 and 7.4. 
Colloidal stability of 5:5 DT-loaded vesicles  
The stability of the 5:5 vesicles was evaluated by measuring the particle size 
of DT-loaded (1.7 mg/ml DT) and empty vesicles by DLS (Table I). The 
z-average mean diameter of the vesicles ranged from 80 to 110 nm. The PDI 
of chosen formulations was less than 0.3, which indicates a moderately 
homogenous size distribution. The vesicles were colloidally stable at 4 ºC 
during a period of at least 14 days after preparation. Interestingly, the size of 
DT-loaded vesicles was marginally larger than that of the empty vesicles at 
pH 4.5, while the DT-loaded and empty vesicles at pH 5.0 and pH 7.4 did not 





Table I. Characteristics of DT-vesicle formulations in buffers with different pHs. Data represent 
mean ± SD of three batches. 
 
L595:PEG-8-L:TR-70 = 5:5:1 (Molar ratio) 
pH Buffer** [DT] mg/ml 
Size (nm)* ζ-potential 
at day 1 (mV) 
Day 1 Day 7 Day 14 
7.4 PB 0 96.1 ± 2.8 92.2 ± 4.0 91.9 ± 2.9 -73.7 ± 3.4 
7.4 PB 1.7 96.9 ± 2.1 95.8 ± 1.0 96.5 ± 2.3 -75.9 ± 3.6 
5.0 CB 0 84.1 ± 2.4 85.2 ± 2.1 84.4 ± 2.5 -86.9 ± 3.4 
5.0 CB 1.7 79.7 ± 2.1 80.3 ± 2.7 79.6 ± 2.9 -83.3 ± 3.5 
4.5 CB 0 84.5 ± 4.9 85.1 ± 5.1 84.3 ± 4.4 -84.2 ± 1.4 
4.5 CB 1.7 103.5 ± 7.2*** 118.3 ± 14.9 114.7 ± 5.0 -77.7 ± 3.6*** 
4.0 Ac 0 80.2 ± 4.4 N.P.** N.P. N.P. 
4.0 Ac 0.2 88.8 ± 5.7 -** - - 
*The PDI ranged from 0.2 to 0.3.  
**N.P.: Not performed; -: Visible precipitation. 
***: Significantly different from the corresponding formulation without DT (p<0.05). 
 
As the isoelectric point of DT is about 4.7, a pH shift from 5.0 to 4.5 will 
change the net charge of DT molecules from negative to slightly positive, 
which may affect the interaction between DT and the vesicles. Therefore, the 
surface charge of DT-loaded vesicles was measured using laser Doppler 
electrophoresis (Table I). The ζ potential of the vesicles varied between -74 
mV (vesicles at pH 7.4) and -87 mV (vesicles at pH 5.0). The DT-loaded 
vesicles prepared at pH 4.5 have a less negative surface potential than the 
vesicles without DT. This difference in surface potential is probably due to the 
presence of association between DT and vesicles. At pH 5.0, no difference in 
ζ potential was observed for vesicles prepared in the presence and absence 
of DT, indicating that less DT is associated to the vesicles at this pH. The 
association between DT and vesicles as a function of pH and ionic strength 
was examined in more details. 
Association of DT with 5:5 vesicles 
pH-dependence (pH selection) 
In these studies, SEC in combination with Lowry-Peterson and ELISA assays 
were used to obtain information about the DT-vesicle association in the 
formulations. The pH of the DT-vesicle formulations was 4.5, 5.0 in CB and 
7.4 in PB, and the DT concentration was 1.7 mg/ml. DT’s association to the 
vesicles exceeded 70% at pH 4.5 and was below 20% at pH 5.0 and 7.4 (Fig. 
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1a). The recoveries measured by Lowry-Peterson and ELISA assays were 
very similar (Fig. 1a and 1b), indicating that associated DT had maintained its 
antigenicity. At pH 4.5 almost 80% of the protein was measured to be 
associated with the vesicles by ELISA.  
















































Figure 1. Effect of pH on association of DT and vesicles (5:5). Protein recovery (a) and 
antigenicity recovery (b) were determined after SEC fractionation of DT-vesicles at pH 4.5, 5.0 
and 7.4. DT solution (1.7 mg/ml) in citrate buffer at pH 5.0 was used as control. Data shown are 
mean + SD (n=3).  
Ionic strength (buffer selection) 
Using SEC and subsequently the Lowry-Peterson protein assay, it was shown 
that the association of DT with the vesicles was independent on the ionic 
strength at all pH values (Fig. 2). This indicates that the ionic strength has 
little influence on the DT-vesicle association. Considering the shorter 
sonication time required for the preparation procedure and the low salt 
concentration leading to less remainder when applying the formulation 
non-occlusively onto the skin, DT-vesicles prepared in CB at pH 4.5 were 
chosen for further studies. 























Figure 2. Influence of ionic strength on the DT-vesicle association (5:5 vesicles with 1.7 mg/ml 
DT). Protein recovery as detected by Lowry-Peterson protein assay was compared between PB 




























































Figure 3. Effect of DT concentration on the particle size and PDI of DT-loaded vesicles (5:5) 
prepared at pH 4.5. Data represent mean + SD of three batches. 
 
Loading capacity (DT concentration selection) 
To study the loading capacity and stability of the 5:5 DT-loaded vesicles at pH 
4.5, formulations with DT concentrations varying from 1.0 to 12.0 mg/ml in CB 
were prepared and evaluated for short-term colloidal stability during 2 weeks. 
The initial particle size increased with higher PDI at increasing DT 
concentrations (Fig. 3).The particle size tended to increase during storage, 
especially for the formulations containing high DT concentrations (Fig. 3). The 
ζ potential of DT-loaded vesicles (Fig. 4) became gradually less negative with 
increasing DT concentration, probably due to more DT association to the 
vesicles. To verify the ζ potential results quantitatively, the association of DT 
as a function of DT concentration was studied by SEC in combination with the 
Lowry-Peterson protein assay and ELISA. Formulation with 1 to 9 mg/ml of 
DT presented 75-95% association to the vesicles (Fig. 5). Similar values were 
seen for DT concentrations up to 3 mg/ml when the antigenicity was 
determined using ELISA (Fig. 5). However, formulations with 6 and 9 mg/ml 
DT showed a significantly lower antigenicity recovery than the detected 
protein recovery. 
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Figure 4. Ζ potential of empty vesicles and DT-loaded vesicles (5:5) with DT concentration from 
0 to 12 mg/ml. Data represent mean + SD of three batches. 
 

























Figure 5. Effect of DT concentration (1 to 9 mg/ml) on the association of DT with vesicles (5:5) at 
pH 4.5. Protein recovery and antigenicity recovery were determined after SEC fractionation of 
the DT-vesicles. Data shown are mean of three batches. *indicates that difference between 
protein recovery and antigenicity recovery at DT concentration of 6 and 9 mg/ml are significant 
(p<0.01). 
Effect of sonication and low pH on the DT structure 
From the above studies, stable DT-vesicle formulations were obtained in CB 
at pH 4.5 by sonication. Since DT molecules may be sensitive to 
environmental factors such as sonication, low pH and the presence of 
vesicles; ELISA, fluorescence spectroscopy and SDS-PAGE were performed 
to determine whether the DT structure was preserved during formulation. 
DT-vesicle formulations at pH 4.5 and pH 5.0, DT solution in CB at pH 5.0 
after 3×30 s sonication were measured with ELISA and compared to the 
control, no significant difference was observed. The conformation of DT was 
studied by intrinsic tryptophan fluorescence spectroscopy. Consistent with 
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previous findings [30], untreated DT showed an average maximum 
fluorescence emission at a wavelength of 335 nm, whereas the maximum 
fluorescence emission wavelength of DT denatured by guanidinium 
hydrochloride was shifted to 353 nm, caused by an increased exposure of the 
tryptophan residues to the aqueous surroundings. The maximal emission 
wavelength of the DT-vesicle formulation at pH 4.5 and pH 5.0 and the DT 
solutions after sonication (3×30 s) remained at 335 nm, which indicates the 
absence of conformational changes of DT. 
 
 
Figure 6. SDS-PAGE of DT solutions before and after sonication and DT-vesicle formulations. 
From lane1 to 9 are: 1) Broad range MW Marker; 2) DT in PBS as control; 3) DT in PBS after 
3×10 s sonication; 4) DT in PBS after 3×30 s sonication; 5) DT vesicles in CB at pH 5.0 (3×5 s 
sonication); 6) DT vesicles in CBS at pH 5.0 (80 s sonication); 7) DT vesicles in CB at pH 4.5 
(3×5 s sonication); 8) Empty vesicle control; 9) DT vesicles in CBS at pH 4.5 (80 s sonication). 
 
SDS-PAGE under non-reducing conditions of DT solutions after 3×10 s or 
3×30 s sonication, the DT-vesicle formulation in CB or CBS at pH 4.5 and pH 
5.0 showed identical bands of similar intensities at the same positions as the 
untreated DT (Fig. 6). This indicates that the sonication used for formulation 
preparation and DT association with vesicles did not induce covalent 
aggregation or fragmentation of the protein. 
The combined results from SDS-PAGE, fluorescence spectroscopy and 
ELISA point to full preservation of the DT structure after its formulation with 
5:5 vesicles in CB at pH 4.5.  
Discussion 
In several TCI studies, DT and also other antigens derived from bacterial 
ADP-ribosylating exotoxins have been investigated. However, typical doses in 
these studies were 100 μg per vaccination [32, 33], which is much higher than 
1   2       3    4    5     6     7    8     9 
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doses for injection. Therefore there is an urgent need for more efficient 
dermal vaccine delivery systems allowing lower antigen doses. In previous 
studies several groups report successful immunization via the dermal route 
using elastic vesicles [11-13]. It was also reported that surfactant-based 
vesicles served as adjuvants for co-administrated antigens given by injection 
[34] and topical immunization [35]. In the study described in this paper, the 
main focus was to formulate DT in colloidally stable elastic vesicle dispersions 
to be used for TCI.  
Selection of DT-vesicle formulations 
The characteristics of DT-vesicle formulations were strongly dependent on 
the vesicles composition and pH. As it has been reported that vesicles with 
L-595/PEG-8-L molar ratios of 7:3 and 5:5 are both elastic [16], these 
surfactant ratios were chosen to prepare DT-loaded vesicles. Our present 
studies revealed that the 5:5 vesicles are more stable than the 7:3 vesicles in 
the presence of DT. As oxyethylene headgroups are known to promote 
entropic stabilization [36], the higher levels of PEG-8-L in the 5:5 vesicles may 
count for the higher stability as compared to the 7:3 vesicles. 
Elastic vesicles may act at least partly as a carrier system. Therefore, it is 
crucial to associate DT with the vesicles. At pH 4.5 DT is slightly positively 
charged and not readily dissolved in the buffer solution. Therefore at this pH 
DT-membrane interactions are facilitated, resulting in more than 70% of DT 
associated with vesicles. It has been reported that DT undergoes irreversible 
conformational change at pH values lower than 4.2, which facilitates the 
interaction between DT and lipid membrane [31]. However, in our studies the 
DT vesicle formulations at pH 4.0 were not stable. Therefore the formulations 
at a pH lower than 4.5 were not further investigated. 
For vaccination, non-occlusive application and drying of the formulation 
during the application period  (typically 1 h) is important for the unique 
interactions between elastic vesicles and skin [21, 22], and only a small 
volume of vesicle formulations can be applied on the limited area of mouse 
skin (~30 μl/cm2). For dermal delivery, antigen concentration is normally of 
more importance than dose. Therefore, in order to determine the highest DT 
concentration at which stable vesicle formulations could be prepared, vesicle 
formulations with a DT concentration ranging from 1 to 12 mg/ml were 
examined. The results indicate that vesicle dispersions at DT concentrations 
higher than 3 mg/ml were not optimal for several reasons, namely; i) at DT 
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concentrations of 6 mg/ml and higher, the PDI increased rapidly indicating 
less homogeneous dispersions; and ii) association studies showed that at DT 
concentrations up to 3 mg/ml, protein recovery and antigenicity follow the 
same trend, whereas at DT concentrations of 6 mg/ml and higher, the 
recovered antigenicity was significantly lower than the amount of protein 
associated with vesicles. Considering the high PDI of these formulations and 
the visible aggregates in some of the 12 mg/ml DT-vesicle formulations, the 
fraction of vesicle-associated DT from 6 and 9 mg/ml DT formulations might 
contain DT aggregates as well, which might reduce the accessibility of the 
detecting antibodies to the epitopes of DT molecules. In conclusion, vesicle 
dispersions at pH 4.5 and a DT concentration up to 3 mg/ml appear to be 
optimal for TCI. 
Mechanism of association 
A pH-sensitive interaction between DT and vesicles was found in the current 
study, which is consistent with previous studies [31]. During SEC separation, 
it is difficult to explain the relatively low (~80%) recovery rate of DT in CB at 
pH 5.0 from the column (Fig. 1). However, nearly 100% of DT was recovered 
from SEC in the presence of the vesicles, probably due to the solubilizing 
properties of vesicle components. In the SEC washout curve, a tail part 
following the peak of vesicles was observed, indicating the possible presence 
of micelles formed mainly by PEG-8-L. Since DT has a pI of about 4.7, at pH 
5.0 and 7.4, DT and vesicles are both negatively charged. Under these 
conditions DT remained ionized in solution and hardly any DT was associated 
with the vesicles. In contrast, at pH 4.5 free DT tends to form aggregates, 
possibly due to a decrease of the net charge and increase of hydrophobicity, 
whereas stable DT-vesicle formulations could be obtained. This indicates that 
DT is stabilized by association with the vesicles. As the ionic strength of the 
buffer did not affect the DT-vesicle association, hydrophobic interactions may 
contribute largely to the association between DT and vesicles. 
However, the reduction in surface potential of DT-loaded vesicles compared 
to the empty vesicles at pH 4.5 indicates the interaction between slightly 
positively charged DT and the negatively charged vesicles. Therefore, the 
DT-vesicle electrostatic interactions might also play a role. Probably the 
opposite charge of the DT and the vesicles triggers the initial (long-range) 
electro statically driven force. Once associated, the hydrophobic interactions 
may contribute significantly because of the short-range van der Waals forces. 
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Therefore probably the hydrophobic domain of DT is intercalated in the bilayer 
of the vesicles. Furthermore, when applying the DT-loaded vesicle fraction 
onto the SEC column again, only vesicle-associated DT but no free DT could 
be eluted at pH 4.5, indicating a stable interaction between DT and the 
vesicles (data not shown). The order of DT addition to the formulation (before 
or after sonication) did not affect the DT-vesicle association in CB at pH 4.5 
and pH 5.0 (data not shown), indicating that energy supply into the system by 
sonication did not promote association or cause degradation but only served 
to reduce the particle size of the vesicles. 
Conclusion 
In the present study, stable DT-containing vesicles with a high loading 
capacity were developed as a potential candidate for transcutaneous 
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Vaccination is a cost-effective way to fight infectious diseases. Currently most 
vaccines are administered by subcutaneous (s.c.) or intramuscular injection. 
The problems with administration via these routes are that they are painful, 
cause stress (especially in children), require trained personnel and may lead 
to side effects. This results in incomplete vaccination coverage and, hence, 
unnecessary deaths from vaccine-preventable diseases. Consequently, 
research is focused on alternative vaccine delivery through oral [1], dermal [2], 
nasal [3] and pulmonary [4] routes. Vaccination via the dermal route is of 
particular interest since the skin is the biggest organ and is easily accessible. 
Antigen-presenting cells (APCs) in the skin, in particular, the Langerhans cells 
(LCs) in the epidermis and the dermal dendritic cells (dDCs) in the dermis are 
the targets for transcutaneous immunization (TCI), i.e. topical vaccine 
application onto intact or pretreated skin. Epidermal LCs usually represent 
about 1% of the total epidermal cell population whereas covering 20% of the 
skin surface [5]. Upon contact with certain antigens together with danger 
signals, e.g. skin barrier disruption or inflammation, LCs and dDCs become 
activated. They capture antigens/pathogens, migrate to the peripheral 
draining lymph nodes, process and present the antigen to the naïve T cells 
and initiate immune responses [6]. However, a major hurdle is to overcome 
the stratum corneum: the upper-most layer of the skin which acts as a barrier. 
This layer consists of corneocytes embedded in a highly organized crystalline 
lamellar structure of the intercellular lipid matrix. The unique arrangement of 
this layer (15-20 μm thick in humans and thinner in mice) makes it 
impermeable for macromolecules, including antigens [7]. 
In the 1970s, Gerstel and Place proposed the use of microneedle arrays as a 
way to overcome this barrier in a minimally-invasive manner[8]. However, it 
was not employed in (trans)dermal drug delivery studies until about ten years 
ago when the technology for fabrication in micron dimensions became 
available and cost-effective [9]. After the skin is treated with a microneedle 
array, tiny conduits are formed transiently with little pain sensation. Antigens 
are able to diffuse through the conduits to the APCs in the epidermis and 
dermis [10]. It was shown in Chapter 3 that microneedle array-pretreatment 
leads to major improvement in the immunogenicity of topically applied 
diphtheria toxoid (DT) in mice. Other studies have also demonstrated the 
promise of microneedle array-aided TCI: Matriano et al. studied the dosing of 
a model antigen, ovalbumin, and the kinetics and the magnitudes of antibody 
Transcutaneous immunization of diphtheria toxoid vesicular formulations 
 117
titers induced in microneedle-mediated TCI in hairless guinea pigs [11]; 
Widera et al. investigated the influences of important fabrication parameters, 
e.g. the needle length, needle density, and covered skin area of the 
ovalbumin-coated microneedle arrays, on the effectiveness of TCI [12]. 
Another approach to overcome the skin barrier in TCI is to formulate antigens 
with vesicles. Elastic vesicles, consisting of highly deformable bilayers, have 
been reported to be able to improve transdermal drug delivery. These vesicle 
formulations were applied non-occlusively as the transdermal osmotic 
gradient is considered the driving force of diffusion across the stratum 
corneum [13]. For example, Transfersomes® have been used successfully for 
a range of small molecule drugs, including steroids, non-steroidal 
anti-inflammatory drugs and local anesthetics [14-16], as well as peptides and 
proteins, e.g. cyclosporin A and insulin [17, 18]. Moreover, TCI with hepatitis 
B surface antigen-loaded elastic liposomes and tetanus toxoid-loaded 
Transfersomes® has been shown to elicit immune responses equivalent to 
those produced by intramuscular injection of alum-adsorbed antigens in 
mouse and rat, respectively [19, 20]. In our group, elastic vesicles composed 
of surfactants have previously been developed. After non-occlusive 
application on the skin, vesicle structures were observed in the deeper layers 
of the stratum corneum close to the stratum corneum-viable epidermis 
junction. Enhanced delivery of lidocaine, rotigotine and ketorolac was 
observed when the drug was associated with vesicles and the formulation 
applied on the skin in a non-occlusive manner [21-23]. Therefore, there is a 
potential for antigen-loaded vesicles as an effective formulation for TCI. 
In this study, for the first time these two approaches were combined, i.e. 
microneedle pretreatment and antigen-loaded vesicle formulations, to assess 
their potential in TCI, using DT (MW: 58 kDa; isoelectric point: 4.7) as an 
antigen. Two types of vesicles have been included. Cationic liposomes were 
made of soybean phosphatidylcholine (SPC) and 1, 
2-dioleoyl-3-trimethylammonium-propane chloride salt (DOTAP). Span 80 
was incorporated to increase elasticity of the vesicle bilayer [24]. These 
liposomes in the absence or presence of Span 80 are referred to as DT-Lip 
and DT-ELip (DT Elastic Liposome), respectively. Characterization of their 
physicochemical properties is reported in this study. Surfactant-based 
vesicles were composed of sucrose-laurate ester (L-595) and sodium 
bistridecyl sulfosuccinate (TR-70). Octaoxyethylene-laurate ester (PEG-8-L) 
was used to increase the vesicle elasticity. This DT-containing vesicle 
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formulation has been developed and characterized in Chapter 5, and referred 
to as DT-Ves in this chapter. Selected formulations were applied in TCI onto 
intact or microneedle-treated skin of mice and compared with intradermal (i.d.) 
and s.c. immunization. Their immunogenicity in vivo was evaluated by 
measuring serum IgG (subtype) and neutralizing antibody titers. Their 
immune stimulatory properties were assessed in vitro using human peripheral 
blood mononuclear cell-derived immature DCs. 
Materials and methods 
Materials 
SPC and DOTAP were kindly supplied by Lipoid GmbH (Ludwigshafen, 
Germany). Diphtheria toxin (batch 79/1), DT (batch 98/40, protein content 
12.6 mg/ml by BCA assay, 1 μg equals to approximately 0.3 Lf), horse anti-DT 
and horseradish peroxidase (HRP) conjugated anti-DT were provided by The 
Netherlands Vaccine Institute (NVI, Bilthoven, The Netherlands). 
HRP-conjugated goat anti-mouse (HRP-GAM) IgG (γ-chain specific), IgG1 
(γ1-chain specific) and IgG2a (γ2a-chain specific) were purchased from 
Southern Biotech (Birmingham, US). Adju-Phos® (alum) was obtained from 
Brenntag Biosector (Copenhagen, Denmark). Chromogen 3, 3', 5, 
5'-tetramethyl-benzidine (TMB) and the substrate buffer were purchased from 
Biosource B.V. (Nivelles, Belgium). Tween 20, lyophilized bovine serum 
albumin, Folin Ciocalteu’s phenol reagent, cholera toxin and Span 80 were 
ordered from Sigma-Aldrich (Zwijndrecht, The Netherlands). Tween 80 was 
purchased from Merck (Darmstadt, Germany). Ficoll and Percoll were 
ordered from GE Healthcare (Eindhoven, The Netherlands). Nimatek® (100 
mg/ml ketamine), Rompun® (20 mg/ml xylasine) and the injection fluid (0.9% 
NaCl) were obtained from a local pharmacy. All other chemicals used were of 
analytical grade and all solutions were prepared with distilled water. 
Methods 
DT vesicle formulation preparation 
The compositions of the DT vesicle formulations are listed in Table I. The 
DT-Lip and DT-ELip were prepared using the film rehydration and extrusion 
method. SPC, Span 80 and DOTAP, dissolved in chloroform, were mixed in 
an appropriate ratio and formed a thin film at the bottom of the flask using a 
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rotary evaporator. Residual organic solvent in the film was removed by 30 min 
nitrogen flow. The film was rehydrated by 10 mM phosphate buffer (PB, pH 
7.4, 7.7 mM Na2HPO4 and 2.3 mM NaH2PO4) or 10 mM citrate buffer (CB, pH 
5.0, 4.0 mM H3C6H5O7 and 6.0 mM Na3C6H5O7) with or without saline (153 
mM NaCl, PBS or CBS) containing 1.5 mg/ml DT. The concentration of lipids 
in the buffer was 5% w/w. The resulting dispersions were shaken at 200 rpm 
in the presence of glass beads for 2 h at room temperature, followed by 2×15 
s tip sonication (20% energy output, Branson Ultrasonics, Danbury, UK). The 
formulations were extruded (LIPEX™ Extruder, Northern Lipids Inc., Canada) 
3 times through a pair of polycarbonate filters with pore size of 200 nm and 3 
times through another pair with pore size of 100 nm (Nucleopore Millipore, 
Amsterdam, The Netherlands). DT-Ves were prepared and characterized in 
Chapter 5. Briefly, the surfactants were dissolved in ethanol, while TR-70 was 
dissolved in an ethanol/isopropanol mixture. After mixing in an appropriate 
ratio, the organic solvents were evaporated overnight in a vacuum centrifuge 
and rehydrated with 10 mM CB (pH 5.0) containing 1.5 mg/ml DT. Vesicles 
were formed after 3×5 s tip sonication (20% energy output, Branson 
Ultrasonics). Subsequently, the pH of the buffer was lowered to 4.5 by 
addition of 0.1 M HCl in order to associate DT with the vesicles. The final 
concentration of the surfactants in buffer was 10% w/w. 
 
Table I. DT-loaded vesicle formulations 
 
Buffer (pH) Components and Molar Ratio: Abbreviated name 
 L-595:PEG-8-L:TR-70  
CB (4.5) 5:5:1 DT-Ves 
 SPC:Span 80:DOTAP  
PBS (7.4) 9:0:1 DT-Lip-PBS 
PBS (7.4) 9:3:1 DT-ELip-PBS 
PB (7.4) 9:0:1 DT-Lip 
PB (7.4) 9:3:1 DT-ELip 
CBS (5.0) 9:0:1 DT-Lip-CBS 
CBS (5.0) 9:3:1 DT-ELip-CBS 
CB (5.0) 9:0:1 DT-Lip-5 
CB (5.0) 9:3:1 DT-ELip-5 
Size and ζ–potential measurements 
The size and polydispersity index (PDI) of all formulations were measured by 
dynamic light scattering using a Zetasizer (Nano ZS, Malvern Ltd., United 
Kingdom). All size measurements were performed at 25°C at an angle of 173° 
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between the laser and the detector. Before measuring, all formulations were 
diluted in their corresponding buffer. Formulations were measured at regular 
time points during a period of two weeks after preparation to evaluate the 
colloidal stability. The ζ-potential was measured by laser Doppler 
electrophoresis using the same device. The formulations were stored at 4 ºC 
in between these measurements. 
DT-vesicle association 
To determine the DT-vesicle association ratios in the formulations, size 
exclusion chromatography was performed using a Sepharose® CL-4B 
(Amersham, Uppsala, Sweden) column as described in Chapter 5. Plain 
vesicles (cationic liposomes or anionic surfactant vesicles) and free DT in 
buffer solution served as controls to determine the time window for fraction 
collection. Each formulation was run with its corresponding buffer as mobile 
phase at a flow speed of 0.40 ml/min. The recovery rate of DT after SEC was 
determined by a modified Lowry-Peterson protein assay, which separates the 
antigen from the lipids/surfactants through a precipitation step and measures 
total protein content in each fraction [25]. The antigenicity of DT in each 
fraction was measured by ELISA, using horse anti-DT serum and a 
HRP-conjugated horse anti-DT, which measures the antigenicity of 
accessible DT in the presence of the vesicle components. Data were 
analyzed using the principle of parallel-line analysis of the OD-log 
concentration plots as described by Tierney et al. [26]. 
To examine the status of DT-liposome association when encountering 
physiological condition, the formulations were eluted in SEC using PBS. The 
resulting liposome associated-DT fractions were further treated by 1% Triton 
X-100 to disrupt the liposome structure and release the encapsulated DT. The 
antigenicity of DT in these fractions were determined by ELISA and compared 
to the corresponding fractions eluted by the original buffers. 
Microneedle array and applicator 
The microneedle array used in this study was manufactured from 
commercially available 30G hypodermic needles (Becton Dickinson, Alphen 
a/d Rijn, The Netherlands) as described previously [27]. The needles were 
assembled as a 300 µm-long, 4×4 array on a polymer back plate with a 
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surface area of about 0.5 cm2. The microneedles were inserted into the skin 
at a speed of 3 m/s using the electric impact applicator. 
Evaluation of vesicle elasticity 
The elasticity of the DT-loaded vesicles was evaluated by extrusion through a 
modified Avanti Mini-Extruder® (Avanti Polar Lipids Inc., Delfzyl, The 
Netherlands). This method evaluates vesicle elasticity by comparing the 
extruded volume of dispersions under constant pressure as a function of time. 
In detail, the Mini-Extruder® was mounted on a scaffold with both syringes 
standing perpendicularly, donor above receptor. A polycarbonate filter with 
pore size of 30 nm was inserted in between the donor and acceptor syringes 
and 1 ml of vesicle dispersion was loaded in the donor syringe. A 1-kg weight 
was mounted to generate a constant pressure of about 10 bar on the piston of 
the donor syringe. Upon release of the weight, the extruded volume of the 
dispersion in the receptor syringe was recorded every minute over a 
10-minute period. This procedure was repeated two more times using freshly 
prepared dispersions. The elasticity of vesicle membrane was calculated 
















Where, D, elasticity index of vesicle membrane; J, volume of dispersion 
extruded over 5 min; rv, size of vesicles; and rp, pore size of the filter. 
Immunization protocol 
Female BALB/c mice (H2d), 8-week old at the start of the experiments, were 
purchased from Charles River (Maastricht, The Netherlands), and maintained 
under standardized conditions in the animal facility of the Leiden/Amsterdam 
Center for Drug Research, Leiden University. The study was conducted in 
conformity with the Public Health Service Policy on use of laboratory animals 
and had been approved by the Research Ethical Committee of Leiden 
University. 
Three immunization studies were carried out. Negatively charged DT-Ves and 
positively charged DT liposome formulations were applied on intact or 
microneedle-treated skin in the first and second study, respectively. 
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Formulations were applied occlusively or non-occlusively, with the presence 
or absence of CT as an adjuvant. Immunization of DT-Lip via i.d. injection was 
carried out in the third study. 
One day before immunization, the abdominal skin of mice of TCI groups was 
shaved and rested for 24 h. During immunization, mice were anesthetized by 
intraperitoneal injection of 150 mg/kg ketamine and 10 mg/kg xylazine. The 
shaved skin area was wiped with 70% ethanol. For microneedle treatment, a 
skin fold was supported by styrofoam and pierced using the microneedle 
array right before the application of DT formulations. 70 μl DT formulations 
containing 100 µg DT (and 100 µg CT if applicable) per mouse were applied 
onto intact or treated skin. The formulations were carefully spread over the 
entire skin area of application, about 2 cm2 restricted by a metal ring. After 1 h 
occlusive or non-occlusive incubation, the skin area was extensively washed 
with lukewarm tap water and patted dry twice. In the third study, 30 µl DT-Lip 
or DT solution containing 5 µg DT were given intradermally. 5 µg of DT 
adsorbed onto alum (DT-alum) in a 100 μl saline suspension was 
administered by s.c. injection for all three studies as a control. The DT-alum 
formulation was prepared as previously described and the adsorption of DT to 
alum was between 70% and 80% [29]. All DT formulations were freshly 
prepared before each vaccination. Mice were immunized at day 1, 21 and 42 
(at approximately the same skin region for the TCI groups) and sacrificed at 
day 56. Blood was sampled from the tail vein one day before each 
immunization and whole blood was collected from the femoral artery during 
sacrifice. Cell free sera were obtained using MiniCollect® tubes (Greiner 
Bio-one, Alphen a/d Rijn, The Netherlands) by centrifugation after clot 
formation and stored at -80 ºC until use. 
Serum antibody assays 
Serum IgG, IgG1 and IgG2a titers were determined by ELISA. Briefly, ELISA 
plates (Microlon®, Greiner Bio-one) were coated with DT at 4°C overnight. 
Two-fold serial dilutions of serum samples were applied in the plates and the 
containing DT-specific antibodies were detected by HRP-GAM IgG, IgG1 or 
IgG2a using TMB as substrate. Antibody titers are expressed as the 
reciprocal of the calculated sample dilution corresponding to half of the 
maximum absorbance at 450 nm of a complete s-shaped absorbance-log 
dilution curve. Mice with serum sample unable to reach the half-saturated 
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absorbance value at the lowest (ten-fold) dilution were considered as 
non-responders. 
Protective immunity against diphtheria depends on the presence of circulating 
neutralizing antibodies, evaluated using Vero cell test: the WHO standard 
method to assess the success of diphtheria vaccination, which relies on the 
inhibition of a cytotoxic dose of diphtheria toxin [30]. In brief, after complement 
inactivation, two-fold serial dilutions of serum samples were prepared with 
complete medium 199 (Gibco, Breda, The Netherlands) and applied to 
microtiter plates (CELLSTAR®, Greiner Bio-one). Subsequently, 2.5×10-5 Lf 
diphtheria toxin was added to each well. After 2 h incubation at 37 ºC for 
neutralization, Vero cell suspension was added to each well. Covered with a 
plate sealer, Vero cells were incubated at 37 ºC in 5% CO2 for 6 days. The 
end point was taken as the highest dilution protecting the Vero cells. 
DC maturation study 
Immature DCs were prepared from human peripheral blood mononuclear 
cells, which were isolated by Ficoll-Percoll density-gradient centrifugation on 
day 0. Monocytes were separated from platelets due to their adherence to the 
plastic surface (24 well plate for cell culture, Costar®, Corning, New York, US) 
after incubation at 37 °C for 60 min. The adherent cells were cultured for 6 
days in RPMI 1640, supplemented with 10% v/v fetal calf serum (FCS, 
Biosource-Invitrogen, Breda, The Netherlands), 1% glutamine, 100 U/ml 
penicillin and 0.1 mg/ml of streptomycin, 250 U/ml granulocyte-macrophage 
colony-stimulating factor (GM-CSF, Biosource-Invitrogen) and 100 U/ml 
interleukin-4 (IL-4, Biosource-Invitrogen) at 37°C with 5% CO2 to differentiate 
into immature DCs. Medium was refreshed at day 3. At day 6, the medium 
was replaced by new medium containing GM-CSF and 2 μg/ml DT, either free, 
mixed with CT or associated in liposomes or vesicles, using 
lipopolysaccharide (LPS, from Escherichia coli, Sigma) as a positive control. 
Then DCs were incubated for 48 h at 37°C. Subsequently, DCs were washed 
3 times with PBS containing 1% w/v BSA and 2% v/v FCS and incubated for 
30 min with a mixture of 20x diluted anti-HLADR-FITC, anti-CD83-PE and 
anti-CD86-APC (Becton Dickinson) on ice. Cells were washed again and the 
expression of MHC II, CD83 and CD86 was quantified using flow cytometry 
(FACS Canto II, Becton Dickinson). The up-regulation of these three surface 
markers by 50 ng/ml LPS were set as 100%. Live cells were gated based on 
forward and side scatter. A minimum of 10,000 DC events were analyzed in 
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each experiment. The study was repeated using DCs from at least three 
different donors. 
Statistical analysis 
IgG (subtype) antibody titers were analyzed with two-way ANOVA with 
Bonferroni posttest, and the neutralizing antibody titers were analyzed using 
one-way ANOVA with the same posttest. Other analyses were performed 
where suitable as indicated. Statistical analysis was carried out using Prism 
Graphpad and a p value less than 0.05 was considered significant.  
Results 
Colloidal properties of DT vesicle formulations 
Particle size and ζ-potential of the DT vesicle formulations are provided in 
Table II. Particle size and ζ-potential measured at day 7 and day 14 were very 
similar to the original values (data not shown), indicating good colloidal 
stability for all formulations listed. Particle sizes of the liposome formulations 
without Span 80 were smaller than those in the presence of Span 80. 
Formulations prepared by extrusion method show lower PDI than those 
prepared by sonication method.  
Association of DT with the vesicles 
The DT-Ves was characterized in Chapter 5 (Table II). The majority of DT was 
associated with vesicles when the pH of the buffer was lowered to 4.5 and 
dissociated when pH was increased to 7.4. This association and dissociation 
were not influenced by the ion strength of the buffer. 
For the DT-containing cationic liposomes, when prepared in PB at pH 7.4 and 
CB at pH 5.0, high DT-liposome association was observed. After SEC of 
DT-Lip and DT-ELip, nearly all protein content was recovered from the 
liposome-associated DT fractions, whereas for DT-Lip-5 and DT-ELip-5 the 
recovery from the liposome-associated DT fraction was about 30% (Fig. 1a). 
However, when prepared in PBS and CBS instead, the liposome-associated 
DT in all four formulations appeared to be lower than 15% (Data not shown). 
This indicates that ionic strength and pH of the buffer play a prominent role in 
the antigen-liposome association. Formulations prepared in PB and CB were 
selected for further studies due to higher DT-liposome association. 
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Association % (1) 
(Lowry-Peterson) 
Encapsulation % (2)
(ELISA) in PBS 
DT-Ves 101 ± 6 0.28 ± 0.03 -77.3 ± 3.0 76.8 ± 2.9 - 
DT-Lip 164 ± 2 0.23 ± 0.02 24.5 ± 1.4 86.7 ± 3.9 36.0 ± 4.5 (3) 
DT-ELip 175 ± 3 0.21 ± 0.03 24.4 ± 0.6 86.7 ± 5.1 46.9 ± 4.3 (4) 
DT-Lip-5 124 ± 9 0.12 ± 0.02 24.6 ± 2.0 29.9 ± 4.0 14.4 ± 4.0 
DT-ELip-5 149 ± 3 0.11 ± 0.01 24.8 ± 1.1 40.0 ± 4.3 13.0 ± 3.3 
(1)Associated DT: includes the surface-attached DT, bilayer-intercalated DT and the liposome-encapsulated DT 
(2)Encapsulated DT: DT released upon Triton x-100 treatment, detected by ELISA 
(3)Significantly high than those of DT-Lip-5 (p<0.001, t-test)  
(4)Significantly high than those of DT-ELip-5 (p<0.001) 
 
When detected with ELISA, the percentages of DT antigenicity in the free-DT 
fractions were similar to those of protein content, while the antigenicity from 
the liposome-associated DT fractions was much less (Fig. 1b). This significant 
loss of DT antigenicity is probably due to the shielding effect of the liposome 
on the encapsulated DT. Selected formulations were eluted with PBS (pH 7.4) 
in SEC to examine the status of DT-liposome association in physiological 
condition. DT antigenicity of the resulting fractions were measured and 
compared with those eluted by CB/PB (Fig. 1c and 1d). These figures show 
that part of the liposome-associated DT, probably attached to the liposome 
surface, was dissociated from the liposomes. When the liposome-associated 
DT fractions were further treated with Triton X-100, increased DT antigenicity 
was detected and the overall recovery rate of DT antigenicity was increased 
to about 80%, comparable to the control group. This increased DT antigenicity 
was previously shielded by liposome and represents the encapsulated DT 
under physiological condition (Table II). The DT-encapsulation ratio in PB at 
pH 7.4 was significantly higher than that in CB at pH 5.0 (p<0.001, t-test), 
most likely due to the higher negative charge of DT at pH 7.4, which facilitates 
the electrostatic interaction between DT and the liposome components. 
Elasticity of the DT-loaded vesicles 
The extruded volumes of DT-loaded vesicle formulations and the calculated 
elasticity indices are shown in Figure 2a and 2b, respectively. The unloaded 
surfactant vesicles showed relatively high elasticity. However, it was 
dramatically reduced by the loading of DT. When 0.2 mg/ml or more DT was 
incorporated, the dispersions could hardly be extruded, similar to the rigid 
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DT-Lip. On the other hand, DT-ELip retained its elasticity and can be extruded 
through filter with 30 nm pore size. The particle size of DT-ELip (~175 nm) 
was much larger than that of empty vesicles (~100 nm). For this reason, even 
though its extrusion speed was slightly slower than the empty surfactant 

























































































































































































Figure 1. DT-liposome association in formulations prepared in CB or PB. The 
liposome-associated DT and free DT were separated through SEC fractionation of formulations 
by their corresponding buffers and determined with Lowry-Peterson protein assay (1a) and 
ELISA (1b), free DT in PB and CB served as control. DT liposome formulations prepared in CB 
and PB were eluted in SEC with PBS (referred to as “eluted by PBS”, 1c and 1d). The resulted 
liposome-associated DT fractions were further treated with 1% Triton X-100 to release the 
encapsulated DT and both were measured with ELISA (referred to as “treated by Triton X-100”). 
Data are shown as mean + SD of three different batches. 
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Figure 2. The vesicle elasticity measured with the extrusion method. DT vesicle formulations 
were extruded through polycarbonate filters with pore size of 30 nm under a constant pressure of 
10 bar. The extruded volumes of these dispersions were recorded once per minute during 10 
min (2a). Particle sizes of the dispersions were measured by DLS and the elasticity indices were 
calculated using the extruded volumes after 5 min (2b). Data shown are mean + SD of three 
batches. 
Analysis of antibody titers induced in TCI 
DT-loaded anionic surfactant vesicles 
Firstly, TCI was performed by applying free DT and DT-Ves onto 
microneedle-treated or intact skin using CT as an adjuvant. The serum IgG 
titers after prime, the first boost and the second boost and the neutralizing 
antibody titers after the second boost through occlusive application are 
provided in Figure 3. Non-occlusive application of the same formulations was 
also studied, and no significant difference was found compared to the 
corresponding occlusive groups. For clarity, only data from non-occlusive 
application of DT-Ves onto intact skin are shown in Figure 3b. Pretreatment of 
the skin using the microneedle array improved the antibody responses 
drastically for both free DT and DT-Ves (Fig. 3a vs. 3b). The presence of CT 
further potentiated the IgG titers for DT-Ves (p>0.05, p<0.001 and p<0.001 
after prime, the first boost and second boost, respectively) and for free DT 
(p<0.05, p<0.001 and p<0.05 after prime, the first boost and second boost, 
respectively). For DT-Ves, IgG titers were very close to those induced by s.c. 
DT-alum after the second boost (p>0.05); whereas for free DT, comparable 
IgG titers were obtained from the first boost on (p>0.05). Surprisingly, DT-Ves 
formulations did not induce higher IgG titers than free DT through either 
occlusive or non-occlusive application (p>0.05 for all three time points). The 
IgG1 followed the IgG and showed slightly lower titers with similar trend, while 



















































































Figure 3. DT-specific IgG titers and neutralizing antibody titers after TCI of DT-Ves and free DT 
using CT as an adjuvant. Formulations were applied occlusively (unless specified in figure 3b) 
on microneedle-treated (3a) or intact skin (3b) at day 0, 21 and 42, s.c. injection of DT-alum 
served as control. Sera were collected after prime, the 1st boost and the 2nd boost (day 20, 41 
and 55) and IgG titers were determined with ELISA. Data shown as mean + SD (n=8). 
Non-responders were given an arbitrary log-value of 1. Neutralizing antibody titers of TCI on 
microneedle-pretreated skin after the 2nd boost were evaluated with Vero cell test. An arbitrary 
log-value of 0 was given when titers were below detection limit (3c). Neutralizing antibody titers 
from intact skin were all below detection limit and therefore not shown (*: p<0.05, **: p<0.01, ***: 
p<0.001). 
 
The neutralizing antibody titers showed the same trend as the IgG titers after 
the second boost (Fig. 3c). The presence of CT enhanced the titers of both 
free DT and DT-Ves (p<0.001 for both). The differences between free DT and 
DT-Ves are more pronounced. DT-Ves induced lower titers than DT (p<0.001 
and p<0.05 for with and without CT, respectively). The titers induced by 
DT-Ves with CT were lower than those of s.c. DT-alum (p<0.001), whereas for 
IgG titers, the difference was not significant. In the presence of CT, free DT 
induced comparable neutralizing antibody titers to those of s.c. DT-alum, the 
same as the IgG titers. 
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In TCI on intact skin, free DT and DT-Ves resulted in neither substantial 
antibody responses nor detectable neutralizing antibody titers. DT-Ves did not 
improve the immune responses of free DT, either. 
As DT is released quickly from DT-Ves at pH 7.4, and the negative surface 
potential may reduce the interactions between vesicles and the cell 
membranes of APCs, positively charged vesicles were included in our studies. 
Initially we focused on developing positively charged, DT-loaded, surfactant 
vesicles to obtain high DT-vesicle association at pH 7.4. However, by 
replacing TR-70 with DOTAP or dimethyl dioctadecyl ammonium as the 
charge inducer, stable formulations could not be obtained. The cationic 
liposome formulations were developed instead; in which considerable amount 
of DT has stable association with liposomes when diluted in PBS. 
DT-loaded cationic liposomes  
On microneedle-treated skin, TCI was performed using DT-Lip, DT-Lip-5 and 
DT-ELip using CT as an adjuvant. Only occlusive application was performed 
as no differences between occlusion and non-occlusion were observed in the 
study of DT-Ves. Serum IgG and neutralizing antibody titers are provided in 
Figure 4. The presence of CT potentiated the IgG titers and neutralizing 
antibody titers of DT-Lip significantly (p<0.001 for IgG titers after the first and 
second boost, and the neutralizing antibody titers, Fig. 4b and 4c). However, 
the DT liposome formulations did not induce higher immune responses than 
free DT, either. DT-ELip resulted in lower IgG titers after prime and the first 
boost, and lower neutralizing antibody titers after the second boost as 
compared to free DT (p<0.01, p<0.001 and p<0.01, respectively). Only after 
the second boost, it induced a comparable level of IgG titers as free DT 
(p>0.05), higher than those of DT-Lip-5 and DT-Lip (p<0.05 and p<0.001, 
respectively, Fig. 4a). DT-Lip and DT-Lip-5 induced lower IgG titers than free 
DT at all three time points (p<0.05, p<0.001 and p<0.001, respectively, 
Fig. 4a) and lower neutralizing antibody titers (p<0.001, Fig. 4c). Similar titers 
induced by DT-Lip and DT-Lip-5 indicate that the immunogenicity is not 
sensitive to the different DT-liposome association ratios (Fig. 4a). In 
accordance to the study of DT-Ves, the IgG1 titers of DT liposome 
formulations followed the IgG titers and showed a similar trend. The IgG2a 
titers were much less developed (data not shown). 
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Figure 4. DT-specific IgG titers and neutralizing antibody titers induced by DT liposome 
formulations in TCI. Formulations were applied occlusively on microneedle-treated skin (unless 
specified in figure 4a) at day 0, 21 and 42, s.c. injection of DT-alum as control. Sera were 
collected after prime, the 1st boost and the 2nd boost (day 20, 41 and 55) and IgG titers were 
determined with ELISA (4a and 4b). Data shown as mean + SD (n=8). Non-responders were 
given an arbitrary log-value of 1. Neutralizing antibody titers after the 2nd boost were evaluated 
with Vero cell test (4c). An arbitrary log-value of 0 was given when titers were below detection 
limit (*: p<0.05, **: p<0.01, ***: p<0.001).  
As for DT-Ves, the loss of vesicle elasticity by the loading of DT was also 
suspected to account for its low immunogenicity on intact skin, TCI of DT-ELip 
on intact skin was included because of its superior elasticity. However, the 
IgG levels induced were low and comparable to those of free DT and DT-Ves 
(Fig. 4a vs. Fig. 3); and occlusive and non-occlusive applications showed no 
difference in serum IgG titers (Fig. 4a). 
Analysis of antibody titers induced via i.d. immunization 
All the data suggest that vesicle formulations do not improve the immune 
response in TCI. To study whether differences in delivery efficiency across 
the skin barrier play a role, DT-Lip and free DT were administered via i.d. 
injection. The resulting serum IgG, IgG1, IgG2a and neutralizing antibody 
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titers are shown in Figure 5. The IgG, IgG1 and neutralizing antibody titers 
from free DT and DT-Lip were not significantly different. Unlike TCI, i.d. 
immunization of free DT and DT-Lip induced substantial IgG2a titers. 
Interestingly, DT-Lip induced a faster increase in IgG2a titers than free DT 
and significantly higher IgG2a titers were found after the first and the second 
boost (Fig. 5b, p<0.001, two-way ANOVA), suggesting immune modulation to 
a more Th1 biased response. 
DC maturation upon contact with DT-loaded vesicles 
To circumvent the complicated factors in delivery efficiency across the skin 
barrier, the direct stimulatory effects of DT formulations on the maturation of 
DCs were investigated in vitro. The up-regulation of the surface markers, 
MHC II, CD83 and CD86 was determined after culturing immature DCs in the 
presence of the DT formulations (Fig. 6). DT alone had no effect on the 
surface markers tested. CT showed the most potent stimulation to the 
immature DCs. It significantly up-regulated MHC II expression to levels higher 
than LPS and at the same time moderately enhanced those of CD86 as 
compared to free DT (p<0.001 and p<0.01, respectively, one way ANOVA). 
DT-Ves, DT-Lip and DT-ELip didn’t show significant up-regulation to all three 
surface markers as compared to free DT. 
Discussion 
In the current study, stable DT-loaded liposome formulations were prepared 
and characterized in terms of their particle size, ζ-potential, degree of 
DT-vesicle association and vesicle elasticity. Two types of DT vesicle 
formulations, cationic liposomes and anionic surfactant vesicles, were studied 
in TCI and the skin was either pretreated with microneedle arrays, or left intact. 
Pretreatment with the microneedle array and co-administration with CT 
improved the immune responses of all of the formulations dramatically. 



























































































Figure 5. DT-specific IgG subtype antibody titers and neutralizing antibody titers after i.d. 
injection of DT-Lip-PB and free DT. Vaccination was performed at day 0, 21 and 42, s.c. injection 
of DT-alum was as control. Sera were collected after prime, the 1st boost and the 2nd boost (day 
20, 41 and 55) and IgG, IgG1 and IgG2a titers were determined with ELISA (5a, 5b and 5c). 
Data shown as mean + SD (n=8). Non-responders were given an arbitrary log-value of 1. 
Neutralizing antibody titers after the 2nd boost were evaluated with Vero cell test (5d). An 
arbitrary log-value of 0 was given when titers were below detection limit (***: p<0.001). 























Figure 6. Stimulatory effects of DT formulations on immature DCs as indicated by the 
up-regulation of the surface markers; MHC II, CD83 and CD86. The up-regulations of these 
three surface markers by 50 ng/ml LPS were set as 100%. The culture medium has a basal level 
of stimulation to the DCs as it contains GM-CSF. The final concentrations of each formulation 
component in culture medium were: DT (2 μg/ml), DT+CT (2 μg/ml DT with 2 μg/ml CT), 
DT-Lip-PB and DT-Sp-Lip-PB (2 μg/ml DT with 70 μg/ml total lipids), DT-Ves (2 μg/ml DT with 
140 μg/ml total surfactants). Data shown are mean + SD (n ≥ 3). 
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Initially, surfactant vesicles were chosen to formulate DT for TCI as a vaccine 
delivery system, as they have been shown to enhance the transport of small 
molecule drugs across human skin. Evidence for an exceptional interaction 
between these vesicles and human skin in vivo was obtained by freeze 
fracture electron microscopy and Fourier transform infrared studies [23, 31]; 
vesicular structures were observed in the deep layers of the stratum corneum 
after one hour non-occlusive application. However, there was no evidence of 
vesicle material in the viable epidermis. The same vesicle system was 
employed for DT delivery in the current study. However, on intact skin, no 
substantial immune response was induced by DT-Ves and free DT, following 
either occlusive or non-occlusive application. The comparable 
immunogenicity of DT-Ves and free DT on intact skin indicates that vesicles 
do not efficiently transport the antigen across the stratum corneum. As this 
could be due to fast DT release from vesicles at pH 7.4 and the loss of vesicle 
elasticity when DT is incorporated, it was decided to prepare DT-ELip, which 
showed association of DT with the vesicles/liposomes at pH 7.4 and 
increased elasticity. However, in the subsequent in vivo immunization study, 
DT-ELip did not enhance the immunogenicity of topically applied DT on intact 
and microneedle pretreated skin. As the composition of the Span liposomes is 
very similar to that of Transfersomes® used in TCI for hepatitis B surface 
antigen and gap junction protein, the outcome of our studies are in contrast to 
those reporting that ultradeformable vesicles induce potent immune 
responses on intact skin after non-occlusive application [19, 32]. In our hands, 
elastic vesicles enhance the transport of small molecules across the skin 
[21-23], but do not improve the immunogenicity of topically applied antigens, 
e.g. DT. In addition, there is no difference between occlusive and 
non-occlusive application for the elastic liposomes. Therefore, the osmotic 
gradient does not seem to play a central role as a driving force for antigen 
diffusion using these formulations. 
To facilitate the transport of antigens into the viable epidermis, inclusion of 
skin barrier disruption methods, e.g. microneedle array pretreatment, tape 
striping or electroporation etc., appears to be crucial [33]. Microneedle 
pretreatment has been shown to enhance the transcutaneous transport 
significantly. Henry et al. demonstrated four orders of magnitude increase in 
permeability for calcein and BSA through human epidermis in vitro after 
pretreatment with a microneedle array of 150 μm needle length [9]; while 
Verbaan et al. showed penetration of 72 kDa dextran across 
microneedle-pretreated human skin in vitro using 300 μm long microneedle 
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array [27]. In the current study, the improved immunogenicity provided by the 
microneedle pretreatment may be attributed not only to enhanced antigen 
transport across the skin barrier, but also to the danger signals (IL-1α, IL-1β, 
GM-CSF and TNF-α released from the surrounding keratinocytes) caused by 
the skin barrier disruption, which sensitize and mobilize the skin APCs [34].  
The induced immune response depends on both the permeation along the 
conduits and the interaction of the formulation with the skin APCs. I.d. 
vaccination was performed to exclude the influence of transport along the 
conduits on the immune responses. In addition, the DC study provided equal 
contact of DT to the APCs in vitro. I.d. vaccination of free DT and DT-Lip 
induced similar IgG1 and neutralizing antibody titers. This indicates that 
liposomes do not stimulate DCs. When comparing i.d. vaccination with TCI on 
microneedle-pretreated skin, where the same dose of DT in DT-Lip induced 
significantly lower immune response than free DT, it is clear that the transport 
of DT-loaded liposomes along the conduits is one of the limiting factors. This 
might be due to non-specific bindings of the positively charged liposomes to 
other cell membranes and negatively charged intercellular proteins, as 
reported by Yan et al. [35]. As the negatively charged vesicles also reduced 
the immune response, it seems that a lower diffusion rate along the conduits 
may also play a role. An application period longer than one hour may enhance 
the diffusion and improve the immune responses in TCI, as the conduits 
formed by the microneedles remain open for at least a few hours as reported 
by Bal et al. [36] and Banga et al. [37]. 
In TCI on microneedle-pretreated skin, it is notable that free DT induced faster 
IgG development than DT liposome formulations (Fig. 4). Most probably the 
soluble antigen diffuses faster along the conduits into the skin, and arrives 
earlier in the viable layers and the peripheral draining lymph nodes. The role 
of direct lymphatic drainage of free antigen and the subsequent capture by 
blood-derived, lymph node-resident DCs for presentation to T cells has been 
highlighted in recent studies [38-41]. So far, a DT/CT mixture, soluble antigen 
with soluble adjuvant, is the most immunogenic formulation in TCI on 
microneedle-pretreated skin. CpG ODN also demonstrated potent immune 
potentiation and modulation properties in our previous TCI study in Chapter 4. 
Moreover, the alum-adsorbed DT, big particles of several microns, reduced 
IgG titers dramatically and diminished the neutralizing antibody titers to 
undetectable level when applied on microneedle-treated skin (data not 
shown). Therefore, including other potent and soluble adjuvants is one of the 
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first directions for further optimization of TCI formulations. Antigen-adjuvant 
conjugates and antigen-adjuvant fusion constructs may also be potential 
candidates. Furthermore, it has been reported that following i.d. injection in 
mice, 20 nm particles are taken up into the lymphatics more readily than 45 or 
100 nm particles and are retained in the lymph nodes for a longer time (up to 
120 h) [42]. These ultra small particles as well as some specific types of 
vesicles, e.g. ISCOMS, virus-like particles and surface-modified liposomes 
[43, 44], hold promise in TCI when combined with microneedle array 
pretreatment. Last but not least, instead of relying on passive diffusion 
following microneedle treatment, the development of a microneedle array 
through which the vaccine formulation could be injected would provide more 
precise dose control and improve the vaccination efficiency. 
Conclusion 
We have demonstrated in the current study that the microneedle array 
pretreatment of the skin and co-administration of CT significantly enhances 
the immunogenicity of topically applied DT. However, formulating the antigen 
with vesicles, rigid or elastic, anionic or cationic, applied occlusively or 




1. Simerska, P, et al., (2009): Oral vaccine delivery--new strategies and technologies. 
Curr Drug Deliv 6, 347-58. 
2. Mikszta, JA and Laurent, PE, (2008): Cutaneous delivery of prophylactic and 
therapeutic vaccines: historical perspective and future outlook. Expert Rev Vaccines 
7, 1329-39. 
3. Slutter, B, et al., (2008): Rational design of nasal vaccines. J Drug Target 16, 1-17. 
4. Lu, D and Hickey, AJ, (2007): Pulmonary vaccine delivery. Expert Rev Vaccines 6, 
213-26. 
5. Valladeau, J and Saeland, S, (2005): Cutaneous dendritic cells. Semin Immunol 17, 
273-83. 
6. Glenn, GM, et al., (2003): Transcutaneous immunization and immunostimulant 
strategies: capitalizing on the immunocompetence of the skin. Expert Rev Vaccines 
2, 253-67. 
7. Bos, JD and Meinardi, MM, (2000): The 500 Dalton rule for the skin penetration of 
chemical compounds and drugs. Exp Dermatol 9, 165-9. 
8. Gerstel, MS and Place, VA, Drug delivery device. 1976: US. 
9. Henry, S, et al., (1998): Microfabricated microneedles: A novel approach to 
transdermal drug delivery. J Pharm Sci 87, 922-5. 
10. Prausnitz, MR, (2004): Microneedles for transdermal drug delivery. Adv Drug Deliv 
Rev 56, 581-7. 
11. Matriano, JA, et al., (2002): Macroflux microprojection array patch technology: a 
new and efficient approach for intracutaneous immunization. Pharm Res 19, 63-70. 
12. Widera, G, et al., (2006): Effect of delivery parameters on immunization to 
ovalbumin following intracutaneous administration by a coated microneedle array 
patch system. Vaccine 24, 1653-64. 
13. Cevc, G and Gebauer, D, (2003): Hydration-driven transport of deformable lipid 
vesicles through fine pores and the skin barrier. Biophys J 84, 1010-24. 
14. Cevc, G and Blume, G, (2004): Hydrocortisone and dexamethasone in very 
deformable drug carriers have increased biological potency, prolonged effect, and 
reduced therapeutic dosage. Biochim Biophys Acta 1663, 61-73. 
15. Cevc, G and Blume, G, (2003): Biological activity and characteristics of 
triamcinolone-acetonide formulated with the self-regulating drug carriers, 
Transfersomes. Biochim Biophys Acta 1614, 156-64. 
16. Benson, HA, (2006): Transfersomes for transdermal drug delivery. Expert Opin 
Drug Deliv 3, 727-37. 
17. Cevc, G, (2003): Transdermal drug delivery of insulin with ultradeformable carriers. 
Clin Pharmacokinet 42, 461-74. 
18. Guo, J, et al., (2000): Lecithin vesicular carriers for transdermal delivery of 
cyclosporin A. Int J Pharm 194, 201-7. 
19. Mishra, D, et al., (2006): Elastic liposomes mediated transcutaneous immunization 
against Hepatitis B. Vaccine 24, 4847-4855. 
20. Gupta, PN, et al., (2005): Tetanus toxoid-loaded transfersomes for topical 
immunization. J Pharm Pharmacol 57, 295-301. 
Transcutaneous immunization of diphtheria toxoid vesicular formulations 
 137
21. Honeywell-Nguyen, PL, et al., (2003): Skin penetration and mechanisms of action in 
the delivery of the D2-agonist rotigotine from surfactant-based elastic vesicle 
formulations. Pharm Res 20, 1619-25. 
22. Honeywell-Nguyen, PL, et al., (2002): The effect of surfactant-based elastic and 
rigid vesicles on the penetration of lidocaine across human skin. STP Pharma 12, 
257-62. 
23. Honeywell-Nguyen, PL, et al., (2004): Quantitative assessment of the transport of 
elastic and rigid vesicle components and a model drug from these vesicle 
formulations into human skin in vivo. J Invest Dermatol 123, 902-10. 
24. El Maghraby, GM, et al., (2000): Oestradiol skin delivery from ultradeformable 
liposomes: refinement of surfactant concentration. Int J Pharm 196, 63-74. 
25. Peterson, GL, (1983): Determination of total protein. Methods Enzymol 91, 95-119. 
26. Tierney, R, et al., (2003): Transcutaneous immunization with tetanus toxoid and 
mutants of Escherichia coli heat-labile enterotoxin as adjuvants elicits strong 
protective antibody responses. J Infect Dis 188, 753-8. 
27. Verbaan, FJ, et al., (2007): Assembled microneedle arrays enhance the transport of 
compounds varying over a large range of molecular weight across human 
dermatomed skin. J Control Release 117, 238-45. 
28. van den Bergh, BA, et al., (2001): Elasticity of vesicles assessed by electron spin 
resonance, electron microscopy and extrusion measurements. Int J Pharm 217, 
13-24. 
29. Metz, B, et al., (2003): Physicochemical and immunochemical techniques predict 
the quality of diphtheria toxoid vaccines. Vaccine 22, 156-67. 
30. Miyamura, K, et al., (1974): Micro cell culture method for determination of 
diphtheria toxin and antitoxin titres using VERO cells. II. Comparison with the 
rabbit skin method and practical application for seroepidemiological studies. J Biol 
Stand 2, 203-9. 
31. Honeywell-Nguyen, PL, et al., (2002): The in vivo and in vitro interactions of elastic 
and rigid vesicles with human skin. Biochim Biophys Acta 1573, 130-40. 
32. Paul, A, et al., (1998): Transdermal immunisation with an integral membrane 
component, gap junction protein, by means of ultradeformable drug carriers, 
transfersomes. Vaccine 16, 188-95. 
33. Mahe, B, et al., (2009): Nanoparticle-based targeting of vaccine compounds to skin 
antigen-presenting cells by hair follicles and their transport in mice. J Invest 
Dermatol 129, 1156-64. 
34. Partidos, CD and Muller, S, (2005): Decision-making at the surface of the intact or 
barrier disrupted skin: potential applications for vaccination or therapy. Cell Mol 
Life Sci 62, 1418-24. 
35. Yan, W, et al., (2007): Mechanism of adjuvant activity of cationic liposome: 
phosphorylation of a MAP kinase, ERK and induction of chemokines. Mol Immunol 
44, 3672-81. 
36. Bal, SM, et al., (2008): In vivo assessment of safety of microneedle arrays in human 
skin. Eur J Pharm Sci 35, 193-202. 
37. Banga, AK, (2009): Microporation applications for enhancing drug delivery. Expert 
Opin Drug Deliv 6, 343-54. 
Chapter 6 
 138
38. Kissenpfennig, A, et al., (2005): Dynamics and function of Langerhans cells in vivo: 
dermal dendritic cells colonize lymph node areas distinct from slower migrating 
Langerhans cells. Immunity 22, 643-54. 
39. Reddy, ST, et al., (2007): Exploiting lymphatic transport and complement activation 
in nanoparticle vaccines. Nat Biotechnol 25, 1159-64. 
40. Iezzi, G, et al., (2006): Lymph node resident rather than skin-derived dendritic cells 
initiate specific T cell responses after Leishmania major infection. J Immunol 177, 
1250-6. 
41. Sixt, M, et al., (2005): The conduit system transports soluble antigens from the 
afferent lymph to resident dendritic cells in the T cell area of the lymph node. 
Immunity 22, 19-29. 
42. Reddy, ST, et al., (2006): In vivo targeting of dendritic cells in lymph nodes with 
poly(propylene sulfide) nanoparticles. J Control Release 112, 26-34. 
43. Saupe, A, et al., (2006): Immunostimulatory colloidal delivery systems for cancer 
vaccines. Expert Opin Drug Deliv 3, 345-54. 
44. Altin, JG, et al., (2004): Targeting dendritic cells with antigen-containing liposomes: 

















The study described in this thesis first evaluated transcutaneous 
immunization (TCI) of mice with diphtheria toxoid (DT) and influenza 
haemagglutinin antigen onto microneedle array-pretreated skin. On this basis, 
immune modulation of various adjuvants, e.g. lpxL1 lipopolysaccharide (LPS), 
Quil A, CpG, cholera toxin (CT) was assessed when mixed with DT and 
co-administrated in TCI. Another approach to overcome the skin barrier and 
improve TCI is to formulate antigens with vesicular carriers. For this purpose, 
two types of DT-containing vesicle formulations were prepared and 
characterized. Their immunogenicity, initiated after TCI of mice onto intact or 
microneedle array-pretreated skin, was also investigated in this thesis. 
Attempts to improve TCI started with the use of microneedle arrays. In 
Chapter 3, an electric impact applicator with an optimized projecting speed 
was employed [1]. It enabled shorter microneedle array (300 µm-long) to 
pierce mouse skin uniformly and reproducibly, indicated by Trypan blue 
staining and trans-epidermal water loss (TEWL). TCI with DT and an 
influenza antigen were performed using CT as an adjuvant. For DT, 
microneedle array pretreatment was crucial to achieve substantial IgG and 
toxin-neutralizing antibody titers. It resulted in a 1000-fold increase in IgG 
levels as compared to TCI without pretreatment. Addition of CT further 
enhanced the immune response to a similar level as was observed following 
subcutaneous injection of DT-alum. In contrast, microneedle array 
pretreatment showed no significant effect on TCI with influenza antigen, 
whereas the response was strongly improved by co-administration of CT. 
These results indicated that the effect of microneedle pretreatment on TCI 
depended on the nature of the antigen used. Therefore, the subsequent 
studies were focused on DT only. 
As vaccines delivered into the skin target different subsets of dendritic cells 
(DCs) compared to conventional injections, in Chapter 4, immune modulation 
by various adjuvants in TCI with DT was investigated. The immune response 
was significantly augmented by microneedle pretreatment of the skin. The 
addition of an adjuvant further increased the DT-specific serum IgG response 
to different extents: Quil A < CpG < CT. The IgG1/IgG2a ratio of DT-specific 
antibodies decreased in the following sequence: plain DT, Quil A, CT and 
CpG. This suggested that the Th2-biased immune response induced by plain 
DT could be skewed towards the Th1 direction, depending on the adjuvant 
Summary, discussion and perspectives 
 143
used. This study demonstrated that the potency and quality of the immune 
response in TCI can be optimized with the use of adjuvants. 
In Chapter 5, a surfactant-based vesicle formulation containing DT was 
developed and characterized, as it has been reported that elastic vesicles 
efficiently transport low-molecular-weight drugs across the skin [2]. The 
vesicles were composed of sucrose-laurate ester and sodium bistridecyl sulfo 
succinate. Octa-oxyethylene laurate ester was included to increase the 
bilayer elasticity [3]. Formulation variables included: molar ratios of the 
components, DT concentration, buffer species, pH and ionic strength. The 
formulations were optimized for colloidal stability and DT-vesicle association. 
It was found that pH had a dramatic effect on DT-vesicle association; at pH 
4.5 more than 70% of the protein was associated with the vesicles, whereas 
less than 20% was associated at pH 5.0. Hydrophobic interactions played an 
important role in this association and the structural integrity of DT was 
preserved during the preparation. 
Chapter 6 reports the combined approach of microneedle array pretreatment 
and the antigen-containing vesicle formulations. TCI of mice was performed 
by occlusive or non-occlusive application of the previously developed 
DT-vesicle formulation onto intact or pretreated skin. However, no improved 
immunogenicity of vesicular DT was observed as compared to free DT. In 
subsequent studies we observed that the loading of DT abolished the 
elasticity of the surfactant vesicles. This elasticity loss, the negative charge of 
the vesicles, and the fast DT dissociation from the vesicles under the neutral 
pH conditions in the skin were suspected for the relatively low titers. For this 
reason, cationic liposome formulations were developed with stable 
DT-liposome association at pH 7.4. The liposomes, composed of soybean 
phosphatidyl choline and 1, 2-dioleoyl-3- trimethylammonium-propane 
chloride salt (DOTAP), were prepared using high-pressure extrusion and 
resulted in stable formulations with sizes of about 150 nm. The 
physicochemical and colloidal properties, e.g. ζ-potential, antigen association 
and vesicle elasticity, were characterized and optimized similarly as 
performed for the DT-vesicles. At pH 7.4, a high DT-loading capacity of the 
liposomes was observed, mainly due to electrostatic interactions. 
Incorporation of Span 80 increased the bilayer elasticity in the presence of DT 
without changing the DT-liposome association ratio. In the following TCI study, 
however, the immunogenicity of DT in cationic liposome formulations was not 
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increased compared to free DT on both intact1 and microneedle-pretreated 
skin2. One of the limiting factors was the lower diffusion rate through the 
conduits of liposomes relative to that of free DT solution. In addition, low 
immune-stimulatory properties of both types of vesicle formulations were 
observed when included in the culture medium of immature DCs. 
In conclusion, application of free antigens (DT and the influenza antigen) and 
DT-containing vesicle formulations onto intact skin does not induce significant 
antibody responses. TCI with the influenza antigen is significantly improved 
by co-administration of adjuvants, independent of microneedle treatment. For 
TCI with DT, microneedle pretreatment and the use of adjuvants, but not 
antigen association to vesicles, enhances the immunogenicity. The potency 
and quality of the immune response in TCI can be further optimized by the 
use of adjuvants. 
Discussion and perspectives 
TCI offers four main advantages over conventional vaccination via injection 
when used in humans: i) potential immunological benefits, as skin contains 
more densely populated antigen-presenting cells (APCs) than muscles or 
subcutaneous tissue [4]; ii) safety potential, as it avoids direct contact of 
adjuvant with the general blood circulation [4]; iii) safe administration without 
long and sharp needles; and iv) economical/logistical advantages as it may be 
self-administrated. The efforts to improve TCI are focused on three 
perspectives: microneedle arrays, adjuvants, and vesicular carriers, as 
discussed below. 
Microneedle arrays 
In this thesis, solid microneedle arrays were used to pretreat the skin, creating 
small conduits to facilitate transcutaneous antigen diffusion. This is a 
relatively straightforward method, proven effective for TCI of DT. Crucial 
fabrication parameters include the number, length, tip shape and diameter of 
the microneedles. These parameters, in addition with the projecting speed, 
determine the uniformity and reproducibility of the piercing. What’s more, the 
diameter of the microneedles likely influences the closure time of the conduits 
and affects the efficacy of TCI. Studies, performed in humans, showed that 
                                                 
1 Both occlusive and non-occlusive application 
2 Occlusive application only 
Summary, discussion and perspectives 
 145
after treatment of the skin with a 300 μm-long microneedle array with a 
diameter of 200 μm, an increased TEWL can be observed up to 120 h when 
the treated skin site was kept occlusive [5]. It is also reported that under 
non-occlusive conditions the conduits are closed within 2-3 h [6]. As current 
TCI studies are performed in mice, an incubation time longer than 1 h is rather 
difficult as animals need to be anesthetized to prevent grooming. For use in 
humans, a patch can easily be worn for more than 24 h. Longer application 
time likely enhances transcutaneous antigen diffusion, increases 
bioavailability of vaccines; and requires lower dose of vaccines for effective 
immune protection. 
To improve dose control and increase bioavailability of vaccines, microneedle 
arrays that are vaccine-coated, dissolvable or hollow are alternative 
approaches. For coated microneedle arrays, technical challenges include: i) 
the number, length and diameter of the microneedles, which should provide 
sufficient surface for vaccine coating; ii) a mild coating procedure, which 
provides a uniform layer of vaccine only on the shaft of microneedles while 
maintaining antigen integrity; and iii) a fast release of the coated vaccine 
when inserted into the skin [7, 8]. For dissolvable microneedles, both the 
vaccine coating and the microneedles will be dissolved and released during 
application. Therefore, instead of a mild coating, a mild fabrication technique 
is needed to preserve the structural integrity of the antigens. Vaccination 
using these two types of microneedle arrays may still be performed by 
vaccinees themselves. 
The added value of hollow microneedle arrays is the precise and reliable dose 
control with potential dose sparing. However, the technical challenge is the 
leakage-free microinjection. The length, the tip shape and the opening of the 
microneedles need to be optimized to minimize the flow resistance [9]. 
Moreover, it requires a syringe or a micro pump and thus trained personnel, 
which will inevitably increase the complexity and cost of such a system. 
Adjuvants and safety 
New generation vaccines are often subunit proteins or peptides, which require 
an adjuvant to increase their immunogenicity. Cutaneous immunization 
targets Langerhans cells and/or dermal DCs. These are equipped with 
different pathogen-recognition receptor (PRR) sets from APCs resident in 
other tissues for their sentinel role. For this reason, the potency of antigen and 
the modulation properties of adjuvants often need to be re-evaluated in the 
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context of TCI. It is known that in vaccination via injection, the use of potent 
adjuvants may be associated with acute safety risks [10]. As vaccines are 
given to a predominant healthy population, safety is a highly emphasized 
issue. The risk for systemic side effects is expected to be lower for TCI than 
for injection. This is partially evidenced by observations in intradermal 
vaccination [4, 11]. This opens perspectives for TCI with broader and more 
powerful manners for safe yet effective immune-potentiation and -modulation. 
However, being a relatively new vaccination route, more safety profiles of TCI 
need to be built up to have a thorough comparison with vaccination via 
injection. 
Vesicular carriers 
Significant efforts have been made in developing antigen-containing vesicle 
or liposome formulations for TCI in the research described in this thesis. 
Although the results are not optimal yet, some conclusions can be drawn for 
future studies. 
The vesicular carriers studied, didn’t improve the immunogenicity of topically 
applied DT. For the rigid, DT-containing cationic liposomes, impaired 
immunogenicity appears to be caused by limited antigen transport through the 
conduits and their low immune stimulation to DCs. For the elastic vesicles, it 
is shown that the immunogenicity of DT on intact skin is not significantly 
influenced by the presence of the trans-epidermal osmotic gradient and the 
vesicle structure. Therefore, it appears that the transcutaneous diffusion 
enhancement of the vesicles, if any, is not sufficient to influence the 
immunogenicity outcome. For TCI with DT, ensuring sufficient transcutaneous 
antigen transport should be of the first concern, even though a study shows 
that enhanced transport may not guarantee improved immunogenicity [12]. 
In vaccination via injection, particulate/vesicular antigen delivery systems 
improve vaccination efficacy by mimicking the size and structure of natural 
pathogens and providing protection and stabilization to encapsulated 
antigens from degradation [13]. Co-encapsulation of antigen and adjuvant in 
the same vesicles/particles is an optimization strategy for both TCI and 
injection vaccination. It may provide stronger immune stimulatory properties 
by targeting antigen and adjuvant to the same APC [14]. In addition, by 
introducing certain endosomal escaping mechanisms into the 
liposomes/vesicles, pH sensitivity for example, cross presentation can be 
Summary, discussion and perspectives 
 147
promoted, which may induce stronger cytotoxic T-cell response, beneficial for 
anti-viral and anti-tumor immunity [15, 16]. 
In this study, high antigen-vesicle association was achieved by adjusting the 
charge of the vesicle components, ionic strength, the species and pH of the 
buffer. Positively charged vesicles/particles may facilitate the interactions with 
the negatively charged DC membrane surface and consequently increase the 
antigen uptake. However, they also tend to stick to other cell surfaces or 
intercellular proteins and block their further diffusion through the conduits. For 
anionic vesicles, diffusion appears to be easier. But high antigen-loading is 
more difficult to achieve with anionic vesicles than with cationic ones, as most 
to the antigens are negatively charged under physiological conditions. If ionic 
strength and pH different from physiological values are used for formulation 
preparation, characterization under both conditions should be performed. 
Recently, with the clarification of functional specialization of skin DC subsets, 
targeted delivery of antigen may provide modulation on the immune response 
induced [17]. As mentioned above, co-encapsulation, surface modification, or 
covalent attachment of other PRR ligands to antigen-containing vesicles can 
be employed to target antigens to a specific skin DC subset. This requires 
more intensive characterization of the formulations and needs to be tuned for 
each individual antigen. Cell lines, better resembling the targeted skin DC 
subset, or immune active skin substitutes containing targeted DC subsets, 
may serve to evaluate the immune-stimulatory properties of the novel 
transcutaneous vaccines in vitro [12]. In vivo studies of the selected 
formulations may start with intradermal injection for a proof of principle test on 
their immunogenicity in TCI. In case of positive results, a combination with a 
proper skin barrier disruption method, i.e. type of microneedle arrays and 
application time, will further optimize their potency after topical application. 
Perspectives 
Microneedle array-mediated TCI of mice with CT-adjuvanted DT can induce 
immune protection as high as that from subcutaneous injection of DT-alum. A 
dose twenty times higher than that for injection was used to ensure sufficient 
diffusion in this study, although only a small fraction entered the viable skin 
layer. Further optimization, e.g. using targeted antigen delivery carriers, more 
potent adjuvants with desired modulation properties, certain type of 
microneedle devices or skin barrier disruption methods, together with longer 
application time, will certainly decrease the required dose of DT. This will 
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essentially enable TCI to challenge injection as a superior vaccine 
administration. 
In this study, the skin showed diverse responses upon contact with different 
types of antigens in vivo, for example, DT vs. CT when applied on intact skin 
or DT vs. influenza haemagglutinin when applied on microneedle-pretreated 
skin. It appears that TCI need to be optimized for each individual antigen. The 
field will benefit from a direct comparison study performing microneedle 
array-aided TCI with antigens of different categories, e.g. different charge, 
size, formation in solution and origin etc. 
Continuous advances in understanding the immune system, especially the 
immune functions of the skin, will facilitate more rational design and 
development of transcutaneous vaccines. Vaccination will continue to be the 
most effective tool in controlling infectious diseases, whereas TCI will 
dramatically improve vaccination practice in developing countries, in cases of 
mass vaccination campaigns and in counteracting bio-terrorism. 
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List of abbreviations: 
Ac:    Sodium acetate buffer 
Alum:   Adju-Phos®, colloidal aluminum phosphate 
APC:   antigen-presenting cell 
BSA:   bovine serum albumin 
CB:   citrate buffer 
CBS:   citrate buffered saline 
CLR:   c-type lectin-like receptor 
CCL:   CC chemokine ligand 
CM199:  complete medium 199 
CRM 197:  cross-reacting material of diphtheria toxin 
CSSS:   cyanoacrylate skin surface stripping 
CT:    cholera toxin 
CTA:   cholera toxin A subunit 
CTB:   cholera toxin B subunit 
CXCL:   C-X-C motif ligand 
DAMP:   danger-associated molecular patterns 
DC:   dendritic cell 
DC-SIGN:  DC-specific ICAM-3-grabbing non-integrin 
DDA:   dimethyl dioctadecyl ammonium 
DLS:   dynamic light scattering 
DOTAP:  1, 2-dioleoyl-3-trimethylammonium-propane (chloride salt) 
DT:    diphtheria toxoid 
DTV:   diphtheria toxoid vesicle formulation 
EPI:   epidermal powder immunization 
ELISA:   enzyme-linked immunosorbent assay 
FCA:   Freund’s complete adjuvant 
FCS:   fetal calf serum 
GJP:   gap junction protein 
GM-CSF:  granulocyte-macrophage colony-stimulating factor 
HB-EGF:  heparin-binding epidermal growth factor precursor 
HBsAg:   hepatitis B surface antigen 
HI:    hemagglutination inhibition  
HRP-GAM:  horseradish peroxidase conjugated goat anti-mouse 
HSA:   human serum albumin 
HSP:   heat shock protein 
ICAM:   intercellular adhesion molecule-3 
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i.d.:    intradermal 
IL-4:   interleukin-4 
i.m.:   intramuscular 
i.p.:    intraperitoneal 
LC:    Langerhans cell 
L-595:   sucrose-laurate ester 
LPS:   lipopolysaccharide 
MEA:   microenhancer array 
MHC:   major histocompatibility complex 
MN:   microneedle array 
MPL:   monophosphoryl lipid A 
Nalp3:   NACHT-LRR-PYD-containing protein 
NLR:   NOD like receptor 
NOD:   nucleotide oligomerization domain 
NSAIDs:  non-steroidal anti-inflammatory drugs 
OPD:   o-phenyldiaminedihydro-chloride 
OPM:   o-palmitoyl mannan 
PAMP:   pathogen-associated molecular patterns 
PB:    phosphate buffer 
PBMC:   peripheral blood mononuclear cell 
PBS:   phosphate buffered saline 
PBST:   phosphate buffered saline containing 0.05% Tween 20 
PDI:   polydispersity index 
PEG-8-L:  octaoxyethylene laurate ester 
PRR:   pathogen recognization receptor 
RIG:   retinoic acid inducible gene 
RLR:   RIG-I-like receptor 
s.c.:   subcutaneous 
SEC:   size exclusion chromatography 
Span 60:  sorbitan monostearate 
Span 80:  sorbitan monooleate 
Span 85:  sorbitan trioleate 
SPC:   soybean phosphatidyl choline 
TCI:   transcutaneous immunization 
TEWL:   trans-epidermal water loss 
TMB:   3, 3', 5, 5'-tetramethylbenzidine 
TNF-α:   tumor necrosis factor-α 
TR-70:   sodium bistridecyl sulfo succinate 
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TT:    tetanus toxoid 
VLP:   virus-like particle 




Transcutane subunit vaccin toediening 
Een gecombineerde benadering van vesiculaire formuleringen en matrices van 
micronaalden 
Samenvatting 
Het onderzoek beschreven in dit proefschrift is gericht op dermale vaccinatie, 
d.w.z. vaccinatie via de huid. 
De natuurlijke functie van de huid is de barrièrefunctie. Die wordt vooral 
gevormd door de buitenste dode huidlaag, de zogenaamde hoornlaag. In de 
daaronder gelegen levende huid bevinden zich o.a. dendritische cellen (DCs), 
die een cruciale rol spelen bij het op gang brengen van de immuunrespons. 
Dermale vaccinatie is vooral attractief omdat dit pijnloos kan gebeuren omdat 
pijnzenuwen afwezig zijn in het buitenste deel van de huid en omdat de 
concentratie DCs in de huid hoog is. Een hoge concentratie DCs maakt het 
mogelijk om efficient te vaccineren. Echter de grootste uitdaging is om het 
antigeen (het actieve gedeelte van het vaccin) in voldoende mate door de 
hoornlaag te transporteren in de richting van de DCs. 
In het onderzoek beschreven in dit proefschrift werden zowel micronaalden 
als vesiculaire formuleringen gebruikt om het transport van het antigeen door 
de hoornlaag te verhogen. Micronaalden zijn naalden korter dan 1 mm met 
een diameter van 300μm of kleiner. De voor dit proefschrift gebruikte 
naalden zijn massief en worden gebruikt om de huid vóór te behandelen 
waarna het vloeibare vaccin wordt opgebracht. Vesiculaire formuleringen 
bevatten deeltjes met een waterige kern omsloten door een hydrofobe laag 
van oppervlakte-actieve stoffen. De vesicles zijn, afhankelijk van hun 
samenstelling, elastisch en de penetratie van stoffen door de huid bevorderen. 
Tevens werden aan de formuleringen adjuvantia toegevoegd om de 
immunogeniciteit te verhogen. 
Om het transport van het antigeen door de huid te bevorderen werd eerst het 
gebruik van micronaalden onderzocht, waarbij kleine gaatjes geprikt worden, 
zodat de barrierefunctie van de huid vermindert en het antigeen efficienter 
door de hoornlaag getransporteerd wordt in de richting van de DCs. Eerst 
werd onderzocht of de micronaalden gaatjes veroorzaken in de huid. Dit 
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onderzoek staat beschreven in hoofdstuk 3. Micronaalden werden getest 
met een lengte varierend tussen 300 en 900 μm. De naaldjes werden 
gemonteerd in een plaatje, zodanig dat er 16 naaldjes in een 4x4 geometrie 
gerangschikt zijn. Het bleek dat micronaaldjes met een lengte van minstens 
550 μm gaatjes in de huid veroorzaken, terwijl de kortere naaldjes niet 
noemenswaardig in de huid prikten. Niet alleen de naaldlengte maar ook de 
snelheid waarmee de naaldjes de huid raken bepaalt of de hoornlaag 
gepenetreerd wordt. Bij te lage snelheid rekt de elastische huid mee en vouwt 
zich om de micronaalden. Daarom werd een speciale electrische applicator 
ontwikkeld waarmee de naalden met constante, relatief hoge snelheid 
gebruikt kunnen worden. Het bleek inderdaad dat met behulp van de 
applicator een array met kortere micronaalden (245-300 µm lang) de 
muizenhuid kan penetreren op een uniforme en reproduceerbare manier. 
Dermale vaccinatie met difterie toxoid en een influenza antigeen werd 
uitgevoerd met cholera toxine (CT) als adjuvans. Hiertoe werd de huid al dan 
niet voorbehandeld met de micronaalden, waarna vervolgens de formulering 
opgebracht werd. In geval van difterie toxoid, was de voorbehandeling met de 
micronaalden noodzakelijk om substantiële immunogeniciteit te bereiken. 
Vergeleken met dermale toediening zonder voorbehandeling, zorgde de 
micronaalden voorbehandeling voor een 1000-voudige verhoging in 
immunogeniciteit. Toevoeging van CT verhoogde de immuunreactie verder 
tot een niveau dat vergelijkbaar was met de immuunrespons na subcutane 
toediening van difterie toxoid geadsorbeerd aan aluminiumfosfaat, de 
postieve controle. Met het influenza antigeen werden andere resultaten 
bereikt. De voorbehandeling met micronaalden zorgde niet voor een 
significant effect, maar de toevoeging van CT verhoogde de immunogeniciteit 
sterk. Deze resultaten tonen aan dat het effect van de voorbehandeling met 
micronaalden voor dermale vaccinatie afhankelijk is van het gebruikte 
antigeen. Er werd besloten in alle vervolgstudies difterie toxoid te gebruiken. 
Vaccins, die toegediend worden via de huid, worden opgenomen door andere 
klassen DCs dan na conventionele intramusculaire of subcutane injecties. 
Daarom werd de invloed van verschillende adjuvantia op het type 
afweerreactie na dermale toediening met difterie toxoid onderzocht. Deze 
studies staan beschreven in Hoofdstuk 4. De immunogeniciteit werd 
verhoogd door de voorbehandeling met micronaalden. De toevoeging van 
een adjuvans verhoogde de immunogeniciteit verder in deze volgorde: Quil A 
< CpG < CT. Het gebruik van adjuvantia had ook invloed op het type respons. 
De verhouding van de zogenaamde Th1/Th2 reactie nam toe in de volgorde: 
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geen adjuvans, Quil A, CT en CpG. Dit suggereert dat de immunogeniciteit, 
die opgewekt wordt door enkel difterie toxoid en die neigt naar een Th2 
reactie, kan overgaan naar een Th1 reactie, afhankelijk van het gebruikte 
adjuvans. Hiermee kan de immunogeniciteit dus gemoduleerd worden. 
In de literatuur staat beschreven dat elastische vesicles (deeltjes met een 
waterige kern omsloten door een hydrofobe laag van oppervlakte actieve 
stoffen) op een efficiënte manier medicijnen met een laag molecuulgewicht 
over de huid kunnen transporteren. In Hoofdstuk 5 werd daarom een difterie 
toxoid bevattende vesiculaire formulering ontwikkeld en gekarakteriseerd. De 
vesicles bestaan uit uit sucrose-lauraat ester en natrium-bistridecyl 
sulfo-succinaat. Octa-oxyethyleen lauraat ester werd toegevoegd om de 
elasticiteit van de vesicles te verhogen. De variabelen voor de formuleringen 
waren de volgende: de verhouding van de verschillende bestanddelen, 
difterie toxoid concentratie, zuurtegraad (pH) en ionsterkte. De formuleringen 
werden geoptimaliseerd wat betreft de colloïdale stabiliteit en difterie 
toxoid-vesicle associatie. De pH had een dramatisch effect op de difterie 
toxoid-vesicle associatie. Bij pH 4.5 was meer dan 70% van het eiwit 
geassocieerd met de vesicles, terwijl minder dan 20% geassocieerd was bij 
pH 5.0. Hydrofobe interacties speelden een belangrijke rol bij deze associatie 
en de structurele integriteit van difterie toxoid bleef behouden tijdens de 
bereiding van de formulering. Omdat elastische vesicles voor laag 
moleculaire farmaca alleen efficient het transport door de huidbarriere 
verhogen indien de farmaca geassocieerd zijn met de vesicles, werd besloten 
om de formulering met een pH van 4.5 te selecteren voor in vivo studies. 
Hoofdstuk 6 beschrijft een benadering, waarbij de voorbehandeling van 
micronaalden werd gecombineerd met vesiculaire formuleringen, die het 
antigeen bevatten. Dermale vaccinatie van muizen werd uitgevoerd d.m.v. het 
occlusief (geen verdamping van water mogelijk) of niet-occlusief (wel 
verdamping van water) aanbrengen van de formulering op de intacte of op de 
met micronaalden voorbehandelde huid. Uit de resultaten bleek dat difterie 
toxoid in vesicles niet tot een verbeterde immunogeniciteit leidde ten opzichte 
van vrij difterie toxoid. In de daaropvolgende studies bleek dat difterie toxoid 
de elasticiteit van de vesicles sterk verminderde. Dit verlies in elasticiteit en 
de snelle afgifte van difterie toxoid uit de vesicles bij pH 7.4 (de pH in de huid) 
zouden de oorzaak kunnen zijn voor de relatief lage immunogeniciteit. 
Daarom werden er positief geladen liposoom (vesicles bestaande uit 
voornamelijk fosfolipiden) formuleringen ontwikkeld, waarbij difterie toxoid 
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(negatief geladen) nog steeds met de liposomen geassocieerd is bij een pH 
van 7.4. De fysisch-chemische en de colloïdale eigenschappen, van de 
liposomen werden onderzocht en geoptimaliseerd, zoals dit ook was 
uitgevoerd voor de difterie toxoid-vesicles. Bij pH 7.4 bleek dat difterie toxoid 
voornamelijk geassocieerd was met de liposomen dankzij de elektrostatische 
interacties. Toevoeging van Span 80 verhoogde de elasticiteit van de 
liposomen in de aanwezigheid van difterie toxoid terwijl de associatie van 
difterie toxoid met de liposomen intact bleef. Echter uit de daaropvolgende 
dermale vaccinatie studie bleek dat difterie toxoid geformuleerd in positief 
geladen vesicles ook niet tot een verhoogde immunigeniteit  leidde ten 
opzichte van vrij difterie toxoid. Dit gold voor zowel de intacte als met 
micronaalden voorbehandelde huid. Uit vervolgstudies bleek dat liposomen 
geen immuunstimulerende eigenschappen vertoonden wanneer ze werden 
toegevoegd aan DCs in vitro. Mogelijk is een verminderd transport over de 
huid de oorzaak van de lagere immunogeniciteit na dermale vaccinatie ten 
opzichte van vrij difterie toxoid, waarbij liposomen op zich niet de 
immunogeniciteit verhogen. Het inbouwen van adjuvantia in liposomen kan 
daar in de toekomst mogelijk verandering in brengen. 
Uit het beschreven onderzoek blijkt dat de toepassing van vrij antigeen 
(difterie toxoid en het influenza antigeen) en difterie toxoid-bevattende 
vesiculaire formuleringen op intacte huid geen immuunrespons veroorzaakt. 
Dermale vaccinatie met het influenza antigeen is efficienter door toevoeging 
van CT, onafhankelijk van voorbehandeling met micronaalden. Wat betreft 
difterie toxoid, is voorbehandeling met micronaalden efficient. De 
immunogeniciteit kan verder verhoogd worden door gebruik van adjuvantia. 
difterie toxoid associatie met vesicles blijkt minder efficient te zijn om de 
immunogeniciteit te verhogen. Dit geld voor zowel onbehandelde huid als 
micronaalden behandelde huid. De sterkte en de kwaliteit van de 
afweerreactie na dermale toediening kan verder worden geoptimaliseerd door 











































白滴度：其效果排序为：皂甙 QuilA<CpG 寡聚核苷酸<霍乱毒素。而 IgG1/IgG2a
两种亚型免疫球蛋白的比值按以下顺序排列：无佐剂<皂甙 QuilA<霍乱毒素<CpG
寡聚核苷酸，说明在这一疫苗输送途径中，取决于使用佐剂的种类，免疫反应








颗粒的相互作用有显著的影响。pH 值 4.5 的时候，超过 70%的抗原和纳米颗粒







































I’d like to start my acknowledgement to the Chinese Scholarship Council. You 
provided financial support for my study in the Netherlands. I’d also like to 
acknowledge Prof Dr Hans. E. Junginger, you forwarded my email to my 
current supervisor, Prof. Dr. Joke A. Bouwstra, and set up the initial contact. 
Around five and a half years ago, Aug. 29th, 2004, I came to The Netherlands. 
During ten hours flight, I had quite some time to think of the exciting, unknown 
future and the sadness of leaving my wife behind shortly after our wedding. 
Thanks for my friends He Shuning, Zhang Hongtao, Liang Junfeng and Yue 
Tao, I was taken good care upon arrival and smoothly adapted to the life in 
Leiden. I will never forget the first day in the lab. It was Stefan who showed 
me around the lab. From then on, I started to feel the friendly and pleasant 
atmosphere of the group. I am grateful to Kharis, Maytal and Connie who took 
care of me during the first days. I appreciated very much the first skin 
handling demonstration by Ferry and the course on vesicle preparation 
provided by Gert. Thanks, Stefan and Dirk-Jan. You supported me for 
handling many mice. Johan, Fred and Ine, you ensured that my experiments 
were performed smoothly. 
It is not easy to start a vaccine delivery project in a group without an 
immunologist. Fortunately, the efforts of building up the immunological arm 
have never been stopped. I am grateful to John, who gave me useful 
suggestions at a very early stage. Elly, besides your enormous efforts in 
setting up the whole scope of immunological methods in our lab, you helped 
me with the in vitro dendritic cell analysis, cytokine determination with 
Luminex and data interpretation. This was especially important for the studies 
described in Chapter 4 and 6 of this thesis. The studies described in Chapter 
4 also benefits from valuable discussion with Rob from RIVM. For other 
members in the vaccine squad, Suus and Bram, I really like the 
brain-storming drawings on the whiteboard and the enlightening discussions 
with you. This happened at work, during experiments or at lunch, and covered 
not only immunology, particles and delivery, but also history, culture and 
everyday life. Thank you also for sharing the literature and discoveries of 
common interest. The team is further strengthened by Myrra, Christophe and 
Ana. I am grateful to all of you for your proof reading of my thesis. Two 
students, Henrietta and Tsambika (Mannheim, Germany) have shared my 
research and enriched my teaching experience. I acknowledge their hard 
working and enthusiasm and I wish them success in their future. I’d like to 
express my thanks to all other (ex-) DDT members: Wouter, Julia, Miranda 
and Miranda, Varsha, Mojgan, Daniel, Andrea, Vasco, Marc, Tomo, Sun, Tue, 
Appendix III 
 164
Aat, Basak, Michelle, Riccardo, Joern, Nuch, Nazmoen, Romano, Robert, 
Dana, Hugo, Francisco and Christian. You made my stay at DDT rich, varied 
and unforgettable. Thanks, Connie, for your excellent logistic support. I am 
also indebted to Hans and Sylvia, for their demonstration and help in handling 
fluorescent and Confocal microscopy. Technical problems were solved by the 
handy guys, Raphael and Henk. You designed and fabricated microneedle 
arrays, applicator, sample holders for microscopy and patch systems etc. in 
an elegant manner. 
This PhD period could have been much more difficult and boring if I had not 
met Robert and Olly. Robert, I feel so grateful to you, not only as an everyday 
advisor, but also to have somebody share the emotional moments in both 
research and life, and to have deep conversations. There were so many 
precious moments. I am sure my wife is grateful to you as well for the 
babysitting internship. Following you, I joined the International Dinner Club 
and a lot more parties, where I got to know many nice friends like Thierry, 
Massimo, Claudia, Karthick, Christian, Hana, Eugenio and Kiri. Thank you all 
for your help and company during my stay in Leiden! Olly, I’d like to thank you 
for your help with my moving, for all our joint birthday parties, for the nice host 
and guide you provided when we visited Belgian cities like Turnhout, Brussels, 
Antwerp, Leuven, Gent and Brugge, for the pleasant company in Vienna 
during CRS 2006, for offering nice digital gadgets, for everyday Dutch 
translation including the translation of the Dutch summary in this thesis and, a 
lot more….. I am really happy that you two are here today, backing me up as 
my paranimfen. 
The success in performing my PhD is the outcome of collaboration with other 
two groups. Firstly, I want to express my gratitude to Hoang, Bernard, 
Leonard, Janny and Jessica from NVI. From you, I learned invaluable 
knowledge and experience. Secondly, I’d like to thank Marjan and Louis from 
the Department of Pharmaceutics of University Utrecht, for your help in 
learning and transferring experimental techniques. 
Chinese students, who studied in Leiden during the past ten years, will 
remember the time spent together in Stationsplein 242 as being a big and 
harmony family. We explored and experienced The Netherlands and shared 
our happiness and pain. I would like to thank the following friends: Ma Yafeng, 
Ye Dan, Ye Kai, Hu Hongbo, Bao Dongping, Qin Yu, Leng Xin, Jia Qi, Hu 
Chunxiu, Shan Junjun, Tu Shengxian, Li Cheng, Jiang Bin, Liu Yingying, Dai 
Lu, Shi Runwei, Mu Zhibo and Liu Zhen. My appreciation also goes to my 
Dutch housemates in DUWO: Cathlijn, Joyce, Astrid, Wouter and John, thank 
you all for your company, and especially, for explaining the Dutch instructions 
Acknowledgements 
 165
on many letters, bottles and bags with patience. I am also grateful to Prof. 
Zhang Junfeng and Zhu Aiwu, who kept in touch and encouraged me during 
this period despite the long distance. 
I’d like to thank my parents and parents-in-law. You care about me all the time. 
You insisted to be woken up at midnight just to make sure your son and 
daughter arrived safe and sound after a long flight. You struggled with 
computers and new techniques just to be able to see your son and to hear his 
voice. You asked me to put on more clothes as soon as you heard from news 






Zhang Wei, my dear wife, it is your love, encouragement and generosity that 
supported me time by time, mentally and practically, which finally make this 
book and everything today possible. I own so much to you as I was not able to 
take care of our newly built family for five years. But, for tomorrow, let’s move 
forward TOGETHER!!! 
 








Zhi Ding was born on June 15th, 1977 in Suqian, Jiangsu, China. In 1994 he 
completed his high-school education with specialization in mathematics and 
natural science at Suqian High School, Jiangsu, China. At the same year, he 
started his bachelor study at the Department of Biochemistry, Nanjing 
University, China. He conducted research on the project entitled “Quantitative 
Modeling of Eukaryotic Gene Transcription Control” for his undergraduate 
dissertation in the group of Prof. Dr. Wang at the State Key Laboratory of 
Pharmaceutical Biotechnology, Department of Biochemistry, Nanjing 
University, China. After his graduation in 1998, he stayed in Nanjing 
University, working as a study advisor and teaching assistant for 
undergraduate students in the same department. In the year 2000, apart from 
his administrative job, he started his graduate study, exempted from the 
entrance examination. He carried out the research project Surface 
Modification of Biomaterial for Tissue Engineering under the supervision of 
Prof. Dr. Zhang in the State Key Laboratory of Pharmaceutical Biotechnology, 
Department of Biochemistry, Nanjing University, China. In August 2004, he 
came to the Netherlands, where he started his study entitled Master of 
Philosophy for one year, which was continued as a PhD project in the Division 
of Drug Delivery Technology, Leiden University. Under the supervision of Prof. 
Dr. J.A. Bouwstra, Prof. Dr. W. Jiskoot and Dr G.F. Kersten he worked on the 
subject Transcutaneous Immunization of Diphtheria Toxoid Using Vesicular 





List of publications 
 169
List of publications 
 
Part I. articles in journals: 
 
Gao, S., Chen, J., Xu, X., Ding, Z., Yang, YH., Hua, Z. and Zhang, J. (2003): 
Galactosylated low molecular weight chitosan as DNA carrier for 
hepatocyte-targeting. Int J Pharm 255, 57-68. 
 
Ding, Z., Chen, J., Gao, S., Chang, J., Zhang, J. and Kang, ET. (2004): 
Immobilization of chitosan onto poly-L-lactic acid film surface by plasma graft 
polymerization to control the morphology of fibroblast and liver cells. Biomaterials 25, 
1059-1067. 
 
Gao, S., Chen, J., Dong, L., Ding, Z., Yang, YH. and Zhang, J. (2005): Targeting 
delivery of oligonucleotide and plasmid DNA to hepatocyte via galactosylated 
chitosan vector. Eur J Pharm Biopharm 60, 327-334. 
 
Guo, T., Zhao, J., Chang, J., Ding, Z., Hong, H., Chen, J. and Zhang, J. (2006): 
Porous chitosan-gelatin scaffold containing plasmid DNA encoding transforming 
growth factor-beta1 for chondrocytes proliferation. Biomaterials 27, 1095-1103. 
 
Jiang, T., Chang, J., Wang, C., Ding, Z., Chen, J., Zhang, J. and Kang, ET. (2007): 
Adsorption of plasmid DNA onto N,N'-(dimethylamino)ethyl-methacrylate graft- 
polymerized poly-L-lactic acid film surface for promotion of in-situ gene delivery. 
Biomacromolecules 8, 1951-1957. 
 
Ding, Z., Bivas-Benita, M., Hirschberg, H., Kersten, GF., Jiskoot, W. and Bouwstra, 
JA. (2008): Preparation and characterization of diphtheria toxoid-loaded elastic 
vesicles for transcutaneous immunization. J Drug Target 16, 555-563. 
 
Ding, Z., Verbaan, FJ., Bivas-Benita, M., Bungener, L., Huckriede, A., van den Berg, 
DJ., Kersten, GF. and Bouwstra, JA. (2009): Microneedle arrays for the 
transcutaneous immunization of diphtheria and influenza in BALB/c mice. J Control 
Release 136, 71-78. 
 
Ding, Z., Van Riet, E., Romeijn, S., Kersten, GF., Jiskoot, W. and Bouwstra, JA. 
(2009): Immune modulation by adjuvants combined with diphtheria toxoid 
administered topically in BALB/c mice after microneedle array pretreatment. Pharm 
Res 26, 1635-1643. 
 
Cheng, X., Zhang, F., Zhou, G., Gao, S., Dong, L., Jiang, W., Ding, Z., Chen, J., and 
Zhang, J., (2009): DNA/chitosan nanocomplex as a novel drug carrier for 
doxorubicin. Drug Deliv 16, 135-44. 
 
Bal, S., Slütter, B., van Riet, E., Kruithof, A., Ding, Z., Kersten, GF., Jiskoot, W. and 
Bouwstra, JA. (2010): Efficient induction of immune responses through intradermal 
Appendix V 
 170
vaccination with N-trimethyl chitosan containing antigen formulations. In press, J 
Control Release. 
 
Ding, Z., Bal, S., Romeijn, S., Kersten, GF., Jiskoot, W. and Bouwstra, JA. (2010): 
Transcutaneous immunization studies in mice using diphtheria toxoid-loaded vesicle 
formulations and a microneedle array. In press, Pharm Res. 
 
Ding, Z., Bal, S., van Riet, E., Jiskoot, W. and Bouwstra, JA. (2010): 
Transcutaneous immunization, a review. Manuscript in preparation. 
 
Slütter B., Soema CP., Ding Z., Verheul R., Hennink W. and Jiskoot W. (2010): 
Conjugation of ovalbumin to trimethyl chitosan improves immunogenicity of the 
antigen. In press, J Control Release. 
 
Part II. contributions to academic conferences 
 
Ding, Z., Hirschberg, H., Kersten, GF., Bivas-Benita, M. and Bouwstra, JA. (2006): 
Formulations of Diphtheria Toxoid with Elastic Vesicles for Dermal Vaccination. The 
33rd Annual Meeting and Exposition of the Controlled Release Society (CRS) at 
Vienna, Austria, July 2006. 
 
Ding, Z., Verbaan, F., Hirschberg, H., Kersten, GF., Jiskoot, W. and Bouwstra, JA. 
(2007): Dermal Vaccination Study of Diphtheria Toxoid on Mice. American 
Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition at 
San Diego, CA, November 2007. 
 
Ding, Z., Romeijn, S., Hirschberg, H., Kersten, GF., Bivas-Benita, M., Jiskoot, W. 
and Bouwstra, JA. (2008): Transcutaneous Immunization with Diphtheria 
Toxoid-loaded Elastic Vesicle Formulations following Microneedle Pretreatment. 
The 35th Annual Meeting and Exposition of the Controlled Release Society at New 
York, NY, July 2008. 
 
Ding, Z., Romeijn, S., Hirschberg, H., Kersten, GF., Jiskoot, W. and Bouwstra, JA. 
(2008): Transcutaneous Immunization of Diphtheria Toxoid using Microneedles. The 
7th biennial Globalization of Pharmaceutics Education Network (GPEN) conference 
at Leuven, Belgium, September 2008. 
 
Ding, Z., Romeijn, S., Hirschberg, H., Kersten, GF., Jiskoot, W. and Bouwstra, JA. 
(2008): Transcutaneous Immunization of Diphtheria Toxoid using Microneedles. 
American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and 
Exposition at Atlanta, GA, November 2008. 
 

